Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

ABSTRACT

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No.16/457,012, filed 28 Jun. 2019, which is a Continuation of U.S. patentapplication Ser. No. 15/445,461, filed 28 Feb. 2017, now U.S. Pat. No.10,400,011, issued 3 Mar. 2019, which claims the benefit of U.S.Provisional Application Ser. No. 62/302,010, filed 1 Mar. 2016, andGreat Britain Application No. 1603568.5, filed 1 Mar. 2016, the contentof each of these applications is herein incorporated by reference intheir entirety.

This application also is related to PCT/EP2017/054559 filed 28 Feb.2017, the content of which is incorporated herein by reference in itsentirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED AS A COMPLIANT ASCII TEXT FILE(.txt)

Pursuant to the EFS-Web legal framework and 37 CFR §§ 1.821-825 (seeMPEP § 2442.03(a)), a Sequence Listing in the form of an ASCII-complianttext file (entitled “Sequence_listing_2912919-063007_ST25.txt” createdon 1 Jun. 2021, and 32,361 bytes in size) is submitted concurrently withthe instant application, and the entire contents of the Sequence Listingare incorporated herein by reference.

FIELD

The present invention relates to peptides, proteins, nucleic acids andcells for use in immunotherapeutic methods. In particular, the presentinvention relates to the immunotherapy of cancer. The present inventionfurthermore relates to tumor-associated T-cell peptide epitopes, aloneor in combination with other tumor-associated peptides that can forexample serve as active pharmaceutical ingredients of vaccinecompositions that stimulate anti-tumor immune responses, or to stimulateT cells ex vivo and transfer into patients. Peptides bound to moleculesof the major histocompatibility complex (MHC), or peptides as such, canalso be targets of antibodies, soluble T-cell receptors, and otherbinding molecules.

The present invention relates to several novel peptide sequences andvariants thereof derived from HLA class I molecules of human tumor cellsthat can be used in vaccine compositions for eliciting anti-tumor immuneresponses, or as targets for the development ofpharmaceutically/immunologically active compounds and cells.

BACKGROUND OF THE INVENTION

The most common type of bladder cancer starts in urothelium ortransitional epithelium, the innermost lining of the bladder, and iscalled urothelial carcinoma or transitional cell carcinoma (TCC).Urothelial cells are located in the other parts of urinary tract, whichby bladder cancer patients can be infiltrated by cancer as well. Theprogressing bladder cancer grows further into or through the otherlayers in the bladder wall, spreads first of all to the lymph nodes, thebones, the lungs, or the liver (American Cancer Society, 2015).

Bladder cancers are characterized by their spread and type of growing.Depending on its expansion, bladder cancer is categorized asnon-invasive and invasive. The non-invasive or superficial bladdercancer is localized exclusively in the innermost layer of bladder wall.In contrast, the invasive bladder cancer is grown into the deeper layersof bladder wall (American Cancer Society, 2015).

Depending on the type of growing, bladder cancer are divided intopapillary and flat carcinomas. Papillary carcinomas grow as slender,finger-like extensions from the inner side of the bladder cancer towardsthe hollow center. Papillary carcinomas are often non-invasive. The veryslow growing, non-invasive papillary cancer is sub classified aspapillary urothelial neoplasm of low-malignant potential (PUNLMP). Thosetumors mostly show a very good therapeutic outcome. Flat carcinomas donot grow towards the center of the bladder cancer. The flat bladdercarcinomas, which are restricted only to the inner layer of bladderwall, are called non-invasive flat carcinoma or a flat carcinoma in situ(CIS). Both papillary and flat carcinomas, which spread further into thedeeper layers of bladder wall, are called invasive urothelial (ortransitional cell) carcinoma (American Cancer Society, 2015).

The other cancer types, which start in the bladder, are squamous celland small cell carcinomas, adenocarcinomas and sarcomas. Those cancertypes are rare (American Cancer Society, 2015). Bladder cancer isdivided into 5 stages. At stage 0, cancer cells are restricted only tothe inner layer of bladder wall. The bladder cancer at stage 0 isdivided in stage 0a by papillary carcinomas or stage Ois by flatcarcinomas. At the following stages I and II, bladder cancer cellsinfiltrate further layers of the bladder wall and get spread into theconnective tissue and muscle tissue, respectively. At the stage III,bladder cancer cells spread further from the bladder into thesurrounding fat or even reproductive organs. At the stage IV, bladdercancer infiltrates the wall of the abdomen or pelvis, lymph nodes andfurther distant organs like lung, bones or liver (National CancerInstitute, 2015).

In the United States, bladder cancer represents the ninth leading causeof cancer death. The percentage of death caused by bladder cancerincreases with the age and is at its highest at the age of 75-84.Bladder cancer accounts to 4.5% of all new cancer cases. The people inthe age of 65-84 are most frequently diagnosed with bladder cancer.Bladder cancer is diagnosed about 4 times more frequently in men than inwomen. Over the last 10 years, the number of new bladder cancer caseshas been decreasing for 0.6% each year, the death rates and 5-yearsrelative survival have remained stable (SEER Stat facts, 2014).

On average the 5-years relative survival for bladder cancer is about77%. In general, the 5-years relative survival depends strongly on thestage, when the bladder cancer has been diagnosed. 51% new bladdercancer cases are recognized on the very early in situ stage, when thebladder cancer is localized only in the originating layer of bladderwall. The 5-years relative survival at this stage accounts for about96%. 35% of the new bladder cancer cases are diagnosed at the localizedstage. In those cases, bladder cancer is restricted to the primary siteand the 5-years relative survival is about 70%. The 5-years relativesurvival of new bladder cancer cases, which are first diagnosed at theregional stage (cancer spread to lymph nodes, 7% of all new bladdercancer cases) and distant stage (metastasizing cancer, 4% of all newbladder cancer cases), accounts for 34 and 5.4%, respectively. The stageof 3% newly diagnosed bladder cancer is unknown. The 5-years relativesurvival for those cancer is about 47% (SEER Stat facts, 2014).

The standard treatment for bladder cancer includes surgery, radiationtherapy, chemotherapy and immunotherapy.

The following types of surgery can be undertaken by the treatment ofbladder cancer: transurethral resection, radical or partial cystectomyand urinary diversion. By the transurethral resection, the cancer isremoved from the bladder inner wall mechanically or by the burning ofthe tumor with high-energy electricity. By the cystectomy, the bladdertogether with any lymph nodes and other by cancer invaded nearby organsis removed partially or completely. The urinary diversion is a type ofsurgery by which the new ways of storage and passing of urine are done.The surgery is often complemented with application of chemotherapy,which intends to lower the risk of the cancer recurrence (NationalCancer Institute, 2015).

At stage 0 and I, the bladder cancer is typically treated bytransurethral resection potentially followed by intravesicalchemotherapy and optionally combined with intravesical immunotherapeutictreatment with BCG (bacillus Calmette-Guérin). Partial or radicalcystectomy is possible. Bladder cancer at stage II and III treated byradical or partial cystectomy, transurethral resection or externalradiation with or without chemotherapy. At the stage IV, the treatmentof bladder cancer depends on how far cancer cells have spread in thebody. If the bladder cancer cells are still restricted only to thebladder, the cancer can be treated by the chemotherapy alone, radicalcystectomy or external-beam radiation either with or withoutchemotherapy. By the invasion of bladder cancer to other parts of thebody, the chemotherapy with or without surgery or radiation therapy isthe first choice of treatment. At this stage, the external-beamradiation, urinary diversion or cystectomy can be applied as palliativetherapy. At any stage of bladder cancer, patients have a possibility toenroll in a clinical trial (National Cancer Institute, 2015).

An effective immunotherapeutic approach is established in the treatmentof aggressive non-muscle invasive bladder cancer (NMIBC). Thereby, aweakened form of the bacterium Mycobacterium bovis (bacillusCalmette-Guérin=BCG) is applied as an intravesical solution. The majoreffect of BCG treatment is a significant long-term (up to 10 years)protection from cancer recurrence and reduced progression rate. Inprinciple, the treatment with BCG induces a local inflammatory responsewhich stimulates the cellular immune response. The immune response toBCG is based on the following key steps: infection of urothelial andbladder cancer cells by BCG, followed by increased expression ofantigen-presenting molecules, induction of immune response mediated viacytokine release, induction of antitumor activity via involvement ofvarious immune cells (thereunder cytotoxic T lymphocytes, neutrophils,natural killer cells, and macrophages) (Fuge et al., 2015; Gandhi etal., 2013).

BCG treatment is in general well tolerated by patients but can be fatalespecially by the immunocompromised patients. BCG refractory is observedin about 30-40% of patients (Fuge et al., 2015; Steinberg et al.,2016a). The treatment of patients who failed the BCG therapy ischallenging. The patients who failed the BCG treatment are at high riskfor developing of muscle-invasive disease. Radical cystectomy is thepreferable treatment option for non-responders (Steinberg et al., 2016b;von Rundstedt and Lerner, 2015). The FDA approved second line therapy ofBCG-failed NMIBC for patients who desire the bladder preservation is thechemotherapeutic treatment with valrubicin. A number of other secondline therapies are available or being currently under investigation aswell, thereunder immunotherapeutic approaches like combinedBCG-interferon or BCG-check point inhibitor treatments, pre-BCGtransdermal vaccination, treatment with Mycobacterium phlei cellwall-nucleic acid (MCNA) complex, mono- or combination chemotherapy withvarious agents like mitomycin C, gemcitabine, docetaxel, nab-paclitaxel,epirubicin, mitomycin/gemcitabine, gemcitabine/docetaxel, anddevice-assisted chemotherapies like thermochemo-, radiochemo-,electromotive or photodynamic therapies (Fuge et al., 2015; Steinberg etal., 2016b; von Rundstedt and Lerner, 2015). Further evaluation ofavailable therapies in clinical trials is still required.

In general, the treatment of advanced bladder cancer with muscleinvasion known as muscle-invasive bladder carcinoma (MIBC) or metastaticbladder cancer is challenging and remained substantially unchanged overthe last few decades. Nowadays available options for treatment ofprogressed bladder cancer are insufficiently effective. New trends inthe clinical management of bladder cancer have been opening up by thelately emerging understanding of genetic background of urothelialcancer. Especially, the recent implementation of predictive genomic andmolecular biomarkers intends to benefit the therapeutic response (Joneset al., 2016; Rouanne et al., 2016; Grivas et al., 2015; Azevedo et al.,2015; Knollman et al., 2015a).

Before 2003 cystectomy alone was established as a standard treatment ofMIBC. The recurrence of cancer at distant body sites after the surgeryshowed the necessity of neoadjuvant chemotherapeutic treatment. Thecombined chemotherapy with high dose-intensity methotrexate,vinblastine, doxorubicin and cisplatin (accelerated MVAC or AMVAC) orgemcitabine and cisplatin (GC) count currently to a standard neoadjuvanttreatment of MIBC in the United States. The adjuvant application ofchemotherapy by the treatment of MIBC is limited by the high surgicalcomplication rate after radical cystectomy. Nevertheless, the usage ofAMVAC, GC or combination of cisplatin, methotrexate and vinblastine(CMV) is currently recommended as adjuvant chemotherapy for high-riskMIBC patients. The similar systematic chemotherapy is used by treatmentof metastatic bladder cancer. In general, only 30 to 40% of patientsrespond to the cisplatin-based chemotherapy. Furthermore, patients withimpaired renal function are ineligible for treatment with cisplatin. Thesecond-line treatment depends on the previous treatment and has not beenscandalized (Knollman et al., 2015b; Rouanne et al., 2016).

The alternative treatment options for advanced bladder cancer are beinginvestigated in ongoing clinical trials. The current clinical trialsfocused on the development of molecularly targeted therapies andimmunotherapies. The targeted therapies investigate the effects ofcancerogenesis related pathway inhibitors (i.e. mTOR, vascularendothelial, fibroblast, or epidermal growth factor receptors,anti-angiogenesis or cell cycle inhibitors) in the treatment of bladdercancer. The development of molecularly targeted therapies remainschallenging due to high degree of genetic diversity of bladder cancer.The main focus of the current immunotherapy is the development ofcheckpoint blockage agents like anti-PD1 monoclonal antibody andadoptive T-cell transfer (Knollman et al., 2015b; Grivas et al., 2015;Jones et al., 2016; Rouanne et al., 2016).

Considering the severe side-effects and expense associated with treatingcancer, there is a need to identify factors that can be used in thetreatment of cancer in general and urinary bladder cancer in particular.There is also a need to identify factors representing biomarkers forcancer in general and urinary bladder cancer in particular, leading tobetter diagnosis of cancer, assessment of prognosis, and prediction oftreatment success.

Immunotherapy of cancer represents an option of specific targeting ofcancer cells while minimizing side effects. Cancer immunotherapy makesuse of the existence of tumor associated antigens.

The current classification of tumor associated antigens (TAAs) comprisesthe following major groups:

a) Cancer-testis antigens: The first TAAs ever identified that can berecognized by T cells belong to this class, which was originally calledcancer-testis (CT) antigens because of the expression of its members inhistologically different human tumors and, among normal tissues, only inspermatocytes/spermatogonia of testis and, occasionally, in placenta.Since the cells of testis do not express class I and II HLA molecules,these antigens cannot be recognized by T cells in normal tissues and cantherefore be considered as immunologically tumor-specific. Well-knownexamples for CT antigens are the MAGE family members and NY-ESO-1.

b) Differentiation antigens: These TAAs are shared between tumors andthe normal tissue from which the tumor arose. Most of the knowndifferentiation antigens are found in melanomas and normal melanocytes.Many of these melanocyte lineage-related proteins are involved inbiosynthesis of melanin and are therefore not tumor specific butnevertheless are widely used for cancer immunotherapy. Examples include,but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma orPSA for prostate cancer.

c) Over-expressed TAAs: Genes encoding widely expressed TAAs have beendetected in histologically different types of tumors as well as in manynormal tissues, generally with lower expression levels. It is possiblethat many of the epitopes processed and potentially presented by normaltissues are below the threshold level for T-cell recognition, whiletheir over-expression in tumor cells can trigger an anticancer responseby breaking previously established tolerance. Prominent examples forthis class of TAAs are Her-2/neu, survivin, telomerase, or WT1.

d) Tumor-specific antigens: These unique TAAs arise from mutations ofnormal genes (such as β-catenin, CDK4, etc.). Some of these molecularchanges are associated with neoplastic transformation and/orprogression. Tumor-specific antigens are generally able to induce strongimmune responses without bearing the risk for autoimmune reactionsagainst normal tissues. On the other hand, these TAAs are in most casesonly relevant to the exact tumor on which they were identified and areusually not shared between many individual tumors. Tumor-specificity (or-association) of a peptide may also arise if the peptide originates froma tumor- (-associated) exon in case of proteins with tumor-specific(-associated) isoforms.

e) TAAs arising from abnormal post-translational modifications: SuchTAAs may arise from proteins which are neither specific noroverexpressed in tumors but nevertheless become tumor associated byposttranslational processes primarily active in tumors. Examples forthis class arise from altered glycosylation patterns leading to novelepitopes in tumors as for MUC1 or events like protein splicing duringdegradation which may or may not be tumor specific.

f) Oncoviral proteins: These TAAs are viral proteins that may play acritical role in the oncogenic process and, because they are foreign(not of human origin), they can evoke a T-cell response. Examples ofsuch proteins are the human papilloma type 16 virus proteins, E6 and E7,which are expressed in cervical carcinoma.

T-cell based immunotherapy targets peptide epitopes derived fromtumor-associated or tumor-specific proteins, which are presented bymolecules of the major histocompatibility complex (MHC). The antigensthat are recognized by the tumor specific T lymphocytes, that is, theepitopes thereof, can be molecules derived from all protein classes,such as enzymes, receptors, transcription factors, etc. which areexpressed and, as compared to unaltered cells of the same origin,usually up-regulated in cells of the respective tumor.

There are two classes of MHC-molecules, MHC class I and MHC class II.MHC class I molecules are composed of an alpha heavy chain andbeta-2-microglobulin, MHC class II molecules of an alpha and a betachain. Their three-dimensional conformation results in a binding groove,which is used for non-covalent interaction with peptides.

MHC class I molecules can be found on most nucleated cells. They presentpeptides that result from proteolytic cleavage of predominantlyendogenous proteins, defective ribosomal products (DRIPs) and largerpeptides. However, peptides derived from endosomal compartments orexogenous sources are also frequently found on MHC class I molecules.This non-classical way of class I presentation is referred to ascross-presentation in the literature (Brossart and Bevan, 1997; Rock etal., 1990). MHC class II molecules can be found predominantly onprofessional antigen presenting cells (APCs), and primarily presentpeptides of exogenous or transmembrane proteins that are taken up byAPCs e.g. during endocytosis, and are subsequently processed.

Complexes of peptide and MHC class I are recognized by CD8-positive Tcells bearing the appropriate T-cell receptor (TCR), whereas complexesof peptide and MHC class II molecules are recognized byCD4-positive-helper-T cells bearing the appropriate TCR. It is wellknown that the TCR, the peptide and the MHC are thereby present in astoichiometric amount of 1:1:1.

CD4-positive helper T cells play an important role in inducing andsustaining effective responses by CD8-positive cytotoxic T cells. Theidentification of CD4-positive T-cell epitopes derived from tumorassociated antigens (TAA) is of great importance for the development ofpharmaceutical products for triggering anti-tumor immune responses(Gnjatic et al., 2003). At the tumor site, T helper cells, support acytotoxic T cell- (CTL-) friendly cytokine milieu (Mortara et al., 2006)and attract effector cells, e.g. CTLs, natural killer (NK) cells,macrophages, and granulocytes (Hwang et al., 2007).

In the absence of inflammation, expression of MHC class II molecules ismainly restricted to cells of the immune system, especially professionalantigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells,macrophages, dendritic cells. In cancer patients, cells of the tumorhave been found to express MHC class II molecules (Dengjel et al.,2006).

Elongated (longer) peptides of the invention can function as MHC classII active epitopes.

T-helper cells, activated by MHC class II epitopes, play an importantrole in orchestrating the effector function of CTLs in anti-tumorimmunity. T-helper cell epitopes that trigger a T-helper cell responseof the TH1 type support effector functions of CD8-positive killer Tcells, which include cytotoxic functions directed against tumor cellsdisplaying tumor-associated peptide/MHC complexes on their cellsurfaces. In this way tumor-associated T-helper cell peptide epitopes,alone or in combination with other tumor-associated peptides, can serveas active pharmaceutical ingredients of vaccine compositions thatstimulate anti-tumor immune responses.

It was shown in mammalian animal models, e.g., mice, that even in theabsence of CD8-positive T lymphocytes, CD4-positive T cells aresufficient for inhibiting manifestation of tumors via inhibition ofangiogenesis by secretion of interferon-gamma (IFNγ) (Beatty andPaterson, 2001; Mumberg et al., 1999). There is evidence for CD4 T cellsas direct anti-tumor effectors (Braumuller et al., 2013; Tran et al.,2014).

Since the constitutive expression of HLA class II molecules is usuallylimited to immune cells, the possibility of isolating class II peptidesdirectly from primary tumors was previously not considered possible.However, Dengjel et al. were successful in identifying a number of MHCClass II epitopes directly from tumors (WO 2007/028574, EP 1 760 088B1).

Since both types of response, CD8 and CD4 dependent, contribute jointlyand synergistically to the anti-tumor effect, the identification andcharacterization of tumor-associated antigens recognized by either CD8+T cells (ligand: MHC class I molecule+peptide epitope) or byCD4-positive T-helper cells (ligand: MHC class II molecule+peptideepitope) is important in the development of tumor vaccines.

For an MHC class I peptide to trigger (elicit) a cellular immuneresponse, it also must bind to an MHC-molecule. This process isdependent on the allele of the MHC-molecule and specific polymorphismsof the amino acid sequence of the peptide. MHC-class-1-binding peptidesare usually 8-12 amino acid residues in length and usually contain twoconserved residues (“anchors”) in their sequence that interact with thecorresponding binding groove of the MHC-molecule. In this way each MHCallele has a “binding motif” determining which peptides can bindspecifically to the binding groove.

In the MHC class I dependent immune reaction, peptides not only have tobe able to bind to certain MHC class I molecules expressed by tumorcells, they subsequently also have to be recognized by T cells bearingspecific T cell receptors (TCR).

For proteins to be recognized by T-lymphocytes as tumor-specific or-associated antigens, and to be used in a therapy, particularprerequisites must be fulfilled. The antigen should be expressed mainlyby tumor cells and not, or in comparably small amounts, by normalhealthy tissues. In a preferred embodiment, the peptide should beover-presented by tumor cells as compared to normal healthy tissues. Itis furthermore desirable that the respective antigen is not only presentin a type of tumor, but also in high concentrations (i.e. copy numbersof the respective peptide per cell). Tumor-specific and tumor-associatedantigens are often derived from proteins directly involved intransformation of a normal cell to a tumor cell due to their function,e.g. in cell cycle control or suppression of apoptosis. Additionally,downstream targets of the proteins directly causative for atransformation may be up-regulated and thus may be indirectlytumor-associated. Such indirect tumor-associated antigens may also betargets of a vaccination approach (Singh-Jasuja et al., 2004). It isessential that epitopes are present in the amino acid sequence of theantigen, in order to ensure that such a peptide (“immunogenic peptide”),being derived from a tumor associated antigen, leads to an in vitro orin vivo T-cell-response.

Basically, any peptide able to bind an MHC molecule may function as aT-cell epitope. A prerequisite for the induction of an in vitro or invivo T-cell-response is the presence of a T cell having a correspondingTCR and the absence of immunological tolerance for this particularepitope.

Therefore, TAAs are a starting point for the development of a T cellbased therapy including but not limited to tumor vaccines. The methodsfor identifying and characterizing the TAAs are usually based on the useof T-cells that can be isolated from patients or healthy subjects, orthey are based on the generation of differential transcription profilesor differential peptide expression patterns between tumors and normaltissues. However, the identification of genes over-expressed in tumortissues or human tumor cell lines, or selectively expressed in suchtissues or cell lines, does not provide precise information as to theuse of the antigens being transcribed from these genes in an immunetherapy. This is because only an individual subpopulation of epitopes ofthese antigens are suitable for such an application since a T cell witha corresponding TCR has to be present and the immunological tolerancefor this particular epitope needs to be absent or minimal. In a verypreferred embodiment of the invention it is therefore important toselect only those over- or selectively presented peptides against whicha functional and/or a proliferating T cell can be found. Such afunctional T cell is defined as a T cell, which upon stimulation with aspecific antigen can be clonally expanded and is able to executeeffector functions (“effector T cell”).

In case of targeting peptide-MHC by specific TCRs (e.g. soluble TCRs)and antibodies or other binding molecules (scaffolds) according to theinvention, the immunogenicity of the underlying peptides is secondary.In these cases, the presentation is the determining factor.

SUMMARY OF THE INVENTION

In a first aspect of the present invention, the present inventionrelates to a peptide comprising an amino acid sequence selected from thegroup consisting of SEQ ID NO: 1 to SEQ ID NO: 149 or a variant sequencethereof which is at least 77%, preferably at least 88%, homologous(preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 toSEQ ID NO: 149, wherein said variant binds to MHC and/or induces T cellscross-reacting with said peptide, or a pharmaceutical acceptable saltthereof, wherein said peptide is not the underlying full-lengthpolypeptide.

The present invention further relates to a peptide of the presentinvention comprising a sequence that is selected from the groupconsisting of SEQ ID NO: 1 to SEQ ID NO: 149 or a variant thereof, whichis at least 77%, preferably at least 88%, homologous (preferably atleast 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 149,wherein said peptide or variant thereof has an overall length of between8 and 100, preferably between 8 and 30, and most preferred of between 8and 14 amino acids.

The following tables show the peptides according to the presentinvention, their respective SEQ ID NOs, and the prospective source(underlying) genes for these peptides. All peptides in Table 1 and Table2 bind to HLA-A*02. The peptides in Table 2 have been disclosed before,but have not been associated with cancer at all before. The peptides inTable 3 are additional peptides that may be useful in combination withthe other peptides of the invention. The peptides in Table 4 arefurthermore useful in the diagnosis and/or treatment of various othermalignancies that involve an over-expression or over-presentation of therespective underlying polypeptide.

TABLE 1 Peptides according to the present invention.J = phospho-serine, U = phospho-threonine SEQ ID No Sequence Gene ID(s)Official Gene Symbol(s) 1 ILLQASVQV 56649 TMPRSS4 2 GLLKAYSIRTA 3855KRT7 3 YLDEIPPKFSM 4070 TACSTD2 4 SLDVVNLLV 57182 ANKRD50 5 IQDPVIFYV57211 GPR126 6 SIVDFLITA 10848 PPP1R13L 7 QMFEGQILDV 55057 AIM1L 8ALSFSSSAGPGLLKA 3855 KRT7 9 SLVDARFQL 130497 OSR1 10 GLWHGMFANV 57609DIP2B 11 AMAELRVVV 126410 CYP4F22 12 GVALTVTGV 2319 FLOT2 13 FLEEKEQAAL10626, 147166, TRIM16, CDRT1, TRIM16L 374286 14 GLAGPVRGV6628, 6638, 8926 SNURF, SNRPB, SNRPN 15 YLAPENGYLMEA 6625 SNRNP70 16ILGPQGNTI 10657 KHDRBS1 17 RLSQLEGVNV 55737 VPS35 18 SIAAYNPVV 10202DHRS2 19 SLATTLTKI 1315 COPB1 20 YLPDSLTQL 55227 LRRC1 21 TLIEDDALNGA3248 HPGD 22 SIAKEGVVGA 6623 SNCG 23 YTLSKTEFL 6282 S100A11 24 SLLGGITVV9043 SPAG9 25 SLDSSGFSL 143 PARP4 26 GLALLYSGV 533 ATP6V0B 27 STTNGGILTV84248 FYTTD1 28 GLIDSLMAYV 5317 PKP1 29 ALSSPPPTV 9372 ZFYVE9 30ILDISRSEV 57720 GPR107 31 SLFDGIATGL 1788 DNMT3A 32 YQAPDIDVQL 29997GLTSCR2 33 VLFGEITRL 4720 NDUFS2 34 ALLDEQQVNV 3397 ID1 35 KLPEPPPLA2086 ERV3-1 36 ALWDEFNQL 6899 TBX1 37 ILSAILVHL 339766 MROH2A 38TLTSIIVAV 339766 MROH2A 39 AMASHLTST 100526737, 10432, RBM4 5936 40VIADRVVTV 127731 VWA5B1 41 FLDDGNQMLL 79659 DYNC2H1 42 FLIDASQRV 256076COL6A5 43 FLIESKLLSL 92749 DRC1 44 GLAQDPKSLQL 23331 TTC28 45 IIDSSPTAL79915 ATAD5 46 SLFIGAEIVAV 405753 DUOXA2 47 VLMDDTDPL 5700 PSMC1 48VLMDDTDPLV 5700 PSMC1 49 SLIGGTNFV 162 AP1B1 50 VLANRVAVV 10202 DHRS2 51ALLDKAQINL 147711, 26974 ZNF285 52 SLATLEGIQL 7776 ZNF236 53 ILVQVIPVV3664 IRF6 54 ALNDEINFL 3855 KRT7 55 KLLETKWTL 3855 KRT7 56 ILLRDLPTL400451 FAM174B 57 GLAHFVNEI 7750 ZMYM2 58 GLDSSVNVQGSVL 9589 WTAP 59WLSTSIPEA 2194 FASN 60 SLSDVRVIV 57186 RALGAPA2 61 VLLDNLPGV 27152 INTU62 GQLDFSEFL 6282 S100A11 63 LLAGLLVGV 54991 C1orf159 64 GLLSQGSPL 2729GCLC 65 IITDLLRSV 8880 FUBP1 66 SLWEENQAL 3911 LAMA5 67 FLTPPLLSV 160AP2A1 68 TMIVSLAAV 23204 ARL6IP1 69 QIWDKILSV 10202 DHRS2 70 KLAEISLGV1830 DSG3 71 LLSEDFVSV 64847 SPATA20 72 SLFTGLRSI 50506, 53905DUOX2, DUOX1 73 VLKVFLENV 121504, 554313, HIST1H4D, HIST1H4J,8294, 8359, 8360, HIST2H4B, HIST1H4L, 8361, 8362, 8363,HIST1H4H, HIST1H4K, 8364, 8365, 8366, HIST1H4A, HIST2H4A,8367, 8368, 8370 HIST1H4B, HIST1H4I, HIST4H4, HIST1H4E,HIST1H4C, HIST1H4F 74 LLQEGEVYSA 10594 PRPF8 75 RVISSVISV 64123 ELTD1 76AVVSSVNTV 6623 SNCG 77 KVFGGFQVV 3280 HES1 78 FIPDFAVAI 1293 COL6A3 79FLDPATPRV 7050 TGIF1 80 ILLDTPLFLL 253190, 94009 SERHL2 81 SLDKGTLYI79887 PLBD1 82 NLHNSYYSV 901 CCNG2 83 VILDKYYFL 56649 TMPRSS4 84ALDPASISV 54165 DCUN1D1 85 HLLDSKVPSV 3691 ITGB4 86 FLIJLIISV 50835TAS2R9 87 RLLELLQEA 150696 PROM2 88 ALASLENHV 51592 TRIM33 89 YLFPETEFI6926 TBX3 90 GMTELYFQL 5591 PRKDC 91 NLDAATYQV 23443 5LC35A3 92ALLDEQQVNVLL 3397 ID1 93 LLDLIQTKV 162, 163 AP2B1, AP1B1 94 ALADGVPVAL91056 AP5B1 95 YLIGQHVTA 23014 FBXO21 96 KLTNGIWVL 162 AP1B1 97TVGPGLLGV 7450 VWF 98 YLIGLDPENLAL 54677 CROT 99 ALIGDDVGL 55421C17orf85 100 SLQSFIHGV 79905 TMC7 101 ILDEMRAQL 4940 OAS3 102 GLYEGLDWL373, 375, 377, 378 ARF3, TRIM23, ARF1, ARF4 103 GLYSGEVLV 89891 WDR34104 NAVVELVTV 10159 ATP6AP2 105 TLFPSKIGV 55233, 92597 MOB1A, MOB1B 106ILLDTPLFL 253190, 94009 SERHL2 107 LULAKLEKV 51531 C9orf156 108YLDPNQRDL 126231 ZNF573

TABLE 2 Additional peptides according to the present invention SEQ IDOfficial No Sequence Gene ID(s) Gene Symbol(s) 109 RLIDDMVAQA 3417 IDH1110 VLFNIDGQGNHV 2625 GATA3 111 LLDVTPKAV 9414 TJP2 112 YLDPSLNSL 55086CXorf57 113 FVFEPPPGV 1778 DYNC1H1 114 IITKDLFQV 1778 DYNC1H1 115SLLDFERSL 84343 HPS3 116 QLAWFDTDL 1499 CTNNB1 117 YMLDIFHEVL 3038 HAS3118 RLLDFPTLLV 54627 MAP10 119 SLDEKQNLV 79828 METTL8 120 IIIPEIQKV 1434CSE1L 121 QLQGYLRSV 6128 RPL6 122 ILEPSLYTV 22818 COPZ1 123 NLAGVYSEV4733 DRG1 124 QIDGTLSTI 100307126, 128866, FBXO34, CHMP4C, CHMP4B,55030, 92421 CHMP4BP1 125 VLDEGSASV 1844 DUSP2 126 SLLRVGWSV221092, 26580 BSCL2, HNRNPUL2 127 KLNATNIEL 5686 PSMA5 128 KLWGQSIQL54823 SWT1 129 YLEPKLTQV 23198 PSME4 130 TLTSKLYSL 29796 UQCR10 131ILTSIQSLL 7319, 7320 UBE2A, UBE2B 132 YILEGEPGKV 6730 SRP68 133GLDPLGYEIQL 57122 NUP107 134 IVAPGTFEV 3608 ILF2 135 FLLPLIIVL 3140 MR1136 GLSEPIFQL 55669 MFN1 137 ALFPHLLQPVL 1434 CSE1L 138 YLTNEGIQYL100529239, 6204 RPS10-NUDT3, RPS10 139 LLYPTEITV 3675 ITGA3 140ALLDGRVQL 375790 AGRN 141 SMFGAGLTV 533 ATP6V0B 142 FLGENISNFL 8542APOL1 143 TLVTGLASV 55669 MFN1 144 YLAGEAPTL 7407 VARS 145 ALYPGQLVQL64333 ARHGAP9 146 YLARIQGFQV 27067 STAU2 147 QMLELITRL 23405 DICER1 148TLGVIPESV 84196 USP48 149 VLLRVLILL 102 ADAM10

TABLE 3 Peptides useful for e.g. personalized cancer therapies. SEQ IDOfficial No Sequence Gene ID(s) Gene Symbol(s) 150 SLFGQDVKAV 26036ZNF451 151 SLAEEKLQASV 2194 FASN 152 RLLDVLAPLV 80781 COL18A1 153GLLDPNVKSIFV 79033 ERI3 154 ILNVDGLIGV 47 ACLY 155 VLSSGLTAA 1459CSNK2A2 156 KLVEFDFLGA 10460 TACC3 157 KLLDTMVDTFL 100527963, 11243PMF1-BGLAP, PMF1 158 ILADTFIGV 222223 KIAA1324L 159 SLIEDLILL 64754SMYD3 160 SLLGGNIRL 2181 ACSL3 161 YLLEKFVAV 1663, 440081, 642846DDX11, DDX12P 162 TLLAAEFLKQV 100288772, 10574 CCT7P2, CCT7 163LLLEEGGLVQV 7353 UFD1L 164 ALADLTGTVV 23385 NCSTN 165 RLPDIPLRQV 55656INTS8 166 YLEPYLKEV 727947, 7381 UQCRB 167 SLWGGDVVL 157680 VPS13B 168LTAPPEALLMV 79050 NOC4L 169 LLIDDEYKV 23065 EMC1 170 GLIEIISNA 23020SNRNP200 171 ALPTVLVGV 5351 PLOD1 172 LLYGHTVTV 347734 SLC35B2 173FVFSFPVSV 1846 DUSP4 174 SLLEKELESV 1819 DRG2 175 FIQLITGV 477, 478ATP1A2, ATP1A3 176 SMSGYDQVL 3187, 3188 HNRNPH1, HNRNPH2 177 NLLQVLEKV144501 KRT80 178 ALNEEAGRLLL 27338 UBE2S 179 TLGQIWDV 1778 DYNC1H1 180GVIAEILRGV 10528 NOP56 181 YLGEGPRMV 5704 PSMC4 182 YLAPFLRNV 23019CNOT1 183 YVFPGVTRL 84221 SPATC1L 184 LMTKEISSV 5591 PRKDC 185GLSNLGIKSI 122553 TRAPPC6B 186 VLYPHEPTAV 29980, 5523 DONSON, PPP2R3A187 KLGAVFNQV 23450 SF3B3 188 KLFNEFIQL 10885 WDR3 189 ALLRTVVSV 2590GALNT2 190 LLFPHPVNQV 8518 IKBKAP 191 VLFQEALWHV 2194 FASN 192 ALNPADITV51497 TH1L 193 ALVQDLAKA 891 CCNB1 194 SLLSHQVLL 57221 KIAA1244 195ATLNIIHSV 51542 VP554 196 LLHEENFSV 6942 TCF20 197 LLLPDYYLV 27044 SND1198 NLIEKSIYL 667 DST 199 ALANQKLYSV 23195 MDN1 200 YLNVQVKEL 10051 SMC4201 KLLDEVTYLEA 1573 CYP2J2 202 TLITDGMRSV 29894 CPSF1 203 FLIPYAIML11254 SLC6A14 204 GVYDGEEHSV 4113 MAGEB2 205 KIVDFSYSV 701 BUB1B

The present invention furthermore generally relates to the peptidesaccording to the present invention for use in the treatment ofproliferative diseases, such as, for example, acute myelogenous leukemia(AML), breast cancer, bile duct cancer, brain cancer, chroniclymphocytic leukemia (CLL), colorectal carcinoma, esophageal cancer,gallbladder cancer, gastric cancer, hepatocellular cancer (HCC), Merkelcell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lungcancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer,renal cell cancer, small cell lung cancer (SCLC) and uterine cancer.

Particularly preferred are the peptides—alone or incombination—according to the present invention selected from the groupconsisting of SEQ ID NO: 1 to SEQ ID NO: 149. More preferred are thepeptides—alone or in combination—selected from the group consisting ofSEQ ID NO: 1 to SEQ ID NO: 48 (see Table 1), and their uses in theimmunotherapy of urinary bladder cancer, acute myelogenous leukemia(AML), breast cancer, bile duct cancer, brain cancer, chroniclymphocytic leukemia (CLL), colorectal carcinoma, esophageal cancer,gallbladder cancer, gastric cancer, hepatocellular cancer (HCC), Merkelcell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lungcancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer,renal cell cancer, small cell lung cancer (SCLC) and uterine cancer, andpreferably urinary bladder cancer.

As shown in the following Table 4, many of the peptides according to thepresent invention are also found on other tumor types and can, thus,also be used in the immunotherapy of other indications. Also refer toFIGS. 1A-1R and Example 1.

TABLE 4 Peptides according to the present invention and their specificuses in other proliferative diseases, especially in other cancerousdiseases. The table shows for selected peptides on which additionaltumor types they were found and either over-presented on more than5% of the measured tumor samples, or presented on more than 5% ofthe measured tumor samples with a ratio of geometric means tumorvs normal tissues being larger than three. Over-presentation isdefined as higher presentation on the tumor sample as comparedto the normal sample with highest presentation. Normal tissuesagainst which over-presentation was tested were: adipose tissue,adrenal gland, blood cells, blood vessel, bone marrow, brain,esophagus, eye, gallbladder, heart, kidney, large intestine,liver, lung, lymph node, nerve, pancreas, parathyroid gland,peritoneum, pituitary, pleura, salivary gland, skeletal muscle,skin, small intestine, spleen, stomach, thymus, thyroid gland,trachea, ureter, and urinary bladder. NSCLC = non-small cell lungcancer, SCLC = small cell lung cancer, RCC = kidney cancer,CRC = colon or rectum cancer, GC = stomach cancer, HCC = livercancer, PC = pancreatic cancer, PrC = prostate cancer,BrCa = breast cancer, MCC = Merkel cell carcinoma, OC = ovariancancer, NHL = non-Hodgkin lymphoma, AML = acute myelogenousleukemia, CLL = chronic lymphatic leukemia SEQ ID No. SequenceOther relevant organs/diseases 1 ILLQASVQVPC, Esophageal Cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer, HNSCC 2 GLLKAYSIRTANSCLC, BRCA, Esophageal Cancer, Uterine Cancer 3 YLDEIPPKFSMPrC, Uterine Cancer 4 SLDVVNLLV CRC, NHL, AML, BRCA, Melanoma, UterineCancer, HNSCC 5 IQDPVIFYV NHL, Uterine Cancer 6 SIVDFLITAUterine Cancer, HNSCC 7 QMFEGQILDVSCLC, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 9SLVDARFQL PrC 10 GLWHGMFANV NSCLC, SCLC, CRC, HCC, AML, OC, BrainCancer, HNSCC 11 AMAELRVVV HCC, BRCA, HNSCC 12 GVALTVTGVCLL, RCC, GC, HCC, NHL 13 FLEEKEQAAL NSCLC, HNSCC 14 GLAGPVRGVAML, Melanoma, HCC 15 YLAPENGYLMEASCLC, CRC, HCC, PrC, NHL, AML, Melanoma, Uterine Cancer, NSCLC, HNSCC 16ILGPQGNTI CLL, NHL, AML, Melanoma, Uterine Cancer 17 RLSQLEGVNVNSCLC, SCLC, RCC, HCC, Melanoma, Uterine Cancer, OC, HNSCC 18 SIAAYNPVVPC, NHL 20 YLPDSLTQL Melanoma, Uterine Cancer, HCC 21 TLIEDDALNGAMelanoma, Gallbladder Cancer, Bile Duct Cancer 23 YTLSKTEFLMelanoma, OC, Uterine Cancer, NSCLC, RCC, GC, HCC, NHL 24 SLLGGITVVMelanoma, Brain Cancer, Uterine Cancer 25 SLDSSGFSL CLL, Melanoma 26GLALLYSGV CLL, AML, BRCA, Melanoma, Uterine Cancer, HCC 27 STTNGGILTVBRCA 28 GLIDSLMAYV NSCLC, NHL, Melanoma, Esophageal Cancer, HNSCC 29ALSSPPPTV Brain Cancer, Esophageal Cancer, HNSCC 30 ILDISRSEVHCC, PC, Uterine Cancer 31 SLFDGIATGLBrain Cancer, HCC, AML, Melanoma, Uterine Cancer 32 YQAPDIDVQLGC, CLL, NHL, Melanoma 33 VLFGEITRL HCC, NHL, AML 34 ALLDEQQVNVRCC, Esophageal Cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer, Brain Cancer, HNSCC 35 KLPEPPPLAUterine Cancer 39 AMASHLTST HCC 41 FLDDGNQMLL Melanoma, HNSCC 45IIDSSPTAL HCC, Melanoma, Uterine Cancer 46 SLFIGAEIVAV CRC 49 SLIGGTNFVAML, BRCA, Melanoma 50 VLANRVAVV NHL 51 ALLDKAQINL SCLC, OC 53 ILVQVIPVVNSCLC, SCLC, PC, BRCA, Esophageal Cancer,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 55 KLLETKWTLOC, NSCLC 56 ILLRDLPTL HCC, PrC, NHL, BRCA, OC, Uterine Cancer 57GLAHFVNEI NSCLC, SCLC, Brain Cancer, CRC, HCC, PrC,NHL, AML, BRCA, Melanoma, Uterine Cancer 58 GLDSSVNVQGSVLNSCLC, HCC, NHL, Melanoma, OC, Uterine Cancer 59 WLSTSIPEASCLC, RCC, CRC, HCC, CLL, NHL, AML,BRCA, Melanoma, OC, Uterine Cancer, HNSCC 60 SLSDVRVIVCRC, HCC, Gallbladder Cancer, Bile Duct Cancer 61 VLLDNLPGVSCLC, Gallbladder Cancer, Bile Duct Cancer 62 GQLDFSEFLBrain Cancer, Melanoma 63 LLAGLLVGV SCLC 64 GLLSQGSPL HNSCC 65 IITDLLRSVPC, CLL, NHL, AML, Melanoma, OC 66 SLWEENQALBRCA, Esophageal Cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 67 FLTPPLLSVBrain Cancer, HCC, PrC, AML, BRCA,Melanoma, Esophageal Cancer, Uterine Cancer 68 TMIVSLAAVNSCLC, SCLC, Brain Cancer, CRC, NHL, AML,BRCA, Melanoma, Uterine Cancer, HNSCC 69 QIWDKILSV PC, NHL 70 KLAEISLGVNSCLC, BRCA, Esophageal Cancer, GallbladderCancer, Bile Duct Cancer, HNSCC 71 LLSEDFVSVBRCA, Melanoma, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 73VLKVFLENV GC, PC, AML, Melanoma, HCC, CLL, NHL 74 LLQEGEVYSACRC, HCC, CLL, NHL, AML, BRCA, MCC,Melanoma, Esophageal Cancer, OC, UterineCancer, Gallbladder Cancer, Bile Duct Cancer 77 KVFGGFQVVNSCLC, SCLC, Brain Cancer, PrC, RCC 78 FIPDFAVAINSCLC, SCLC, GC, BRCA, NHL 79 FLDPATPRV NSCLC, CLL, NHL, AML, Melanoma,Esophageal Cancer, OC, Gallbladder Cancer, Bile Duct Cancer, HNSCC 80ILLDTPLFLL CLL, AML, BRCA 83 VILDKYYFLCRC, Esophageal Cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer, PC, HNSCC 84 ALDPASISVHCC, Melanoma, Gallbladder Cancer, Bile Duct Cancer, NSCLC, BRCA, HNSCC85 HLLDSKVPSV NSCLC, SCLC, HCC, Esophageal Cancer, HNSCC 87 RLLELLQEABRCA, Esophageal Cancer, OC, Gallbladder Cancer, Bile Duct Cancer, HNSCC89 YLFPETEFI HCC, PrC 90 GMTELYFQL PC, HNSCC 91 NLDAATYQVCRC, HCC, BRCA, Uterine Cancer 92 ALLDEQQVNVLLRCC, Gallbladder Cancer, Bile Duct Cancer, HNSCC 93 LLDLIQTKVSCLC, CLL, NHL, Melanoma, OC 94 ALADGVPVALAML, Melanoma, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 95YLIGQHVTA RCC, Melanoma, OC, Uterine Cancer, HNSCC 96 KLTNGIWVLAML, Melanoma, NSCLC 97 TVGPGLLGVRCC, Brain Cancer, HCC, Melanoma, Uterine Cancer 98 YLIGLDPENLALBrain Cancer, HCC, HNSCC 99 ALIGDDVGLCRC, CLL, NHL, AML, Melanoma, NSCLC 100 SLQSFIHGV Brain Cancer, CRC 101ILDEMRAQL BRCA, Melanoma, Esophageal Cancer, Uterine Cancer, HNSCC 102GLYEGLDWL PC, AML 103 GLYSGEVLV BRCA, AML 104 NAVVELVTV GC, PC 105TLFPSKIGV Uterine Cancer 106 ILLDTPLFL HCC, BRCA, AML 108 YLDPNQRDLBrain Cancer, Melanoma 109 RLIDDMVAQAGallbladder Cancer, Bile Duct Cancer 110 VLFNIDGQGNHV BRCA, Melanoma 111LLDVTPKAV Brain Cancer, NHL, Melanoma, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer, HNSCC 112 YLDPSLNSL Brain Cancer113 FVFEPPPGV NHL, BRCA, Melanoma, HNSCC 114 IITKDLFQVUterine Cancer, Melanoma 115 SLLDFERSL HCC, BRCA, Melanoma 116 QLAWFDTDLRCC, CRC, HCC, BRCA, OC, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 117 YMLDIFHEVL HNSCC 118 RLLDFPTLLVAML, OC 119 SLDEKQNLV HNSCC 120 IIIPEIQKV GC, PC 121 QLQGYLRSVSCLC, CRC, HCC, NHL, Esophageal Cancer,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 122ILEPSLYTV NSCLC, GC, CRC, HCC, PC, PrC, NHL, AML,BRCA, Melanoma, Esophageal Cancer, OC,Uterine Cancer, Gallbladder Cancer, Bile DuctCancer, Brain Cancer, HNSCC 123 NLAGVYSEVMelanoma, Esophageal Cancer, Uterine Cancer 124 QIDGTLSTIAML, Brain Cancer 125 VLDEGSASV CRC, NHL, Esophageal Cancer, CLL 126SLLRVGWSV NSCLC, SCLC, Brain Cancer, GC, HCC, PrC,CLL, NHL, AML, Melanoma, OC, HNSCC 127 KLNATNIEL BRCA, Esophageal Cancer128 KLWGQSIQL NHL, AML, Esophageal Cancer, HNSCC 129 YLEPKLTQVNSCLC, SCLC, HCC, AML, Melanoma, UterineCancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 131 ILTSIQSLLCLL, NHL, Uterine Cancer, Gallbladder Cancer,Bile Duct Cancer, HCC, AML, HNSCC 132 YILEGEPGKVSCLC, Melanoma, Esophageal Cancer, HCC, HNSCC 133 GLDPLGYEIQLSCLC, RCC, CLL, NHL, AML, BRCA, OC,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 134IVAPGTFEV RCC, Brain Cancer, HCC, CLL, NHL, AML,BRCA, Melanoma, Esophageal Cancer, Uterine Cancer, GC 135 FLLPLIIVLNHL, PrC, CLL, Melanoma, AML, HNSCC 136 GLSEPIFQL Melanoma 137ALFPHLLQPVL NSCLC, SCLC, RCC, HCC, CLL, MCC,Melanoma, OC, PC, PrC, HNSCC 138 YLTNEGIQYLSCLC, CLL, NHL, Melanoma, EsophagealCancer, OC, Gallbladder Cancer, Bile Duct Cancer, NSCLC, HNSCC 139LLYPTEITV RCC, Melanoma, Esophageal Cancer,Gallbladder Cancer, Bile Duct Cancer, HNSCC 140 ALLDGRVQLNSCLC, SCLC, RCC, Brain Cancer, GC, CRC,HCC, PC, PrC, CLL, AML, BRCA, Melanoma,Esophageal Cancer, OC, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 141 SMFGAGLTVGC, HCC, PC, AML, BRCA, Melanoma 142 FLGENISNFLNSCLC, SCLC, GC, PC, Melanoma, UterineCancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 143 TLVTGLASVSCLC, CLL, NHL, BRCA, Melanoma, OC,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer, HNSCC 144YLAGEAPTL HCC, CLL, NHL, AML, Melanoma, Uterine Cancer, HNSCC 145ALYPGQLVQL CLL, AML, NHL 146 YLARIQGFQV OC, AML, NHL 147 QMLELITRLCLL, Melanoma, AML, NHL 148 TLGVIPESVSCLC, Brain Cancer, CLL, Melanoma, OC,Esophageal Cancer, Uterine Cancer, GallbladderCancer, Bile Duct Cancer, AML, NHL, HNSCC 149 VLLRVLILLPC, CLL, BRCA, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 1, 7, 21, 34, 53, 60, 61, 66, 70, 74, 79, 83, 84, 87,92, 109, 111, 116, 121, 122, 129, 138, 139, 140, 142, 143, 148, and 149for the—in one preferred embodiment combined—treatment of gallbladdercancer and/or bile duct cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 2, 4, 11, 26, 27, 49, 53, 57, 59, 66, 67, 68, 70, 74,78, 80, 84, 87, 101, 103, 106, 110, 113, 115, 116, 122, 127, 133, 134,140, 141, 143, and 149 for the—in one preferred embodimentcombined—treatment of BRCA.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 4, 14, 15, 16, 17, 20, 21, 23, 24, 25, 26, 28, 31, 32,41, 45, 49, 57, 58, 59, 62, 65, 67, 68, 71, 73, 74, 79, 84, 93, 94, 95,96, 97, 99, 101, 108, 110, 111, 113, 114, 115, 122, 123, 126, 129, 132,134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 147, and 148 forthe—in one preferred embodiment combined—treatment of melanoma.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 1, 18, 30, 53, 65, 69, 73, 83, 90, 102, 104, 120, 122,137, 140, 141, 142, and 149 for the—in one preferred embodimentcombined—treatment of PC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 1, 2, 28, 29, 34, 53, 66, 67, 70, 74, 79, 83, 85, 86,101, 121, 122, 123, 125, 127, 128, 132, 134, 138, 139, 140, and 148 forthe—in one preferred embodiment combined—treatment of esophageal cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 1, 3, 4, 5, 6, 7, 15, 16, 17, 20, 23, 24, 26, 30, 31,34, 35, 45, 53, 56, 57, 58, 59, 66, 67, 68, 71, 74, 83, 91, 94, 95, 97,101, 105, 111, 114, 116, 121, 122, 123, 131, 133, 134, 140, 142, 143,144, 148, and 149 for the—in one preferred embodiment combined—treatmentof uterine cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 2, 10, 13, 15, 17, 23, 28, 53, 55, 57, 58, 68, 70, 77,78, 79, 84, 85, 96, 99, 122, 126, 129, 137, 138, 140, and 142 for the—inone preferred embodiment combined—treatment of NSCLC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 10, 24, 29, 30, 34, 57, 62, 67, 68, 77, 97, 98, 100,108, 111, 112, 122, 124, 126, 134, 140, and 148 for the—in one preferredembodiment combined—treatment of brain cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 4, 5, 12, 15, 16, 18, 23, 28, 32, 33, 50, 56, 57, 58,59, 65, 68, 69, 73, 74, 78, 79, 93, 99, 111, 113, 121, 122, 125, 126,128, 131, 133, 134, 135, 138, 143, 144, 145, 146, 147, and 148 forthe—in one preferred embodiment combined—treatment of NHL.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 4, 10, 15, 46, 57, 59, 60, 68, 91, 99, 100, 116, 121,and 122 for the—in one preferred embodiment combined—treatment of CRC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 4, 10, 14, 15, 16, 26, 31, 33, 49, 57, 65, 67, 68, 73,74, 79, 80, 94, 96, 99, 102, 103, 106, 118, 122, 124, 126, 128, 129,131, 133, 134, 135, 140, 141, 144, 145, 146, 147, and 148 for the—in onepreferred embodiment combined—treatment of AML.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 3, 9, 15, 56, 57, 67, 89, 122, 126, 135, 137, and 140for the—in one preferred embodiment combined—treatment of PrC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 10, 11, 12, 14, 15, 17, 20, 23, 26, 30, 31, 33, 39,45, 56, 57, 58, 59, 60, 67, 73, 74, 84, 85, 89, 91, 97, 98, 106, 115,116, 121, 122, 126, 129, 131, 132, 134, 137, 140, 141, and 144 forthe—in one preferred embodiment combined—treatment of HCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 10, 17, 23, 51, 55, 56, 58, 59, 65, 74, 79, 87, 93,95, 116, 118, 122, 126, 133, 137, 138, 140, 143, 146, and 148 for the—inone preferred embodiment combined—treatment of OC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 12, 17, 23, 34, 59, 77, 92, 95, 97, 116, 133, 134,137, 139, and 140 for the—in one preferred embodiment combined—treatmentof RCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 7, 10, 15, 17, 51, 53, 57, 59, 61, 63, 68, 77, 78, 85,93, 121, 126, 129, 132, 133, 137, 138, 140, 142, 143, and 148 for the—inone preferred embodiment combined—treatment of SCLC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 1, 4, 6, 7, 10, 11, 13, 15, 17, 28, 29, 34, 41, 53,59, 64, 68, 70, 79, 83, 84, 85, 90, 92, 95, 98, 101, 111, 113, 117, 119,121, 122, 126, 128, 129, 131, 132, 133, 135, 137, 138, 139, 142, 143,144, and 148 for the—in one preferred embodiment combined—treatment ofHNSCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 12, 23, 32, 73, 78, 104, 120, 122, 126, 134, 140, 141,and 142 for the—in one preferred embodiment combined—treatment of GC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID No. 12, 16, 25, 26, 32, 59, 65, 73, 74, 79, 80, 93, 99,125, 126, 131, 133, 134, 135, 137, 138, 140, 143, 144, 145, 147, 148,and 149 for the—in one preferred embodiment combined—treatment of CLL.

Thus, another aspect of the present invention relates to the use of thepeptides according to the present invention for the—preferablycombined—treatment of a proliferative disease selected from the group ofurinary bladder cancer, acute myelogenous leukemia (AML), breast cancer,bile duct cancer, brain cancer, chronic lymphocytic leukemia (CLL),colorectal carcinoma, esophageal cancer, gallbladder cancer, gastriccancer, hepatocellular cancer (HCC), Merkel cell carcinoma, melanoma,non-Hodgkin lymphoma, non-small cell lung cancer (NSCLC), ovariancancer, pancreatic cancer, prostate cancer, renal cell cancer, smallcell lung cancer (SCLC) and uterine cancer.

The present invention furthermore relates to peptides according to thepresent invention that have the ability to bind to a molecule of thehuman major histocompatibility complex (MHC) class-I or—in an elongated(longer) form, such as a length-variant—MHC class-II.

The present invention further relates to the peptides according to thepresent invention wherein said peptides (each) consist or consistessentially of an amino acid sequence according to SEQ ID NO: 1 to SEQID NO: 149.

The present invention further relates to the peptides according to thepresent invention, wherein said peptide is modified and/or includesnon-peptide bonds.

The present invention further relates to the peptides according to thepresent invention, wherein said peptide is part of a fusion protein, inparticular fused to the N-terminal amino acids of the HLA-DRantigen-associated invariant chain (Ii), or fused to (or into thesequence of) an antibody, such as, for example, an antibody that isspecific for dendritic cells.

The present invention further relates to a nucleic acid, encoding thepeptides according to the present invention. The present inventionfurther relates to the nucleic acid according to the present inventionthat is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable ofexpressing and/or expressing a nucleic acid according to the presentinvention.

The present invention further relates to a peptide according to thepresent invention, a nucleic acid according to the present invention oran expression vector according to the present invention for use in thetreatment of diseases and in medicine, in particular in the treatment ofcancer.

The present invention further relates to antibodies that are specificagainst the peptides according to the present invention or complexes ofsaid peptides according to the present invention with MHC, and methodsof making these.

The present invention further relates to T-cell receptors (TCRs), inparticular soluble TCR (sTCRs) and cloned TCRs engineered intoautologous or allogeneic T cells, and methods of making these, as wellas NK cells or other cells bearing said TCR or cross-reacting with saidTCRs.

The antibodies and TCRs are additional embodiments of theimmunotherapeutic use of the peptides according to the invention athand.

The present invention further relates to a host cell comprising anucleic acid according to the present invention or an expression vectoras described before. The present invention further relates to the hostcell according to the present invention that is an antigen presentingcell, and preferably is a dendritic cell.

The present invention further relates to a method for producing apeptide according to the present invention, said method comprisingculturing the host cell according to the present invention, andisolating the peptide from said host cell or its culture medium.

The present invention further relates to said method according to thepresent invention, wherein the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellor artificial antigen-presenting cell by contacting a sufficient amountof the antigen with an antigen-presenting cell.

The present invention further relates to the method according to thepresent invention, wherein the antigen-presenting cell comprises anexpression vector capable of expressing or expressing said peptidecontaining SEQ ID No. 1 to SEQ ID No.: 149, preferably containing SEQ IDNo. 1 to SEQ ID No. 48, or a variant amino acid sequence.

The present invention further relates to activated T cells, produced bythe method according to the present invention, wherein said T cellselectively recognizes a cell which expresses a polypeptide comprisingan amino acid sequence according to the present invention.

The present invention further relates to a method of killing targetcells in a patient which target cells aberrantly express a polypeptidecomprising any amino acid sequence according to the present invention,the method comprising administering to the patient an effective numberof T cells as produced according to the present invention.

The present invention further relates to the use of any peptide asdescribed, the nucleic acid according to the present invention, theexpression vector according to the present invention, the cell accordingto the present invention, the activated T lymphocyte, the T cellreceptor or the antibody or other peptide- and/or peptide-MHC-bindingmolecules according to the present invention as a medicament or in themanufacture of a medicament. Preferably, said medicament is activeagainst cancer.

Preferably, said medicament is a cellular therapy, a vaccine or aprotein based on a soluble TCR or antibody.

The present invention further relates to a use according to the presentinvention, wherein said cancer cells are urinary bladder cancer, acutemyelogenous leukemia (AML), breast cancer, bile duct cancer, braincancer, chronic lymphocytic leukemia (CLL), colorectal carcinoma,esophageal cancer, gallbladder cancer, gastric cancer, hepatocellularcancer (HCC), Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma,non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer,prostate cancer, renal cell cancer, small cell lung cancer (SCLC) anduterine cancer, and preferably urinary bladder cancer cells.

The present invention further relates to biomarkers based on thepeptides according to the present invention, herein called “targets”that can be used in the diagnosis of cancer, preferably urinary bladdercancer. The marker can be over-presentation of the peptide(s)themselves, or over-expression of the corresponding gene(s). The markersmay also be used to predict the probability of success of a treatment,preferably an immunotherapy, and most preferred an immunotherapytargeting the same target that is identified by the biomarker. Forexample, an antibody or soluble TCR can be used to stain sections of thetumor to detect the presence of a peptide of interest in complex withMHC. Optionally, the antibody carries a further effector function suchas an immune stimulating domain or toxin.

The present invention also relates to the use of these novel targets inthe context of cancer treatment.

ARF1 was shown to be over-expressed in highly invasive breast cancercell lines and breast tumors of the most aggressive and advancedsubtypes, and to play a key role in the invasion of breast cancer cellsthrough the regulation of the Rho/MLC pathway. Thus, lowered expressionof ARF1 was shown to impair growth of primary breast tumors and inhibitslung metastasis in murine xenograft model. Over-expression of ARF1 inthe MCF7 (ER+) breast cancer cell line was shown to lead toepithelial-mesenchymal transition, whereby ARF1 was shown to controlcell-cell adhesion, oncogenic Ras activation and expression of EMTinducers (Schlienger et al., 2016; Schlienger et al., 2014). ARF1 wasshown to be up-regulated in prostate cancer. Aberrant oncogenic MAPKsignaling in prostate cancer was shown to be, at least in part, underthe control of ARF1, suggesting that ARF1 is a critical regulator inprostate cancer progression, and thus may represent a key moleculartarget for prostate cancer therapeutics and diagnosis (Davis et al.,2016).

ARF3 was shown to be a gene with de-regulated expression which islocated within a breakpoint region in the radiation-transformedepithelial breast cancer cell lines B42-11 and B42-16 (Unger et al.,2010). ARF3 was shown to be down-regulated in primary gastric cancer(Chang et al., 2009).

ARF4 was shown being implicated in lung adenocarcinoma (Bidkhori et al.,2013). ARF4 was described as a mediator of the EGF-dependent signalpathway. Whereby, the regulation of ARF4 was shown to be involved inbreast cancer cell migration, indicating that ARF4 may serve as apotential therapeutic target for treating breast cancer invasion andmetastasis (Jang et al., 2012).

COL6A3 mutation(s) significantly predicted a better overall survival inpatients with colorectal carcinoma independent of tumor differentiationand TNM staging (Yu et al., 2015). COL6A3 expression was reported to beincreased in pancreatic cancer, colon cancer, gastric cancer,mucoepidermoid carcinomas and ovarian cancer. Cancer associatedtranscript variants including exons 3, 4 and 6 were detected in coloncancer, bladder cancer, prostate cancer and pancreatic cancer (Arafat etal., 2011; Smith et al., 2009; Yang et al., 2007; Xie et al., 2014;Leivo et al., 2005; Sherman-Baust et al., 2003; Gardina et al., 2006;Thorsen et al., 2008). In ovarian cancer COL6A3 levels correlated withhigher tumor grade and in pancreatic cancer COL6A3 was shown torepresent a suitable diagnostic serum biomarker (Sherman-Baust et al.,2003; Kang et al., 2014).

IDH1 mutation was described as an important prognostic marker in gliomaand was shown to be common in grade II-Ill glioma and secondaryglioblastoma. Thus, mutant IDH1 might play a critical role in the cellproliferation and angiogenesis of glioma (Zhang et al., 2015b; Shi etal., 2016). IDH1 and several other mutations were described as recurrentmolecular genetic alterations that occur concurrently with1p/19q-codeletion and allow the identification of oligodendrogliomas(Cahill et al., 2015). A novel metabolic-related IDH1 mutation was shownto be associated with metastatic pancreatic cancer and described as arare opportunity for a targeted therapy as a treatment option forpancreatic ductal adenocarcinoma (Brody et al., 2016).

Studies have shown that the level of LAMAS was elevated in basal cellcarcinoma, cervical cancer and breast carcinoma (Simonova et al., 2015;Scotto et al., 2008; Mostafa et al., 2010; Georgiou et al., 2013).

LRRC1 was shown to be aberrantly up-regulated in hepatocellularcarcinoma specimens compared with adjacent non-cancerous livers (Li etal., 2013).

NUP107 encodes nucleoporin 107, a member of the nucleoporin family. Itis an essential component of the nuclear pore complex (RefSeq, 2002).Fusion of MDM1-NUP107 was identified as a recurrent alternative splicingevent in portal vein tumor thrombus, the most serious complication ofhepatocellular carcinoma, compared to the corresponding hepatocellularcarcinoma samples. NUP107 was shown to be up-regulated in pancreaticcell line with a high potential of invasion-metastasis compared toanother pancreatic cell line with a low potential (Zhang et al., 2015a;Tan et al., 2010).

OSR1 is methylated in gastric cancer causing its down-regulation whichis correlated with poor survival. OSR1 over-expression inhibits cellgrowth resulting in cell cycle arrest and induced apoptotic cell deathin gastric cancer cell lines. Furthermore, OSR1 induces p53, p21, Fas,and death receptor-5 transcription and repressed the expression ofTCF-1, cyclin D1, cyclin-dependent kinase 4, cytoplasmic beta-catenin,and LEF1 (Otani et al., 2014; Huang et al., 2004). OSR1 isdifferentially methylated in lung adenocarcinoma and may be used asbiomarker (Rauch et al., 2012; Daugaard et al., 2016). OSR1 is a markerfor intermediate mesoderm (Zhang et al., 2011; So and Danielian, 1999;Oeda et al., 2013). Arsen targets stem cells and partiallydifferentiated progenitor cells for oncogenic transformation resultingin over-expression of OSR1 (Tokar et al., 2013).

PKP1 was shown to be down-regulated in prostate cancer and esophagealadenocarcinoma (Kaz et al., 2012; Yang et al., 2015). Knock-down of PKP1in the non-neoplastic, prostatic BPH-1 cell line led to reducedapoptosis and differential expression of genes such as the prostatecancer-associated SPOCK1 gene (Yang et al., 2015). Collectively, alteredexpression of PKP1 and SPOCK1 appears to be frequent and critical eventin prostate cancer and PKP1 is suggested to have a tumor-suppressivefunction (Yang et al., 2015). Reduced expression of PKP1 was shown to beassociated with significantly shorter time to onset of distantmetastasis in oral cavity squamous cell carcinoma (Harris et al., 2015).PKP1 loss through promoter methylation was described to be associatedwith the progression of Barrett's esophagus to esophageal adenocarcinoma(Kaz et al., 2012). PKP1 was shown to be up-regulated in non-small celllung cancer and may be a good marker to distinguish squamous-cellcarcinomas samples (Sanchez-Palencia et al., 2011). PKP1 was shown to beup-regulated in the well-differentiated liposarcoma cell line GOT3(Persson et al., 2008). Decreased PKP1 expression was described topromote increased motility in head and neck squamous cell carcinomacells (Sobolik-Delmaire et al., 2007). PKP1 loss was shown to beassociated with cervical carcinogenesis (Schmitt-Graeff et al., 2007).PKP1 was shown to be associated with local recurrences or metastases aswell as poor survival in patients with squamous cell carcinoma of theoropharynx (Papagerakis et al., 2003).

Stimulation of an immune response is dependent upon the presence ofantigens recognized as foreign by the host immune system. The discoveryof the existence of tumor associated antigens has raised the possibilityof using a host's immune system to intervene in tumor growth. Variousmechanisms of harnessing both the humoral and cellular arms of theimmune system are currently being explored for cancer immunotherapy.

Specific elements of the cellular immune response are capable ofspecifically recognizing and destroying tumor cells. The isolation ofT-cells from tumor-infiltrating cell populations or from peripheralblood suggests that such cells play an important role in natural immunedefense against cancer. CD8-positive T-cells in particular, whichrecognize class I molecules of the major histocompatibility complex(MHC)-bearing peptides of usually 8 to 10 amino acid residues derivedfrom proteins or defect ribosomal products (DRIPS) located in thecytosol, play an important role in this response. The MHC-molecules ofthe human are also designated as human leukocyte-antigens (HLA).

The term “T-cell response” means the specific proliferation andactivation of effector functions induced by a peptide in vitro or invivo. For MHC class I restricted cytotoxic T cells, effector functionsmay be lysis of peptide-pulsed, peptide-precursor pulsed or naturallypeptide-presenting target cells, secretion of cytokines, preferablyInterferon-gamma, TNF-alpha, or IL-2 induced by peptide, secretion ofeffector molecules, preferably granzymes or perforins induced bypeptide, or degranulation.

The term “peptide” is used herein to designate a series of amino acidresidues, connected one to the other typically by peptide bonds betweenthe alpha-amino and carbonyl groups of the adjacent amino acids. Thepeptides are preferably 9 amino acids in length, but can be as short as8 amino acids in length, and as long as 10, 11, 12, 13, 14 or 15 orlonger, and in case of MHC class II peptides (elongated variants of thepeptides of the invention) they can be as long as 16, 17, 18, 19, 20, 21or 22 or more amino acids in length.

Furthermore, the term “peptide” shall include salts of a series of aminoacid residues, connected one to the other typically by peptide bondsbetween the alpha-amino and carbonyl groups of the adjacent amino acids.Preferably, the salts are pharmaceutical acceptable salts of thepeptides, such as, for example, the chloride or acetate(trifluoroacetate) salts. It has to be noted that the salts of thepeptides according to the present invention differ substantially fromthe peptides in their state(s) in vivo, as the peptides are not salts invivo.

The term “peptide” shall also include “oligopeptide”. The term“oligopeptide” is used herein to designate a series of amino acidresidues, connected one to the other typically by peptide bonds betweenthe alpha-amino and carbonyl groups of the adjacent amino acids. Thelength of the oligopeptide is not critical to the invention, as long asthe correct epitope or epitopes are maintained therein. Theoligopeptides are typically less than about 30 amino acid residues inlength, and greater than about 15 amino acids in length.

The term “polypeptide” designates a series of amino acid residues,connected one to the other typically by peptide bonds between thealpha-amino and carbonyl groups of the adjacent amino acids. The lengthof the polypeptide is not critical to the invention as long as thecorrect epitopes are maintained. In contrast to the terms peptide oroligopeptide, the term polypeptide is meant to refer to moleculescontaining more than about 30 amino acid residues.

A peptide, oligopeptide, protein or polynucleotide coding for such amolecule is “immunogenic” (and thus is an “immunogen” within the presentinvention), if it is capable of inducing an immune response. In the caseof the present invention, immunogenicity is more specifically defined asthe ability to induce a T-cell response. Thus, an “immunogen” would be amolecule that is capable of inducing an immune response, and in the caseof the present invention, a molecule capable of inducing a T-cellresponse. In another aspect, the immunogen can be the peptide, thecomplex of the peptide with MHC, oligopeptide, and/or protein that isused to raise specific antibodies or TCRs against it.

A class I T cell “epitope” requires a short peptide that is bound to aclass I MHC receptor, forming a ternary complex (MHC class I alphachain, beta-2-microglobulin, and peptide) that can be recognized by a Tcell bearing a matching T-cell receptor binding to the MHC/peptidecomplex with appropriate affinity. Peptides binding to MHC class Imolecules are typically 8-14 amino acids in length, and most typically 9amino acids in length.

In humans there are three different genetic loci that encode MHC class Imolecules (the MHC-molecules of the human are also designated humanleukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02,and HLA-B*07 are examples of different MHC class I alleles that can beexpressed from these loci.

TABLE 5 Expression frequencies F of HLA-A*02 and HLA-A*24 and the mostfrequent HLA-DR serotypes. Frequencies are deduced from haplotypefrequencies Gf within the American population adapted from Mori et al.(Mori et al., 1997) employing the Hardy-Weinberg formula F = 1 −(1-Gf)². Combinations of A*02 or A*24 with certain HLA-DR alleles mightbe enriched or less frequent than expected from their single frequenciesdue to linkage disequilibrium. For details refer to Chanock et al.(Chanock et al., 2004). Calculated phenotype from allele AllelePopulation frequency A*02 Caucasian (North America)  49.1% A*02 AfricanAmerican (North America)  34.1% A*02 Asian American (North America) 43.2% A*02 Latin American (North American)  48.3% DR1 Caucasian (NorthAmerica)  19.4% DR2 Caucasian (North America)  28.2% DR3 Caucasian(North America)  20.6% DR4 Caucasian (North America)  30.7% DR5Caucasian (North America)  23.3% DR6 Caucasian (North America)  26.7%DR7 Caucasian (North America)  24.8% DR8 Caucasian (North America)  5.7%DR9 Caucasian (North America)  2.1% DR1 African (North) American 13.20%DR2 African (North) American 29.80% DR3 African (North) American 24.80%DR4 African (North) American 11.10% DR5 African (North) American 31.10%DR6 African (North) American 33.70% DR7 African (North) American 19.20%DR8 African (North) American 12.10% DR9 African (North) American  5.80%DR1 Asian (North) American  6.80% DR2 Asian (North) American 33.80% DR3Asian (North) American  9.20% DR4 Asian (North) American 28.60% DR5Asian (North) American 30.00% DR6 Asian (North) American 25.10% DR7Asian (North) American 13.40% DR8 Asian (North) American 12.70% DR9Asian (North) American 18.60% DR1 Latin (North) American 15.30% DR2Latin (North) American 21.20% DR3 Latin (North) American 15.20% DR4Latin (North) American 36.80% DR5 Latin (North) American 20.00% DR6Latin (North) American 31.10% DR7 Latin (North) American 20.20% DR8Latin (North) American 18.60% DR9 Latin (North) American  2.10% A*24Philippines   65% A*24 Russia Nenets   61% A*24:02 Japan   59% A*24Malaysia   58% A*24:02 Philippines   54% A*24 India   47% A*24 SouthKorea   40% A*24 Sri Lanka   37% A*24 China   32% A*24:02 India   29%A*24 Australia West   22% A*24 USA   22% A*24 Russia Samara   20% A*24South America   20% A*24 Europe   18%

The peptides of the invention, preferably when included into a vaccineof the invention as described herein bind to A*02. A vaccine may alsoinclude pan-binding MHC class II peptides. Therefore, the vaccine of theinvention can be used to treat cancer in patients that are A*02positive, whereas no selection for MHC class II allotypes is necessarydue to the pan-binding nature of these peptides.

If A*02 peptides of the invention are combined with peptides binding toanother allele, for example A*24, a higher percentage of any patientpopulation can be treated compared with addressing either MHC class Iallele alone. While in most populations less than 50% of patients couldbe addressed by either allele alone, a vaccine comprising HLA-A*24 andHLA-A*02 epitopes can treat at least 60% of patients in any relevantpopulation. Specifically, the following percentages of patients will bepositive for at least one of these alleles in various regions: USA 61%,Western Europe 62%, China 75%, South Korea 77%, Japan 86% (calculatedfrom www.allelefrequencies.net).

In a preferred embodiment, the term “nucleotide sequence” refers to aheteropolymer of deoxyribonucleotides.

The nucleotide sequence coding for a particular peptide, oligopeptide,or polypeptide may be naturally occurring or they may be syntheticallyconstructed. Generally, DNA segments encoding the peptides,polypeptides, and proteins of this invention are assembled from cDNAfragments and short oligonucleotide linkers, or from a series ofoligonucleotides, to provide a synthetic gene that is capable of beingexpressed in a recombinant transcriptional unit comprising regulatoryelements derived from a microbial or viral operon.

As used herein the term “a nucleotide coding for (or encoding) apeptide” refers to a nucleotide sequence coding for the peptideincluding artificial (man-made) start and stop codons compatible for thebiological system the sequence is to be expressed by, for example, adendritic cell or another cell system useful for the production of TCRs.

As used herein, reference to a nucleic acid sequence includes bothsingle stranded and double stranded nucleic acid. Thus, for example forDNA, the specific sequence, unless the context indicates otherwise,refers to the single strand DNA of such sequence, the duplex of suchsequence with its complement (double stranded DNA) and the complement ofsuch sequence.

The term “coding region” refers to that portion of a gene which eithernaturally or normally codes for the expression product of that gene inits natural genomic environment, i.e., the region coding in vivo for thenative expression product of the gene.

The coding region can be derived from a non-mutated (“normal”), mutatedor altered gene, or can even be derived from a DNA sequence, or gene,wholly synthesized in the laboratory using methods well known to thoseof skill in the art of DNA synthesis.

The term “expression product” means the polypeptide or protein that isthe natural translation product of the gene and any nucleic acidsequence coding equivalents resulting from genetic code degeneracy andthus coding for the same amino acid(s).

The term “fragment”, when referring to a coding sequence, means aportion of DNA comprising less than the complete coding region, whoseexpression product retains essentially the same biological function oractivity as the expression product of the complete coding region.

The term “DNA segment” refers to a DNA polymer, in the form of aseparate fragment or as a component of a larger DNA construct, which hasbeen derived from DNA isolated at least once in substantially pure form,i.e., free of contaminating endogenous materials and in a quantity orconcentration enabling identification, manipulation, and recovery of thesegment and its component nucleotide sequences by standard biochemicalmethods, for example, by using a cloning vector. Such segments areprovided in the form of an open reading frame uninterrupted by internalnon-translated sequences, or introns, which are typically present ineukaryotic genes. Sequences of non-translated DNA may be presentdownstream from the open reading frame, where the same do not interferewith manipulation or expression of the coding regions.

The term “primer” means a short nucleic acid sequence that can be pairedwith one strand of DNA and provides a free 3′-OH end at which a DNApolymerase starts synthesis of a deoxyribonucleotide chain.

The term “promoter” means a region of DNA involved in binding of RNApolymerase to initiate transcription.

The term “isolated” means that the material is removed from its originalenvironment (e.g., the natural environment, if it is naturallyoccurring). For example, a naturally-occurring polynucleotide orpolypeptide present in a living animal is not isolated, but the samepolynucleotide or polypeptide, separated from some or all of thecoexisting materials in the natural system, is isolated. Suchpolynucleotides could be part of a vector and/or such polynucleotides orpolypeptides could be part of a composition, and still be isolated inthat such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides,disclosed in accordance with the present invention may also be in“purified” form. The term “purified” does not require absolute purity;rather, it is intended as a relative definition, and can includepreparations that are highly purified or preparations that are onlypartially purified, as those terms are understood by those of skill inthe relevant art. For example, individual clones isolated from a cDNAlibrary have been conventionally purified to electrophoretichomogeneity. Purification of starting material or natural material to atleast one order of magnitude, preferably two or three orders, and morepreferably four or five orders of magnitude is expressly contemplated.Furthermore, a claimed polypeptide which has a purity of preferably99.999%, or at least 99.99% or 99.9%; and even desirably 99% by weightor greater is expressly encompassed.

The nucleic acids and polypeptide expression products disclosedaccording to the present invention, as well as expression vectorscontaining such nucleic acids and/or such polypeptides, may be in“enriched form”. As used herein, the term “enriched” means that theconcentration of the material is at least about 2, 5, 10, 100, or 1000times its natural concentration (for example), advantageously 0.01%, byweight, preferably at least about 0.1% by weight. Enriched preparationsof about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. Thesequences, constructs, vectors, clones, and other materials comprisingthe present invention can advantageously be in enriched or isolatedform. The term “active fragment” means a fragment, usually of a peptide,polypeptide or nucleic acid sequence, that generates an immune response(i.e., has immunogenic activity) when administered, alone or optionallywith a suitable adjuvant or in a vector, to an animal, such as a mammal,for example, a rabbit or a mouse, and also including a human, suchimmune response taking the form of stimulating a T-cell response withinthe recipient animal, such as a human. Alternatively, the “activefragment” may also be used to induce a T-cell response in vitro.

As used herein, the terms “portion”, “segment” and “fragment”, when usedin relation to polypeptides, refer to a continuous sequence of residues,such as amino acid residues, which sequence forms a subset of a largersequence. For example, if a polypeptide were subjected to treatment withany of the common endopeptidases, such as trypsin or chymotrypsin, theoligopeptides resulting from such treatment would represent portions,segments or fragments of the starting polypeptide. When used in relationto polynucleotides, these terms refer to the products produced bytreatment of said polynucleotides with any of the endonucleases.

In accordance with the present invention, the term “percent identity” or“percent identical”, when referring to a sequence, means that a sequenceis compared to a claimed or described sequence after alignment of thesequence to be compared (the “Compared Sequence”) with the described orclaimed sequence (the “Reference Sequence”). The percent identity isthen determined according to the following formula:

percent identity=100[1−(C/R)]

wherein C is the number of differences between the Reference Sequenceand the Compared Sequence over the length of alignment between theReference Sequence and the Compared Sequence, wherein

(i) each base or amino acid in the Reference Sequence that does not havea corresponding aligned base or amino acid in the Compared Sequence and

(ii) each gap in the Reference Sequence and

(iii) each aligned base or amino acid in the Reference Sequence that isdifferent from an aligned base or amino acid in the Compared Sequence,constitutes a difference and

(iiii) the alignment has to start at position 1 of the alignedsequences;

and R is the number of bases or amino acids in the Reference Sequenceover the length of the alignment with the Compared Sequence with any gapcreated in the Reference Sequence also being counted as a base or aminoacid.

If an alignment exists between the Compared Sequence and the ReferenceSequence for which the percent identity as calculated above is aboutequal to or greater than a specified minimum Percent Identity then theCompared Sequence has the specified minimum percent identity to theReference Sequence even though alignments may exist in which the hereinabove calculated percent identity is less than the specified percentidentity.

As mentioned above, the present invention thus provides a peptidecomprising a sequence that is selected from the group of consisting ofSEQ ID NO: 1 to SEQ ID NO: 149 or a variant thereof which is 88%homologous to SEQ ID NO: 1 to SEQ ID NO: 149, or a variant thereof thatwill induce T cells cross-reacting with said peptide. The peptides ofthe invention have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class-! or elongated versions of saidpeptides to class II.

In the present invention, the term “homologous” refers to the degree ofidentity (see percent identity above) between sequences of two aminoacid sequences, i.e. peptide or polypeptide sequences. Theaforementioned “homology” is determined by comparing two sequencesaligned under optimal conditions over the sequences to be compared. Sucha sequence homology can be calculated by creating an alignment using,for example, the ClustalW algorithm. Commonly available sequenceanalysis software, more specifically, Vector NTI, GENETYX or other toolsare provided by public databases.

A person skilled in the art will be able to assess, whether T cellsinduced by a variant of a specific peptide will be able to cross-reactwith the peptide itself (Appay et al., 2006; Colombetti et al., 2006;Fong et al., 2001; Zaremba et al., 1997).

By a “variant” of the given amino acid sequence the inventors mean thatthe side chains of, for example, one or two of the amino acid residuesare altered (for example by replacing them with the side chain ofanother naturally occurring amino acid residue or some other side chain)such that the peptide is still able to bind to an HLA molecule insubstantially the same way as a peptide consisting of the given aminoacid sequence in consisting of SEQ ID NO: 1 to SEQ ID NO: 149. Forexample, a peptide may be modified so that it at least maintains, if notimproves, the ability to interact with and bind to the binding groove ofa suitable MHC molecule, such as HLA-A*02 or -DR, and in that way it atleast maintains, if not improves, the ability to bind to the TCR ofactivated T cells.

These T cells can subsequently cross-react with cells and kill cellsthat express a polypeptide that contains the natural amino acid sequenceof the cognate peptide as defined in the aspects of the invention. Ascan be derived from the scientific literature and databases (Rammenseeet al., 1999; Godkin et al., 1997), certain positions of HLA bindingpeptides are typically anchor residues forming a core sequence fittingto the binding motif of the HLA receptor, which is defined by polar,electrophysical, hydrophobic and spatial properties of the polypeptidechains constituting the binding groove. Thus, one skilled in the artwould be able to modify the amino acid sequences set forth in SEQ ID NO:1 to SEQ ID NO 149, by maintaining the known anchor residues, and wouldbe able to determine whether such variants maintain the ability to bindMHC class I or II molecules. The variants of the present inventionretain the ability to bind to the TCR of activated T cells, which cansubsequently cross-react with and kill cells that express a polypeptidecontaining the natural amino acid sequence of the cognate peptide asdefined in the aspects of the invention.

The original (unmodified) peptides as disclosed herein can be modifiedby the substitution of one or more residues at different, possiblyselective, sites within the peptide chain, if not otherwise stated.Preferably those substitutions are located at the end of the amino acidchain. Such substitutions may be of a conservative nature, for example,where one amino acid is replaced by an amino acid of similar structureand characteristics, such as where a hydrophobic amino acid is replacedby another hydrophobic amino acid. Even more conservative would bereplacement of amino acids of the same or similar size and chemicalnature, such as where leucine is replaced by isoleucine. In studies ofsequence variations in families of naturally occurring homologousproteins, certain amino acid substitutions are more often tolerated thanothers, and these are often show correlation with similarities in size,charge, polarity, and hydrophobicity between the original amino acid andits replacement, and such is the basis for defining “conservativesubstitutions.”

Conservative substitutions are herein defined as exchanges within one ofthe following five groups: Group 1-small aliphatic, nonpolar or slightlypolar residues (Ala, Ser, Thr, Pro, Gly); Group 2-polar, negativelycharged residues and their amides (Asp, Asn, Glu, Gln); Group 3-polar,positively charged residues (His, Arg, Lys); Group 4-large, aliphatic,nonpolar residues (Met, Leu, Ile, Val, Cys); and Group 5-large, aromaticresidues (Phe, Tyr, Trp).

Less conservative substitutions might involve the replacement of oneamino acid by another that has similar characteristics but is somewhatdifferent in size, such as replacement of an alanine by an isoleucineresidue. Highly non-conservative replacements might involve substitutingan acidic amino acid for one that is polar, or even for one that isbasic in character. Such “radical” substitutions cannot, however, bedismissed as potentially ineffective since chemical effects are nottotally predictable and radical substitutions might well give rise toserendipitous effects not otherwise predictable from simple chemicalprinciples.

Of course, such substitutions may involve structures other than thecommon L-amino acids. Thus, D-amino acids might be substituted for theL-amino acids commonly found in the antigenic peptides of the inventionand yet still be encompassed by the disclosure herein. In addition,non-standard amino acids (i.e., other than the common naturallyoccurring proteinogenic amino acids) may also be used for substitutionpurposes to produce immunogens and immunogenic polypeptides according tothe present invention.

If substitutions at more than one position are found to result in apeptide with substantially equivalent or greater antigenic activity asdefined below, then combinations of those substitutions will be testedto determine if the combined substitutions result in additive orsynergistic effects on the antigenicity of the peptide. At most, no morethan 4 positions within the peptide would be simultaneously substituted.

A peptide consisting essentially of the amino acid sequence as indicatedherein can have one or two non-anchor amino acids (see below regardingthe anchor motif) exchanged without that the ability to bind to amolecule of the human major histocompatibility complex (MHC) class-I or-II is substantially changed or is negatively affected, when compared tothe non-modified peptide. In another embodiment, in a peptide consistingessentially of the amino acid sequence as indicated herein, one or twoamino acids can be exchanged with their conservative exchange partners(see herein below) without that the ability to bind to a molecule of thehuman major histocompatibility complex (MHC) class-I or -II issubstantially changed, or is negatively affected, when compared to thenon-modified peptide.

The amino acid residues that do not substantially contribute tointeractions with the T-cell receptor can be modified by replacementwith other amino acid whose incorporation does not substantially affectT-cell reactivity and does not eliminate binding to the relevant MHC.Thus, apart from the proviso given, the peptide of the invention may beany peptide (by which term the inventors include oligopeptide orpolypeptide), which includes the amino acid sequences or a portion orvariant thereof as given.

TABLE 6 Variants and motif of the peptides according to SEQ ID NO: 1, 3,and 15 Position 1 2 3 4 5 6 7 8 9 10 11 12 SEQ ID No I L L Q A S V Q V 1Variants I L A M M I M L M A A A I A L A A V V I V L V A T T I T L T A QQ I Q L Q A SEQ ID No Y L D E I P P K F S M 3 Variants V I L A M V M I ML Q L Q

Longer (elongated) peptides may also be suitable. It is possible thatMHC class I epitopes, although usually between 8 and 11 amino acidslong, are generated by peptide processing from longer peptides orproteins that include the actual epitope. It is preferred that theresidues that flank the actual epitope are residues that do notsubstantially affect proteolytic cleavage necessary to expose the actualepitope during processing.

The peptides of the invention can be elongated by up to four aminoacids, that is 1, 2, 3 or 4 amino acids can be added to either end inany combination between 4:0 and 0:4. Combinations of the elongationsaccording to the invention can be found in Table 7.

TABLE 7 Combinations of the elongations of peptides of the inventionC-terminus N-terminus 4 0 3 0 or 1 2 0 or 1 or 2 1 0 or 1 or 2 or 3 0 0or 1 or 2 or 3 or 4 N-terminus C-terminus 4 0 3 0 or 1 2 0 or 1 or 2 1 0or 1 or 2 or 3 0 0 or 1 or 2 or 3 or 4

The amino acids for the elongation/extension can be the peptides of theoriginal sequence of the protein or any other amino acid(s). Theelongation can be used to enhance the stability or solubility of thepeptides.

Thus, the epitopes of the present invention may be identical tonaturally occurring tumor-associated or tumor-specific epitopes or mayinclude epitopes that differ by no more than four residues from thereference peptide, as long as they have substantially identicalantigenic activity.

In an alternative embodiment, the peptide is elongated on either or bothsides by more than 4 amino acids, preferably to a total length of up to30 amino acids. This may lead to MHC class II binding peptides. Bindingto MHC class II can be tested by methods known in the art.

Accordingly, the present invention provides peptides and variants of MHCclass I epitopes, wherein the peptide or variant has an overall lengthof between 8 and 100, preferably between 8 and 30, and most preferredbetween 8 and 14, namely 8, 9, 10, 11, 12, 13, 14 amino acids, in caseof the elongated class II binding peptides the length can also be 15,16, 17, 18, 19, 20, 21 or 22 amino acids.

Of course, the peptide or variant according to the present inventionwill have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class I or II. Binding of a peptide ora variant to a MHC complex may be tested by methods known in the art.

Preferably, when the T cells specific for a peptide according to thepresent invention are tested against the substituted peptides, thepeptide concentration at which the substituted peptides achieve half themaximal increase in lysis relative to background is no more than about 1mM, preferably no more than about 1 μM, more preferably no more thanabout 1 nM, and still more preferably no more than about 100 pM, andmost preferably no more than about 10 pM. It is also preferred that thesubstituted peptide be recognized by T cells from more than oneindividual, at least two, and more preferably three individuals.

In a particularly preferred embodiment of the invention the peptideconsists or consists essentially of an amino acid sequence according toSEQ ID NO: 1 to SEQ ID NO: 149.

“Consisting essentially of” shall mean that a peptide according to thepresent invention, in addition to the sequence according to any of SEQID NO: 1 to SEQ ID NO 149 or a variant thereof contains additional N-and/or C-terminally located stretches of amino acids that are notnecessarily forming part of the peptide that functions as an epitope forMHC molecules epitope.

Nevertheless, these stretches can be important to provide an efficientintroduction of the peptide according to the present invention into thecells. In one embodiment of the present invention, the peptide is partof a fusion protein which comprises, for example, the 80 N-terminalamino acids of the HLA-DR antigen-associated invariant chain (p33, inthe following “Ii”) as derived from the NCBI, GenBank Accession numberX00497. In other fusions, the peptides of the present invention can befused to an antibody as described herein, or a functional part thereof,in particular into a sequence of an antibody, so as to be specificallytargeted by said antibody, or, for example, to or into an antibody thatis specific for dendritic cells as described herein.

In addition, the peptide or variant may be modified further to improvestability and/or binding to MHC molecules in order to elicit a strongerimmune response. Methods for such an optimization of a peptide sequenceare well known in the art and include, for example, the introduction ofreverse peptide bonds or non-peptide bonds.

In a reverse peptide bond amino acid residues are not joined by peptide(—CO—NH—) linkages but the peptide bond is reversed. Such retro-inversopeptidomimetics may be made using methods known in the art, for examplesuch as those described in Meziere et al (1997) (Meziere et al., 1997),incorporated herein by reference. This approach involves makingpseudopeptides containing changes involving the backbone, and not theorientation of side chains. Meziere et al. (Meziere et al., 1997) showthat for MHC binding and T helper cell responses, these pseudopeptidesare useful. Retro-inverse peptides, which contain NH—CO bonds instead ofCO—NH peptide bonds, are much more resistant to proteolysis.

A non-peptide bond is, for example, —CH₂—NH, —CH₂S—, —CH₂CH₂—, —CH═CH—,—COCH₂—, —CH(OH)CH₂—, and —CH₂SO—. U.S. Pat. No. 4,897,445 provides amethod for the solid phase synthesis of non-peptide bonds (—CH₂—NH) inpolypeptide chains which involves polypeptides synthesized by standardprocedures and the non-peptide bond synthesized by reacting an aminoaldehyde and an amino acid in the presence of NaCNBH₃.

Peptides comprising the sequences described above may be synthesizedwith additional chemical groups present at their amino and/or carboxytermini, to enhance the stability, bioavailability, and/or affinity ofthe peptides. For example, hydrophobic groups such as carbobenzoxyl,dansyl, or t-butyloxycarbonyl groups may be added to the peptides' aminotermini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonylgroup may be placed at the peptides' amino termini. Additionally, thehydrophobic group, t-butyloxycarbonyl, or an amido group may be added tothe peptides' carboxy termini.

Further, the peptides of the invention may be synthesized to alter theirsteric configuration. For example, the D-isomer of one or more of theamino acid residues of the peptide may be used, rather than the usualL-isomer. Still further, at least one of the amino acid residues of thepeptides of the invention may be substituted by one of the well-knownnon-naturally occurring amino acid residues. Alterations such as thesemay serve to increase the stability, bioavailability and/or bindingaction of the peptides of the invention.

Similarly, a peptide or variant of the invention may be modifiedchemically by reacting specific amino acids either before or aftersynthesis of the peptide. Examples for such modifications are well knownin the art and are summarized e.g. in R. Lundblad, Chemical Reagents forProtein Modification, 3rd ed. CRC Press, 2004 (Lundblad, 2004), which isincorporated herein by reference. Chemical modification of amino acidsincludes but is not limited to, modification by acylation, amidination,pyridoxylation of lysine, reductive alkylation, trinitrobenzylation ofamino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amidemodification of carboxyl groups and sulphydryl modification by performicacid oxidation of cysteine to cysteic acid, formation of mercurialderivatives, formation of mixed disulphides with other thiol compounds,reaction with maleimide, carboxymethylation with iodoacetic acid oriodoacetamide and carbamoylation with cyanate at alkaline pH, althoughwithout limitation thereto. In this regard, the skilled person isreferred to Chapter 15 of Current Protocols In Protein Science, Eds.Coligan et al. (John Wiley and Sons NY 1995-2000) (Coligan et al., 1995)for more extensive methodology relating to chemical modification ofproteins.

Briefly, modification of e.g. arginyl residues in proteins is oftenbased on the reaction of vicinal dicarbonyl compounds such asphenylglyoxal, 2,3-butanedione, and 1,2-cyclohexanedione to form anadduct. Another example is the reaction of methylglyoxal with arginineresidues. Cysteine can be modified without concomitant modification ofother nucleophilic sites such as lysine and histidine. As a result, alarge number of reagents are available for the modification of cysteine.The websites of companies such as Sigma-Aldrich(http://www.sigma-aldrich.com) provide information on specific reagents.

Selective reduction of disulfide bonds in proteins is also common.Disulfide bonds can be formed and oxidized during the heat treatment ofbiopharmaceuticals. Woodward's Reagent K may be used to modify specificglutamic acid residues. N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimidecan be used to form intra-molecular crosslinks between a lysine residueand a glutamic acid residue. For example, diethylpyrocarbonate is areagent for the modification of histidyl residues in proteins. Histidinecan also be modified using 4-hydroxy-2-nonenal. The reaction of lysineresidues and other α-amino groups is, for example, useful in binding ofpeptides to surfaces or the cross-linking of proteins/peptides. Lysineis the site of attachment of poly(ethylene)glycol and the major site ofmodification in the glycosylation of proteins. Methionine residues inproteins can be modified with e.g. iodoacetamide, bromoethylamine, andchloramine T.

Tetranitromethane and N-acetylimidazole can be used for the modificationof tyrosyl residues. Cross-linking via the formation of dityrosine canbe accomplished with hydrogen peroxide/copper ions.

Recent studies on the modification of tryptophan have usedN-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide or3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-indole (BPNS-skatole).

Successful modification of therapeutic proteins and peptides with PEG isoften associated with an extension of circulatory half-life whilecross-linking of proteins with glutaraldehyde, polyethylene glycoldiacrylate and formaldehyde is used for the preparation of hydrogels.

Chemical modification of allergens for immunotherapy is often achievedby carbamylation with potassium cyanate.

A peptide or variant, wherein the peptide is modified or includesnon-peptide bonds is a preferred embodiment of the invention.

Another embodiment of the present invention relates to a non-naturallyoccurring peptide wherein said peptide consists or consists essentiallyof an amino acid sequence according to SEQ ID No: 1 to SEQ ID No: 149and has been synthetically produced (e.g. synthesized) as apharmaceutically acceptable salt. Methods to synthetically producepeptides are well known in the art. The salts of the peptides accordingto the present invention differ substantially from the peptides in theirstate(s) in vivo, as the peptides as generated in vivo are no salts. Thenon-natural salt form of the peptide mediates the solubility of thepeptide, in particular in the context of pharmaceutical compositionscomprising the peptides, e.g. the peptide vaccines as disclosed herein.A sufficient and at least substantial solubility of the peptide(s) isrequired in order to efficiently provide the peptides to the subject tobe treated. Preferably, the salts are pharmaceutically acceptable saltsof the peptides. These salts according to the invention include alkalineand earth alkaline salts such as salts of the Hofmeister seriescomprising as anions PO₄ ³⁻, SO₄ ²⁻, CH₃COO⁻, Cl⁻, Br⁻, NO₃ ⁻, ClO₄ ⁻,I⁻, SCN⁻ and as cations NH₄ ⁺, Rb⁺, K⁺, Na⁺, Cs⁺, Li⁺, Zn₂ ⁺, Mg₂ ⁺, Ca₂⁺, Mn₂ ⁺, Cu₂ ⁺ and Ba₂ ⁺. Particularly salts are selected from(NH₄)₃PO₄, (NH₄)₂HPO₄, (NH₄)H₂PO₄, (NH₄)₂SO₄, NH₄CH₃COO, NH₄Cl, NH₄Br,NH₄NO₃, NH₄ClO₄, NH₄I, NH₄SCN, Rb₃PO₄, Rb₂HPO₄, RbH₂PO₄, Rb₂SO₄,Rb₄CH₃COO, Rb₄Cl, Rb₄Br, Rb₄NO₃, Rb₄ClO₄, Rb₄I, Rb₄SCN, K₃PO₄, K₂HPO₄,KH₂PO₄, K₂SO₄, KCH₃COO, KCl, KBr, KNO₃, KClO₄, KI, KSCN, Na₃PO₄,Na₂HPO₄, NaH₂PO₄, Na₂SO₄, NaCH₃COO, NaCl, NaBr, NaNO₃, NaClO₄, NaI,NaSCN, ZnCl₂ Cs₃PO₄, Cs₂HPO₄, CsH₂PO₄, Cs₂SO₄, CsCH₃COO, CsCl, CsBr,CsNO₃, CsClO₄, CsI, CsSCN, Li₃PO₄, Li₂HPO₄, LiH₂PO₄, Li₂SO₄, LiCH₃COO,LiCl, LiBr, LiNO₃, LiClO₄, LiI, LiSCN, Cu₂SO₄, Mg₃(PO₄)₂, Mg₂HPO₄,Mg(H₂PO₄)₂, Mg₂SO₄, Mg(CH₃COO)₂, MgCl₂, MgBr₂, Mg(NO₃)₂, Mg(ClO₄)₂,MgI₂, Mg(BCN)₂, MnCl₂, Ca₃(PO₄), Ca₂HPO₄, Ca(H₂PO₄)₂, CaSO₄,Ca(CH₃COO)₂, CaCl₂), CaBr₂, Ca(NO₃)₂, Ca(ClO₄)₂, CaI₂, Ca(SCN)₂,Ba₃(PO₄)₂, Ba₂HPO₄, Ba(H₂PO₄)₂, BaSO₄, Ba(CH₃COO)₂, BaCl₂, BaBr₂,Ba(NO₃)₂, Ba(ClO₄)₂, BaI₂, and Ba(SCN)₂. Particularly preferred are NHacetate, MgCl₂, KH₂PO₄, Na₂SO₄, KCl, NaCl, and CaCl₂), such as, forexample, the chloride or acetate (trifluoroacetate) salts.

Generally, peptides and variants (at least those containing peptidelinkages between amino acid residues) may be synthesized by theFmoc-polyamide mode of solid-phase peptide synthesis as disclosed byLukas et al. (Lukas et al., 1981) and by references as cited therein.Temporary N-amino group protection is afforded by the9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of thishighly base-labile protecting group is done using 20% piperidine in N,N-dimethylformamide. Side-chain functionalities may be protected astheir butyl ethers (in the case of serine threonine and tyrosine), butylesters (in the case of glutamic acid and aspartic acid),butyloxycarbonyl derivative (in the case of lysine and histidine),trityl derivative (in the case of cysteine) and4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case ofarginine). Where glutamine or asparagine are C-terminal residues, use ismade of the 4,4′-dimethoxybenzhydryl group for protection of the sidechain amido functionalities. The solid-phase support is based on apolydimethyl-acrylamide polymer constituted from the three monomersdimethylacrylamide (backbone-monomer), bisacryloylethylene diamine(cross linker) and acryloylsarcosine methyl ester (functionalizingagent). The peptide-to-resin cleavable linked agent used is theacid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All aminoacid derivatives are added as their preformed symmetrical anhydridederivatives with the exception of asparagine and glutamine, which areadded using a reversed N,N-dicyclohexyl-carbodiimide/1hydroxybenzotriazole mediated couplingprocedure. All coupling and deprotection reactions are monitored usingninhydrin, trinitrobenzene sulphonic acid or isotin test procedures.Upon completion of synthesis, peptides are cleaved from the resinsupport with concomitant removal of side-chain protecting groups bytreatment with 95% trifluoroacetic acid containing a 50% scavenger mix.Scavengers commonly used include ethanedithiol, phenol, anisole andwater, the exact choice depending on the constituent amino acids of thepeptide being synthesized. Also a combination of solid phase andsolution phase methodologies for the synthesis of peptides is possible(see, for example, (Bruckdorfer et al., 2004), and the references ascited therein).

Trifluoroacetic acid is removed by evaporation in vacuo, with subsequenttrituration with diethyl ether affording the crude peptide. Anyscavengers present are removed by a simple extraction procedure which onlyophilization of the aqueous phase affords the crude peptide free ofscavengers. Reagents for peptide synthesis are generally available frome.g. Calbiochem-Novabiochem (Nottingham, UK).

Purification may be performed by any one, or a combination of,techniques such as re-crystallization, size exclusion chromatography,ion-exchange chromatography, hydrophobic interaction chromatography and(usually) reverse-phase high performance liquid chromatography usinge.g. acetonitrile/water gradient separation.

Analysis of peptides may be carried out using thin layer chromatography,electrophoresis, in particular capillary electrophoresis, solid phaseextraction (CSPE), reverse-phase high performance liquid chromatography,amino-acid analysis after acid hydrolysis and by fast atom bombardment(FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF massspectrometric analysis.

In order to select over-presented peptides, a presentation profile iscalculated showing the median sample presentation as well as replicatevariation. The profile juxtaposes samples of the tumor entity ofinterest to a baseline of normal tissue samples. Each of these profilescan then be consolidated into an over-presentation score by calculatingthe p-value of a Linear Mixed-Effects Model (Pinheiro et al., 2015)adjusting for multiple testing by False Discovery Rate (Benjamini andHochberg, 1995) (cf. Example 1, FIGS. 1A-1R).

For the identification and relative quantitation of HLA ligands by massspectrometry, HLA molecules from shock-frozen tissue samples werepurified and HLA-associated peptides were isolated. The isolatedpeptides were separated and sequences were identified by onlinenano-electrospray-ionization (nanoESI) liquid chromatography-massspectrometry (LC-MS) experiments. The resulting peptide sequences wereverified by comparison of the fragmentation pattern of naturaltumor-associated peptides (TUMAPs) recorded from urinary bladder cancersamples (N=15 A*02-positive samples) with the fragmentation patterns ofcorresponding synthetic reference peptides of identical sequences. Sincethe peptides were directly identified as ligands of HLA molecules ofprimary tumors, these results provide direct evidence for the naturalprocessing and presentation of the identified peptides on primary cancertissue obtained from 15 urinary bladder cancer patients.

The discovery pipeline XPRESIDENT® v2.1 (see, for example, US2013-0096016, which is hereby incorporated by reference in its entirety)allows the identification and selection of relevant over-presentedpeptide vaccine candidates based on direct relative quantitation ofHLA-restricted peptide levels on cancer tissues in comparison to severaldifferent non-cancerous tissues and organs. This was achieved by thedevelopment of label-free differential quantitation using the acquiredLC-MS data processed by a proprietary data analysis pipeline, combiningalgorithms for sequence identification, spectral clustering, ioncounting, retention time alignment, charge state deconvolution andnormalization.

Presentation levels including error estimates for each peptide andsample were established. Peptides exclusively presented on tumor tissueand peptides over-presented in tumor versus non-cancerous tissues andorgans have been identified.

HLA-peptide complexes from urinary bladder cancer tissue samples werepurified and HLA-associated peptides were isolated and analyzed by LC-MS(see examples). All TUMAPs contained in the present application wereidentified with this approach on primary urinary bladder cancer samplesconfirming their presentation on primary urinary bladder cancer.

TUMAPs identified on multiple urinary bladder cancer and normal tissueswere quantified using ion-counting of label-free LC-MS data. The methodassumes that LC-MS signal areas of a peptide correlate with itsabundance in the sample. All quantitative signals of a peptide invarious LC-MS experiments were normalized based on central tendency,averaged per sample and merged into a bar plot, called presentationprofile. The presentation profile consolidates different analysismethods like protein database search, spectral clustering, charge statedeconvolution (decharging) and retention time alignment andnormalization.

Besides over-presentation of the peptide, mRNA expression of theunderlying gene was tested. mRNA data were obtained via RNASeq analysesof normal tissues and cancer tissues (cf. Example 2, FIGS. 2A-2D). Anadditional source of normal tissue data was a database of publiclyavailable RNA expression data from around 3000 normal tissue samples(Lonsdale, 2013). Peptides which are derived from proteins whose codingmRNA is highly expressed in cancer tissue, but very low or absent invital normal tissues, were preferably included in the present invention.

The present invention provides peptides that are useful in treatingcancers/tumors, preferably urinary bladder cancer that over- orexclusively present the peptides of the invention. These peptides wereshown by mass spectrometry to be naturally presented by HLA molecules onprimary human urinary bladder cancer samples.

Many of the source gene/proteins (also designated “full-length proteins”or “underlying proteins”) from which the peptides are derived were shownto be highly over-expressed in cancer compared with normaltissues—“normal tissues” in relation to this invention shall mean eitherhealthy urinary bladder cells or other normal tissue cells,demonstrating a high degree of tumor association of the source genes(see Example 2). Moreover, the peptides themselves are stronglyover-presented on tumor tissue—“tumor tissue” in relation to thisinvention shall mean a sample from a patient suffering from urinarybladder cancer, but not on normal tissues (see Example 1).

HLA-bound peptides can be recognized by the immune system, specificallyT lymphocytes. T cells can destroy the cells presenting the recognizedHLA/peptide complex, e.g. urinary bladder cancer cells presenting thederived peptides.

The peptides of the present invention have been shown to be capable ofstimulating T cell responses and/or are over-presented and thus can beused for the production of antibodies and/or TCRs, such as soluble TCRs,according to the present invention (see Example 3, Example 4).Furthermore, the peptides when complexed with the respective MHC can beused for the production of antibodies and/or TCRs, in particular sTCRs,according to the present invention, as well. Respective methods are wellknown to the person of skill, and can be found in the respectiveliterature as well. Thus, the peptides of the present invention areuseful for generating an immune response in a patient by which tumorcells can be destroyed. An immune response in a patient can be inducedby direct administration of the described peptides or suitable precursorsubstances (e.g. elongated peptides, proteins, or nucleic acids encodingthese peptides) to the patient, ideally in combination with an agentenhancing the immunogenicity (i.e. an adjuvant). The immune responseoriginating from such a therapeutic vaccination can be expected to behighly specific against tumor cells because the target peptides of thepresent invention are not presented on normal tissues in comparable copynumbers, preventing the risk of undesired autoimmune reactions againstnormal cells in the patient.

The present description further relates to T-cell receptors (TCRs)comprising an alpha chain and a beta chain (“alpha/beta TCRs”). Alsoprovided are peptides according to the invention capable of binding toTCRs and antibodies when presented by an MHC molecule. The presentdescription also relates to nucleic acids, vectors and host cells forexpressing TCRs and peptides of the present description; and methods ofusing the same.

The present description also relates to fragments of the TCRs accordingto the invention that are capable of binding to a peptide antigenaccording to the present invention when presented by an HLA molecule.The term particularly relates to soluble TCR fragments, for example TCRsmissing the transmembrane parts and/or constant regions, single chainTCRs, and fusions thereof to, for example, with 1 g.

The term “T-cell receptor” (abbreviated TCR) refers to a heterodimericmolecule comprising an alpha polypeptide chain (alpha chain) and a betapolypeptide chain (beta chain), wherein the heterodimeric receptor iscapable of binding to a peptide antigen presented by an HLA molecule.The term also includes so-called gamma/delta TCRs.

In one embodiment the description provides a method of producing a TCRas described herein, the method comprising culturing a host cell capableof expressing the TCR under conditions suitable to promote expression ofthe TCR.

The description in another aspect relates to methods according to thedescription, wherein the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellor artificial antigen-presenting cell by contacting a sufficient amountof the antigen with an antigen-presenting cell or the antigen is loadedonto class I or II MHC tetramers by tetramerizing the antigen/class I orII MHC complex monomers.

The alpha and beta chains of alpha/beta TCR's, and the gamma and deltachains of gamma/delta TCRs, are generally regarded as each having two“domains”, namely variable and constant domains. The variable domainconsists of a concatenation of variable region (V), and joining region(J). The variable domain may also include a leader region (L). Beta anddelta chains may also include a diversity region (D). The alpha and betaconstant domains may also include C-terminal transmembrane (TM) domainsthat anchor the alpha and beta chains to the cell membrane.

With respect to gamma/delta TCRs, the term “TCR gamma variable domain”as used herein refers to the concatenation of the TCR gamma V (TRGV)region without leader region (L), and the TCR gamma J (TRGJ) region, andthe term TCR gamma constant domain refers to the extracellular TRGCregion, or to a C-terminal truncated TRGC sequence. Likewise the term“TCR delta variable domain” refers to the concatenation of the TCR deltaV (TRDV) region without leader region (L) and the TCR delta D/J(TRDD/TRDJ) region, and the term “TCR delta constant domain” refers tothe extracellular TRDC region, or to a C-terminal truncated TRDCsequence.

TCRs of the present description preferably bind to an peptide-HLAmolecule complex with a binding affinity (KD) of about 100 μM or less,about 50 μM or less, about 25 μM or less, or about 10 μM or less. Morepreferred are high affinity TCRs having binding affinities of about 1 μMor less, about 100 nM or less, about 50 nM or less, about 25 nM or less.Non-limiting examples of preferred binding affinity ranges for TCRs ofthe present invention include about 1 nM to about 10 nM; about 10 nM toabout 20 nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM;about 40 nM to about 50 nM; about 50 nM to about 60 nM; about 60 nM toabout 70 nM; about 70 nM to about 80 nM; about 80 nM to about 90 nM; andabout 90 nM to about 100 nM.

As used herein in connect with TCRs of the present description,“specific binding” and grammatical variants thereof are used to mean aTCR having a binding affinity (KD) for a peptide-HLA molecule complex of100 μM or less.

Alpha/beta heterodimeric TCRs of the present description may have anintroduced disulfide bond between their constant domains. Preferred TCRsof this type include those which have a TRAC constant domain sequenceand a TRBC1 or TRBC2 constant domain sequence except that Thr 48 of TRACand Ser 57 of TRBC1 or TRBC2 are replaced by cysteine residues, the saidcysteines forming a disulfide bond between the TRAC constant domainsequence and the TRBC1 or TRBC2 constant domain sequence of the TCR.

With or without the introduced inter-chain bond mentioned above,alpha/beta hetero-dimeric TCRs of the present description may have aTRAC constant domain sequence and a TRBC1 or TRBC2 constant domainsequence, and the TRAC constant domain sequence and the TRBC1 or TRBC2constant domain sequence of the TCR may be linked by the nativedisulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 ofTRBC1 or TRBC2.

TCRs of the present description may comprise a detectable label selectedfrom the group consisting of a radionuclide, a fluorophore and biotin.TCRs of the present description may be conjugated to a therapeuticallyactive agent, such as a radionuclide, a chemotherapeutic agent, or atoxin.

In an embodiment, a TCR of the present description having at least onemutation in the alpha chain and/or having at least one mutation in thebeta chain has modified glycosylation compared to the unmutated TCR.

In an embodiment, a TCR comprising at least one mutation in the TCRalpha chain and/or TCR beta chain has a binding affinity for, and/or abinding half-life for, a peptide-HLA molecule complex, which is at leastdouble that of a TCR comprising the unmutated TCR alpha chain and/orunmutated TCR beta chain. Affinity-enhancement of tumor-specific TCRs,and its exploitation, relies on the existence of a window for optimalTCR affinities. The existence of such a window is based on observationsthat TCRs specific for HLA-A2-restricted pathogens have KD values thatare generally about 10-fold lower when compared to TCRs specific forHLA-A2-restricted tumor-associated self-antigens. It is now known,although tumor antigens have the potential to be immunogenic, becausetumors arise from the individual's own cells only mutated proteins orproteins with altered translational processing will be seen as foreignby the immune system. Antigens that are upregulated or overexpressed (socalled self-antigens) will not necessarily induce a functional immuneresponse against the tumor: T-cells expressing TCRs that are highlyreactive to these antigens will have been negatively selected within thethymus in a process known as central tolerance, meaning that onlyT-cells with low-affinity TCRs for self-antigens remain. Therefore,affinity of TCRs or variants of the present description to pepides canbe enhanced by methods well known in the art.

The present description further relates to a method of identifying andisolating a TCR according to the present description, said methodcomprising incubating PBMCs from HLA-A*02-negative healthy donors withA2/peptide monomers, incubating the PBMCs with tetramer-phycoerythrin(PE) and isolating the high avidity T-cells by fluo-rescence activatedcell sorting (FACS)-Calibur analysis.

The present description further relates to a method of identifying andisolating a TCR according to the present description, said methodcomprising obtaining a transgenic mouse with the entire human TCRαβ geneloci (1.1 and 0.7 Mb), whose T-cells express a diverse human TCRrepertoire that compensates for mouse TCR deficiency, immunizing themouse with a peptide, incubating PBMCs obtained from the transgenic micewith tetramer-phycoerythrin (PE), and isolating the high avidity T-cellsby fluorescence activated cell sorting (FACS)-Calibur analysis.

In one aspect, to obtain T-cells expressing TCRs of the presentdescription, nucleic acids encoding TCR-alpha and/or TCR-beta chains ofthe present description are cloned into expression vectors, such asgamma retrovirus or lentivirus. The recombinant viruses are generatedand then tested for functionality, such as antigen specificity andfunctional avidity. An aliquot of the final product is then used totransduce the target T-cell population (generally purified from patientPBMCs), which is expanded before infusion into the patient.

In another aspect, to obtain T-cells expressing TCRs of the presentdescription, TCR RNAs are synthesized by techniques known in the art,e.g., in vitro transcription sys-tems. The in vitro-synthesized TCR RNAsare then introduced into primary CD8+ T-cells obtained from healthydonors by electroporation to re-express tumor specific TCR-alpha and/orTCR-beta chains.

To increase the expression, nucleic acids encoding TCRs of the presentdescription may be operably linked to strong promoters, such asretroviral long terminal repeats (LTRs), cytomegalovirus (CMV), murinestem cell virus (MSCV) U3, phosphoglycerate kinase (PGK), β-actin,ubiquitin, and a simian virus 40 (SV40)/CD43 composite promoter,elongation factor (EF)-1a and the spleen focus-forming virus (SFFV)promoter. In a preferred embodiment, the promoter is heterologous to thenucleic acid being expressed.

In addition to strong promoters, TCR expression cassettes of the presentdescription may contain additional elements that can enhance transgeneexpression, including a central polypurine tract (cPPT), which promotesthe nuclear translocation of lentiviral constructs (Follenzi et al.,2000), and the woodchuck hepatitis virus posttranscriptional regulatoryelement (wPRE), which increases the level of transgene expression byincreasing RNA stability (Zufferey et al., 1999).

The alpha and beta chains of a TCR of the present invention may beencoded by nucleic acids located in separate vectors, or may be encodedby polynucleotides located in the same vector.

Achieving high-level TCR surface expression requires that both theTCR-alpha and TCR-beta chains of the introduced TCR be transcribed athigh levels. To do so, the TCR-alpha and TCR-beta chains of the presentdescription may be cloned into bi-cistronic constructs in a singlevector, which has been shown to be capable of over-coming this obstacle.The use of a viral intraribosomal entry site (IRES) between theTCR-alpha and TCR-beta chains results in the coordinated expression ofboth chains, because the TCR-alpha and TCR-beta chains are generatedfrom a single transcript that is broken into two proteins duringtranslation, ensuring that an equal molar ratio of TCR-alpha andTCR-beta chains are produced (Schmitt et al., 2009).

Nucleic acids encoding TCRs of the present description may be codonoptimized to increase expression from a host cell. Redundancy in thegenetic code allows some amino acids to be encoded by more than onecodon, but certain codons are less “op-timal” than others because of therelative availability of matching tRNAs as well as other factors(Gustafsson et al., 2004). Modifying the TCR-alpha and TCR-beta genesequences such that each amino acid is encoded by the optimal codon formammalian gene expression, as well as eliminating mRNA instabilitymotifs or cryptic splice sites, has been shown to significantly enhanceTCR-alpha and TCR-beta gene expression (Scholten et al., 2006).

Furthermore, mispairing between the introduced and endogenous TCR chainsmay result in the acquisition of specificities that pose a significantrisk for autoimmunity. For example, the formation of mixed TCR dimersmay reduce the number of CD3 molecules available to form properly pairedTCR complexes, and therefore can significantly decrease the functionalavidity of the cells expressing the introduced TCR (Kuball et al.,2007).

To reduce mispairing, the C-terminus domain of the introduced TCR chainsof the present description may be modified in order to promoteinterchain affinity, while de-creasing the ability of the introducedchains to pair with the endogenous TCR. These strategies may includereplacing the human TCR-alpha and TCR-beta C-terminus domains with theirmurine counterparts (murinized C-terminus domain); generating a secondinterchain disulfide bond in the C-terminus domain by introducing asecond cysteine residue into both the TCR-alpha and TCR-beta chains ofthe introduced TCR (cysteine modification); swapping interactingresidues in the TCR-alpha and TCR-beta chain C-terminus domains(“knob-in-hole”); and fusing the variable domains of the TCR-alpha andTCR-beta chains directly to CD3ζ (CD3ζ fusion) (Schmitt et al., 2009).

In an embodiment, a host cell is engineered to express a TCR of thepresent description. In preferred embodiments, the host cell is a humanT-cell or T-cell progenitor. In some embodiments the T-cell or T-cellprogenitor is obtained from a cancer patient. In other embodiments theT-cell or T-cell progenitor is obtained from a healthy donor. Host cellsof the present description can be allogeneic or autologous with respectto a patient to be treated. In one embodiment, the host is a gamma/deltaT-cell transformed to express an alpha/beta TCR.

A “pharmaceutical composition” is a composition suitable foradministration to a human being in a medical setting. Preferably, apharmaceutical composition is sterile and produced according to GMPguidelines.

The pharmaceutical compositions comprise the peptides either in the freeform or in the form of a pharmaceutically acceptable salt (see alsoabove). As used herein, “a pharmaceutically acceptable salt” refers to aderivative of the disclosed peptides wherein the peptide is modified bymaking acid or base salts of the agent. For example, acid salts areprepared from the free base (typically wherein the neutral form of thedrug has a neutral —NH2 group) involving reaction with a suitable acid.Suitable acids for preparing acid salts include both organic acids,e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalicacid, malic acid, malonic acid, succinic acid, maleic acid, fumaricacid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelicacid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonicacid, salicylic acid, and the like, as well as inorganic acids, e.g.,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acidphosphoric acid and the like. Conversely, preparation of basic salts ofacid moieties which may be present on a peptide are prepared using apharmaceutically acceptable base such as sodium hydroxide, potassiumhydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or thelike.

In an especially preferred embodiment, the pharmaceutical compositionscomprise the peptides as salts of acetic acid (acetates), trifluoroacetates or hydrochloric acid (chlorides).

Preferably, the medicament of the present invention is animmunotherapeutic such as a vaccine. It may be administered directlyinto the patient, into the affected organ or systemically i.d., i.m.,s.c., i.p. and i.v., or applied ex vivo to cells derived from thepatient or a human cell line which are subsequently administered to thepatient, or used in vitro to select a subpopulation of immune cellsderived from the patient, which are then re-administered to the patient.If the nucleic acid is administered to cells in vitro, it may be usefulfor the cells to be transfected so as to co-express immune-stimulatingcytokines, such as interleukin-2. The peptide may be substantially pure,or combined with an immune-stimulating adjuvant (see below) or used incombination with immune-stimulatory cytokines, or be administered with asuitable delivery system, for example liposomes. The peptide may also beconjugated to a suitable carrier such as keyhole limpet haemocyanin(KLH) or mannan (see WO 95/18145 and (Longenecker et al., 1993)). Thepeptide may also be tagged, may be a fusion protein, or may be a hybridmolecule. The peptides whose sequence is given in the present inventionare expected to stimulate CD4 or CD8 T cells. However, stimulation ofCD8 T cells is more efficient in the presence of help provided by CD4T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 Tcells the fusion partner or sections of a hybrid molecule suitablyprovide epitopes which stimulate CD4-positive T cells. CD4- andCD8-stimulating epitopes are well known in the art and include thoseidentified in the present invention.

In one aspect, the vaccine comprises at least one peptide having theamino acid sequence set forth SEQ ID No. 1 to SEQ ID No. 149, and atleast one additional peptide, preferably two to 50, more preferably twoto 25, even more preferably two to 20 and most preferably two, three,four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen,fourteen, fifteen, sixteen, seventeen or eighteen peptides. Thepeptide(s) may be derived from one or more specific TAAs and may bind toMHC class I molecules.

A further aspect of the invention provides a nucleic acid (for example apolynucleotide) encoding a peptide or peptide variant of the invention.The polynucleotide may be, for example, DNA, cDNA, PNA, RNA orcombinations thereof, either single- and/or double-stranded, or nativeor stabilized forms of polynucleotides, such as, for example,polynucleotides with a phosphorothioate backbone and it may or may notcontain introns so long as it codes for the peptide. Of course, onlypeptides that contain naturally occurring amino acid residues joined bynaturally occurring peptide bonds are encodable by a polynucleotide. Astill further aspect of the invention provides an expression vectorcapable of expressing a polypeptide according to the invention.

A variety of methods have been developed to link polynucleotides,especially DNA, to vectors for example via complementary cohesivetermini. For instance, complementary homopolymer tracts can be added tothe DNA segment to be inserted to the vector DNA. The vector and DNAsegment are then joined by hydrogen bonding between the complementaryhomopolymeric tails to form recombinant DNA molecules.

Synthetic linkers containing one or more restriction sites provide analternative method of joining the DNA segment to vectors. Syntheticlinkers containing a variety of restriction endonuclease sites arecommercially available from a number of sources including InternationalBiotechnologies Inc. New Haven, Conn., USA.

A desirable method of modifying the DNA encoding the polypeptide of theinvention employs the polymerase chain reaction as disclosed by Saiki RK, et al. (Saiki et al., 1988). This method may be used for introducingthe DNA into a suitable vector, for example by engineering in suitablerestriction sites, or it may be used to modify the DNA in other usefulways as is known in the art. If viral vectors are used, pox- oradenovirus vectors are preferred.

The DNA (or in the case of retroviral vectors, RNA) may then beexpressed in a suitable host to produce a polypeptide comprising thepeptide or variant of the invention. Thus, the DNA encoding the peptideor variant of the invention may be used in accordance with knowntechniques, appropriately modified in view of the teachings containedherein, to construct an expression vector, which is then used totransform an appropriate host cell for the expression and production ofthe polypeptide of the invention. Such techniques include thosedisclosed, for example, in U.S. Pat. Nos. 4,440,859, 4,530,901,4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006,4,766,075, and 4,810,648.

The DNA (or in the case of retroviral vectors, RNA) encoding thepolypeptide constituting the compound of the invention may be joined toa wide variety of other DNA sequences for introduction into anappropriate host. The companion DNA will depend upon the nature of thehost, the manner of the introduction of the DNA into the host, andwhether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as aplasmid, in proper orientation and correct reading frame for expression.If necessary, the DNA may be linked to the appropriate transcriptionaland translational regulatory control nucleotide sequences recognized bythe desired host, although such controls are generally available in theexpression vector. The vector is then introduced into the host throughstandard techniques. Generally, not all of the hosts will be transformedby the vector. Therefore, it will be necessary to select for transformedhost cells. One selection technique involves incorporating into theexpression vector a DNA sequence, with any necessary control elements,that codes for a selectable trait in the transformed cell, such asantibiotic resistance.

Alternatively, the gene for such selectable trait can be on anothervector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of theinvention are then cultured for a sufficient time and under appropriateconditions known to those skilled in the art in view of the teachingsdisclosed herein to permit the expression of the polypeptide, which canthen be recovered.

Many expression systems are known, including bacteria (for example E.coli and Bacillus subtilis), yeasts (for example Saccharomycescerevisiae), filamentous fungi (for example Aspergillus spec.), plantcells, animal cells and insect cells. Preferably, the system can bemammalian cells such as CHO cells available from the ATCC Cell BiologyCollection.

A typical mammalian cell vector plasmid for constitutive expressioncomprises the CMV or SV40 promoter with a suitable poly A tail and aresistance marker, such as neomycin. One example is pSVL available fromPharmacia, Piscataway, N.J., USA. An example of an inducible mammalianexpression vector is pMSG, also available from Pharmacia. Useful yeastplasmid vectors are pRS403-406 and pRS413-416 and are generallyavailable from Stratagene Cloning Systems, La Jolla, Calif. 92037, USA.Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integratingplasmids (Ylps) and incorporate the yeast selectable markers HIS3, TRP1,LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps).CMV promoter-based vectors (for example from Sigma-Aldrich) providetransient or stable expression, cytoplasmic expression or secretion, andN-terminal or C-terminal tagging in various combinations of FLAG,3×FLAG, c-myc or MAT. These fusion proteins allow for detection,purification and analysis of recombinant protein. Dual-tagged fusionsprovide flexibility in detection.

The strong human cytomegalovirus (CMV) promoter regulatory region drivesconstitutive protein expression levels as high as 1 mg/L in COS cells.For less potent cell lines, protein levels are typically ˜0.1 mg/L. Thepresence of the SV40 replication origin will result in high levels ofDNA replication in SV40 replication permissive COS cells. CMV vectors,for example, can contain the pMB1 (derivative of pBR322) origin forreplication in bacterial cells, the b-lactamase gene for ampicillinresistance selection in bacteria, hGH polyA, and the f1 origin. Vectorscontaining the pre-pro-trypsin leader (PPT) sequence can direct thesecretion of FLAG fusion proteins into the culture medium forpurification using ANTI-FLAG antibodies, resins, and plates. Othervectors and expression systems are well known in the art for use with avariety of host cells.

In another embodiment two or more peptides or peptide variants of theinvention are encoded and thus expressed in a successive order (similarto “beads on a string” constructs). In doing so, the peptides or peptidevariants may be linked or fused together by stretches of linker aminoacids, such as for example LLLLLL, or may be linked without anyadditional peptide(s) between them. These constructs can also be usedfor cancer therapy, and may induce immune responses both involving MHC Iand MHC II.

The present invention also relates to a host cell transformed with apolynucleotide vector construct of the present invention. The host cellcan be either prokaryotic or eukaryotic. Bacterial cells may bepreferred prokaryotic host cells in some circumstances and typically area strain of E. coli such as, for example, the E. coli strains DH5available from Bethesda Research Laboratories Inc., Bethesda, Md., USA,and RR1 available from the American Type Culture Collection (ATCC) ofRockville, Md., USA (ATCC No 31343). Preferred eukaryotic host cellsinclude yeast, insect and mammalian cells, preferably vertebrate cellssuch as those from a mouse, rat, monkey or human fibroblastic and coloncell lines. Yeast host cells include YPH499, YPH500 and YPH501, whichare generally available from Stratagene Cloning Systems, La Jolla,Calif. 92037, USA. Preferred mammalian host cells include Chinesehamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swissmouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkeykidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293cells which are human embryonic kidney cells. Preferred insect cells areSf9 cells which can be transfected with baculovirus expression vectors.An overview regarding the choice of suitable host cells for expressioncan be found in, for example, the textbook of Paulina Balbás and ArgeliaLorence “Methods in Molecular Biology Recombinant Gene Expression,Reviews and Protocols,” Part One, Second Edition, ISBN978-1-58829-262-9, and other literature known to the person of skill.

Transformation of appropriate cell hosts with a DNA construct of thepresent invention is accomplished by well-known methods that typicallydepend on the type of vector used. With regard to transformation ofprokaryotic host cells, see, for example, Cohen et al. (Cohen et al.,1972) and (Green and Sambrook, 2012). Transformation of yeast cells isdescribed in Sherman et al. (Sherman et al., 1986). The method of Beggs(Beggs, 1978) is also useful. With regard to vertebrate cells, reagentsuseful in transfecting such cells, for example calcium phosphate andDEAE-dextran or liposome formulations, are available from StratageneCloning Systems, or Life Technologies Inc., Gaithersburg, Md. 20877,USA. Electroporation is also useful for transforming and/or transfectingcells and is well known in the art for transforming yeast cell,bacterial cells, insect cells and vertebrate cells.

Successfully transformed cells, i.e. cells that contain a DNA constructof the present invention, can be identified by well-known techniquessuch as PCR. Alternatively, the presence of the protein in thesupernatant can be detected using antibodies.

It will be appreciated that certain host cells of the invention areuseful in the preparation of the peptides of the invention, for examplebacterial, yeast and insect cells. However, other host cells may beuseful in certain therapeutic methods. For example, antigen-presentingcells, such as dendritic cells, may usefully be used to express thepeptides of the invention such that they may be loaded into appropriateMHC molecules. Thus, the current invention provides a host cellcomprising a nucleic acid or an expression vector according to theinvention.

In a preferred embodiment the host cell is an antigen presenting cell,in particular a dendritic cell or antigen presenting cell. APCs loadedwith a recombinant fusion protein containing prostatic acid phosphatase(PAP) were approved by the U.S. Food and Drug Administration (FDA) onApr. 29, 2010, to treat asymptomatic or minimally symptomatic metastaticHRPC (Sipuleucel-T) (Rini et al., 2006; Small et al., 2006).

A further aspect of the invention provides a method of producing apeptide or its variant, the method comprising culturing a host cell andisolating the peptide from the host cell or its culture medium.

In another embodiment the peptide, the nucleic acid or the expressionvector of the invention are used in medicine. For example, the peptideor its variant may be prepared for intravenous (i.v.) injection,sub-cutaneous (s.c.) injection, intradermal (i.d.) injection,intraperitoneal (i.p.) injection, intramuscular (i.m.) injection.Preferred methods of peptide injection include s.c., i.d., i.p., i.m.,and i.v. Preferred methods of DNA injection include i.d., i.m., s.c.,i.p. and i.v. Doses of e.g. between 50 μg and 1.5 mg, preferably 125 μgto 500 μg, of peptide or DNA may be given and will depend on therespective peptide or DNA. Dosages of this range were successfully usedin previous trials (Walter et al., 2012).

The polynucleotide used for active vaccination may be substantiallypure, or contained in a suitable vector or delivery system. The nucleicacid may be DNA, cDNA, PNA, RNA or a combination thereof. Methods fordesigning and introducing such a nucleic acid are well known in the art.An overview is provided by e.g. Teufel et al. (Teufel et al., 2005).Polynucleotide vaccines are easy to prepare, but the mode of action ofthese vectors in inducing an immune response is not fully understood.Suitable vectors and delivery systems include viral DNA and/or RNA, suchas systems based on adenovirus, vaccinia virus, retroviruses, herpesvirus, adeno-associated virus or hybrids containing elements of morethan one virus. Non-viral delivery systems include cationic lipids andcationic polymers and are well known in the art of DNA delivery.Physical delivery, such as via a “gene-gun” may also be used. Thepeptide or peptides encoded by the nucleic acid may be a fusion protein,for example with an epitope that stimulates T cells for the respectiveopposite CDR as noted above.

The medicament of the invention may also include one or more adjuvants.Adjuvants are substances that non-specifically enhance or potentiate theimmune response (e.g., immune responses mediated by CD8-positive T cellsand helper-T (TH) cells to an antigen, and would thus be considereduseful in the medicament of the present invention. Suitable adjuvantsinclude, but are not limited to, 1018 ISS, aluminum salts, AMPLIVAX®,AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLRS ligandsderived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod(ALDARA®), resiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13,IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, ISPatch, ISS, ISCOMATRIX, ISCOMs, JuvImmune®, LipoVac, MALP2, MF59,monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, MontanideISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions,OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system,poly(lactid co-glycolid) [PLG]-based and dextran microparticles,talactoferrin SRL172, Virosomes and other Virus-like particles, YF-17D,VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which isderived from saponin, mycobacterial extracts and synthetic bacterialcell wall mimics, and other proprietary adjuvants such as Ribi's Detox,Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred.Several immunological adjuvants (e.g., MF59) specific for dendriticcells and their preparation have been described previously (Allison andKrummel, 1995). Also cytokines may be used. Several cytokines have beendirectly linked to influencing dendritic cell migration to lymphoidtissues (e.g., TNF-), accelerating the maturation of dendritic cellsinto efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF,IL-1 and IL-4) (U.S. Pat. No. 5,849,589, specifically incorporatedherein by reference in its entirety) and acting as immunoadjuvants(e.g., IL-12, IL-15, IL-23, IL-7, IFN-alpha. IFN-beta) (Gabrilovich etal., 1996).

CpG immunostimulatory oligonucleotides have also been reported toenhance the effects of adjuvants in a vaccine setting. Without beingbound by theory, CpG oligonucleotides act by activating the innate(non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9.CpG triggered TLR9 activation enhances antigen-specific humoral andcellular responses to a wide variety of antigens, including peptide orprotein antigens, live or killed viruses, dendritic cell vaccines,autologous cellular vaccines and polysaccharide conjugates in bothprophylactic and therapeutic vaccines. More importantly it enhancesdendritic cell maturation and differentiation, resulting in enhancedactivation of TH1 cells and strong cytotoxic T-lymphocyte (CTL)generation, even in the absence of CD4 T cell help. The TH1 bias inducedby TLR9 stimulation is maintained even in the presence of vaccineadjuvants such as alum or incomplete Freund's adjuvant (IFA) thatnormally promote a TH2 bias. CpG oligonucleotides show even greateradjuvant activity when formulated or co-administered with otheradjuvants or in formulations such as microparticles, nanoparticles,lipid emulsions or similar formulations, which are especially necessaryfor inducing a strong response when the antigen is relatively weak. Theyalso accelerate the immune response and enable the antigen doses to bereduced by approximately two orders of magnitude, with comparableantibody responses to the full-dose vaccine without CpG in someexperiments (Krieg, 2006). U.S. Pat. No. 6,406,705 B1 describes thecombined use of CpG oligonucleotides, non-nucleic acid adjuvants and anantigen to induce an antigen-specific immune response. A CpG TLR9antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen(Berlin, Germany) which is a preferred component of the pharmaceuticalcomposition of the present invention. Other TLR binding molecules suchas RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

Other examples for useful adjuvants include, but are not limited tochemically modified CpGs (e.g. CpR, Idera), dsRNA analogues such asPoly(I:C) and derivates thereof (e.g. AmpliGen®, Hiltonal®, poly-(ICLC),poly(IC-R), poly(I:C12U), non-CpG bacterial DNA or RNA as well asimmunoactive small molecules and antibodies such as cyclophosphamide,sunitinib, Bevacizumab®, celebrex, NCX-4016, sildenafil, tadalafil,vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632,pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodiestargeting key structures of the immune system (e.g. anti-CD40,anti-TGFbeta, anti-TNFalpha receptor) and SC58175, which may acttherapeutically and/or as an adjuvant. The amounts and concentrations ofadjuvants and additives useful in the context of the present inventioncan readily be determined by the skilled artisan without undueexperimentation.

Preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF,cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, CpGoligonucleotides and derivates, poly-(I:C) and derivates, RNA,sildenafil, and particulate formulations with PLG or virosomes.

In a preferred embodiment, the pharmaceutical composition according tothe invention the adjuvant is selected from the group consisting ofcolony-stimulating factors, such as Granulocyte Macrophage ColonyStimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod,resiquimod, and interferon-alpha.

In a preferred embodiment, the pharmaceutical composition according tothe invention the adjuvant is selected from the group consisting ofcolony-stimulating factors, such as Granulocyte Macrophage ColonyStimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimodand resiquimod. In a preferred embodiment of the pharmaceuticalcomposition according to the invention, the adjuvant iscyclophosphamide, imiquimod or resiquimod. Even more preferred adjuvantsare Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, MontanideISA-51, poly-ICLC (Hiltonal®) and anti-CD40 mAB, or combinationsthereof.

This composition is used for parenteral administration, such assubcutaneous, intradermal, intramuscular or oral administration. Forthis, the peptides and optionally other molecules are dissolved orsuspended in a pharmaceutically acceptable, preferably aqueous carrier.In addition, the composition can contain excipients, such as buffers,binding agents, blasting agents, diluents, flavors, lubricants, etc. Thepeptides can also be administered together with immune stimulatingsubstances, such as cytokines. An extensive listing of excipients thatcan be used in such a composition, can be, for example, taken from A.Kibbe, Handbook of Pharmaceutical Excipients (Kibbe, 2000). Thecomposition can be used for a prevention, prophylaxis and/or therapy ofadenomatous or cancerous diseases. Exemplary formulations can be foundin, for example, EP2112253.

It is important to realize that the immune response triggered by thevaccine according to the invention attacks the cancer in differentcell-stages and different stages of development. Furthermore differentcancer associated signaling pathways are attacked. This is an advantageover vaccines that address only one or few targets, which may cause thetumor to easily adapt to the attack (tumor escape). Furthermore, not allindividual tumors express the same pattern of antigens. Therefore, acombination of several tumor-associated peptides ensures that everysingle tumor bears at least some of the targets. The composition isdesigned in such a way that each tumor is expected to express several ofthe antigens and cover several independent pathways necessary for tumorgrowth and maintenance. Thus, the vaccine can easily be used“off-the-shelf” for a larger patient population. This means that apre-selection of patients to be treated with the vaccine can berestricted to HLA typing, does not require any additional biomarkerassessments for antigen expression, but it is still ensured that severaltargets are simultaneously attacked by the induced immune response,which is important for efficacy (Banchereau et al., 2001; Walter et al.,2012).

As used herein, the term “scaffold” refers to a molecule thatspecifically binds to an (e.g. antigenic) determinant. In oneembodiment, a scaffold is able to direct the entity to which it isattached (e.g. a (second) antigen binding moiety) to a target site, forexample to a specific type of tumor cell or tumor stroma bearing theantigenic determinant (e.g. the complex of a peptide with MHC, accordingto the application at hand). In another embodiment a scaffold is able toactivate signaling through its target antigen, for example a T cellreceptor complex antigen. Scaffolds include but are not limited toantibodies and fragments thereof, antigen binding domains of anantibody, comprising an antibody heavy chain variable region and anantibody light chain variable region, binding proteins comprising atleast one ankyrin repeat motif and single domain antigen binding (SDAB)molecules, aptamers, (soluble) TCRs and (modified) cells such asallogenic or autologous T cells. To assess whether a molecule is ascaffold binding to a target, binding assays can be performed.

“Specific” binding means that the scaffold binds the peptide-MHC-complexof interest better than other naturally occurring peptide-MHC-complexes,to an extent that a scaffold armed with an active molecule that is ableto kill a cell bearing the specific target is not able to kill anothercell without the specific target but presenting other peptide-MHCcomplex(es). Binding to other peptide-MHC complexes is irrelevant if thepeptide of the cross-reactive peptide-MHC is not naturally occurring,i.e. not derived from the human HLA-peptidome. Tests to assess targetcell killing are well known in the art. They should be performed usingtarget cells (primary cells or cell lines) with unaltered peptide-MHCpresentation, or cells loaded with peptides such that naturallyoccurring peptide-MHC levels are reached.

Each scaffold can comprise a labelling which provides that the boundscaffold can be detected by determining the presence or absence of asignal provided by the label. For example, the scaffold can be labelledwith a fluorescent dye or any other applicable cellular marker molecule.Such marker molecules are well known in the art. For example afluorescence-labelling, for example provided by a fluorescence dye, canprovide a visualization of the bound aptamer by fluorescence or laserscanning microscopy or flow cytometry.

Each scaffold can be conjugated with a second active molecule such asfor example IL-21, anti-CD3, and anti-CD28. For further information onpolypeptide scaffolds see for example the background section of WO2014/071978A1 and the references cited therein.

The present invention further relates to aptamers. Aptamers (see forexample WO 2014/191359 and the literature as cited therein) are shortsingle-stranded nucleic acid molecules, which can fold into definedthree-dimensional structures and recognize specific target structures.They have appeared to be suitable alternatives for developing targetedtherapies. Aptamers have been shown to selectively bind to a variety ofcomplex targets with high affinity and specificity.

Aptamers recognizing cell surface located molecules have been identifiedwithin the past decade and provide means for developing diagnostic andtherapeutic approaches. Since aptamers have been shown to possess almostno toxicity and immunogenicity they are promising candidates forbiomedical applications. Indeed aptamers, for example prostate-specificmembrane-antigen recognizing aptamers, have been successfully employedfor targeted therapies and shown to be functional in xenograft in vivomodels. Furthermore, aptamers recognizing specific tumor cell lines havebeen identified.

DNA aptamers can be selected to reveal broad-spectrum recognitionproperties for various cancer cells, and particularly those derived fromsolid tumors, while non-tumorigenic and primary healthy cells are notrecognized. If the identified aptamers recognize not only a specifictumor sub-type but rather interact with a series of tumors, this rendersthe aptamers applicable as so-called broad-spectrum diagnostics andtherapeutics.

Further, investigation of cell-binding behavior with flow cytometryshowed that the aptamers revealed very good apparent affinities that arewithin the nanomolar range.

Aptamers are useful for diagnostic and therapeutic purposes. Further, itcould be shown that some of the aptamers are taken up by tumor cells andthus can function as molecular vehicles for the targeted delivery ofanti-cancer agents such as siRNA into tumor cells.

Aptamers can be selected against complex targets such as cells andtissues and complexes of the peptides comprising, preferably consistingof, a sequence according to any of SEQ ID NO 1 to SEQ ID NO 149,according to the invention at hand with the MHC molecule, using thecell-SELEX (Systematic Evolution of Ligands by Exponential enrichment)technique.

The peptides of the present invention can be used to generate anddevelop specific antibodies against MHC/peptide complexes. These can beused for therapy, targeting toxins or radioactive substances to thediseased tissue. Another use of these antibodies can be targetingradionuclides to the diseased tissue for imaging purposes such as PET.This use can help to detect small metastases or to determine the sizeand precise localization of diseased tissues.

Therefore, it is a further aspect of the invention to provide a methodfor producing a recombinant antibody specifically binding to a humanmajor histocompatibility complex (MHC) class I or II being complexedwith a HLA-restricted antigen, the method comprising: immunizing agenetically engineered non-human mammal comprising cells expressing saidhuman major histocompatibility complex (MHC) class I or II with asoluble form of a MHC class I or II molecule being complexed with saidHLA-restricted antigen; isolating mRNA molecules from antibody producingcells of said non-human mammal; producing a phage display librarydisplaying protein molecules encoded by said mRNA molecules; andisolating at least one phage from said phage display library, said atleast one phage displaying said antibody specifically binding to saidhuman major histocompatibility complex (MHC) class I or II beingcomplexed with said HLA-restricted antigen.

It is a further aspect of the invention to provide an antibody thatspecifically binds to a human major histocompatibility complex (MHC)class I or II being complexed with a HLA-restricted antigen, wherein theantibody preferably is a polyclonal antibody, monoclonal antibody,bi-specific antibody and/or a chimeric antibody.

Respective methods for producing such antibodies and single chain classI major histocompatibility complexes, as well as other tools for theproduction of these antibodies are disclosed in WO 03/068201, WO2004/084798, WO 01/72768, WO 03/070752, and in publications (Cohen etal., 2003a; Cohen et al., 2003b; Denkberg et al., 2003), which for thepurposes of the present invention are all explicitly incorporated byreference in their entireties.

Preferably, the antibody is binding with a binding affinity of below 20nanomolar, preferably of below 10 nanomolar, to the complex, which isalso regarded as “specific” in the context of the present invention.

The present invention relates to a peptide comprising a sequence that isselected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 149, ora variant thereof which is at least 88% homologous (preferablyidentical) to SEQ ID NO: 1 to SEQ ID NO: 149 or a variant thereof thatinduces T cells cross-reacting with said peptide, wherein said peptideis not the underlying full-length polypeptide.

The present invention further relates to a peptide comprising a sequencethat is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:149 or a variant thereof which is at least 88% homologous (preferablyidentical) to SEQ ID NO: 1 to SEQ ID NO: 149, wherein said peptide orvariant has an overall length of between 8 and 100, preferably between 8and 30, and most preferred between 8 and 14 amino acids.

The present invention further relates to the peptides according to theinvention that have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class-I or -II.

The present invention further relates to the peptides according to theinvention wherein the peptide consists or consists essentially of anamino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 149.

The present invention further relates to the peptides according to theinvention, wherein the peptide is (chemically) modified and/or includesnon-peptide bonds.

The present invention further relates to the peptides according to theinvention, wherein the peptide is part of a fusion protein, inparticular comprising N-terminal amino acids of the HLA-DRantigen-associated invariant chain (Ii), or wherein the peptide is fusedto (or into) an antibody, such as, for example, an antibody that isspecific for dendritic cells.

The present invention further relates to a nucleic acid, encoding thepeptides according to the invention, provided that the peptide is notthe complete (full) human protein.

The present invention further relates to the nucleic acid according tothe invention that is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable ofexpressing a nucleic acid according to the present invention.

The present invention further relates to a peptide according to thepresent invention, a nucleic acid according to the present invention oran expression vector according to the present invention for use inmedicine, in particular in the treatment of urinary bladder cancer.

The present invention further relates to a host cell comprising anucleic acid according to the invention or an expression vectoraccording to the invention. The present invention further relates to thehost cell according to the present invention that is an antigenpresenting cell, and preferably a dendritic cell.

The present invention further relates to a method of producing a peptideaccording to the present invention, said method comprising culturing thehost cell according to the present invention, and isolating the peptidefrom said host cell or its culture medium.

The present invention further relates to the method according to thepresent invention, wherein the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellby contacting a sufficient amount of the antigen with anantigen-presenting cell.

The present invention further relates to the method according to theinvention, wherein the antigen-presenting cell comprises an expressionvector capable of expressing said peptide containing SEQ ID NO: 1 to SEQID NO: 149 or said variant amino acid sequence.

The present invention further relates to activated T cells, produced bythe method according to the present invention, wherein said T cellsselectively recognizes a cell which aberrantly expresses a polypeptidecomprising an amino acid sequence according to the present invention.

The present invention further relates to a method of killing targetcells in a patient which target cells aberrantly express a polypeptidecomprising any amino acid sequence according to the present invention,the method comprising administering to the patient an effective numberof T cells as according to the present invention.

The present invention further relates to the use of any peptidedescribed, a nucleic acid according to the present invention, anexpression vector according to the present invention, a cell accordingto the present invention, or an activated cytotoxic T lymphocyteaccording to the present invention as a medicament or in the manufactureof a medicament. The present invention further relates to a useaccording to the present invention, wherein the medicament is activeagainst cancer.

The present invention further relates to a use according to theinvention, wherein the medicament is a vaccine. The present inventionfurther relates to a use according to the invention, wherein themedicament is active against cancer.

The present invention further relates to a use according to theinvention, wherein said cancer cells are urinary bladder cancer cells orother solid or hematological tumor cells such as acute myelogenousleukemia (AML), breast cancer, bile duct cancer, brain cancer, chroniclymphocytic leukemia (CLL), colorectal carcinoma, esophageal cancer,gallbladder cancer, gastric cancer, hepatocellular cancer (HCC), Merkelcell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lungcancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer,renal cell cancer, small cell lung cancer (SCLC) and uterine cancer.

The present invention further relates to particular marker proteins andbiomarkers based on the peptides according to the present invention,herein called “targets” that can be used in the diagnosis and/orprognosis of urinary bladder cancer. The present invention also relatesto the use of these novel targets for cancer treatment.

The term “antibody” or “antibodies” is used herein in a broad sense andincludes both polyclonal and monoclonal antibodies. In addition tointact or “full” immunoglobulin molecules, also included in the term“antibodies” are fragments (e.g. CDRs, Fv, Fab and Fc fragments) orpolymers of those immunoglobulin molecules and humanized versions ofimmunoglobulin molecules, as long as they exhibit any of the desiredproperties (e.g., specific binding of a urinary bladder cancer marker(poly)peptide, delivery of a toxin to a urinary bladder cancer cellexpressing a cancer marker gene at an increased level, and/or inhibitingthe activity of a urinary bladder cancer marker polypeptide) accordingto the invention.

Whenever possible, the antibodies of the invention may be purchased fromcommercial sources. The antibodies of the invention may also begenerated using well-known methods. The skilled artisan will understandthat either full length urinary bladder cancer marker polypeptides orfragments thereof may be used to generate the antibodies of theinvention.

A polypeptide to be used for generating an antibody of the invention maybe partially or fully purified from a natural source, or may be producedusing recombinant DNA techniques.

For example, a cDNA encoding a peptide according to the presentinvention, such as a peptide according to SEQ ID NO: 1 to SEQ ID NO: 149polypeptide, or a variant or fragment thereof, can be expressed inprokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast,insect, or mammalian cells), after which the recombinant protein can bepurified and used to generate a monoclonal or polyclonal antibodypreparation that specifically bind the urinary bladder cancer markerpolypeptide used to generate the antibody according to the invention.

One of skill in the art will realize that the generation of two or moredifferent sets of monoclonal or polyclonal antibodies maximizes thelikelihood of obtaining an antibody with the specificity and affinityrequired for its intended use (e.g., ELISA, immunohistochemistry, invivo imaging, immunotoxin therapy). The antibodies are tested for theirdesired activity by known methods, in accordance with the purpose forwhich the antibodies are to be used (e.g., ELISA, immunohistochemistry,immunotherapy, etc.; for further guidance on the generation and testingof antibodies, see, e.g., Greenfield, 2014 (Greenfield, 2014)). Forexample, the antibodies may be tested in ELISA assays or, Western blots,immunohistochemical staining of formalin-fixed cancers or frozen tissuesections. After their initial in vitro characterization, antibodiesintended for therapeutic or in vivo diagnostic use are tested accordingto known clinical testing methods.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a substantially homogeneous population of antibodies,i.e.; the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. The monoclonal antibodies herein specifically include“chimeric” antibodies in which a portion of the heavy and/or light chainis identical with or homologous to corresponding sequences in antibodiesderived from a particular species or belonging to a particular antibodyclass or subclass, while the remainder of the chain(s) is identical withor homologous to corresponding sequences in antibodies derived fromanother species or belonging to another antibody class or subclass, aswell as fragments of such antibodies, so long as they exhibit thedesired antagonistic activity (U.S. Pat. No. 4,816,567, which is herebyincorporated in its entirety).

Monoclonal antibodies of the invention may be prepared using hybridomamethods. In a hybridoma method, a mouse or other appropriate host animalis typically immunized with an immunizing agent to elicit lymphocytesthat produce or are capable of producing antibodies that willspecifically bind to the immunizing agent. Alternatively, thelymphocytes may be immunized in vitro.

The monoclonal antibodies may also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567. DNA encoding themonoclonal antibodies of the invention can be readily isolated andsequenced using conventional procedures (e.g., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of murine antibodies).

In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof, particularly Fabfragments, can be accomplished using routine techniques known in theart. For instance, digestion can be performed using papain. Examples ofpapain digestion are described in WO 94/29348 and U.S. Pat. No.4,342,566. Papain digestion of antibodies typically produces twoidentical antigen binding fragments, called Fab fragments, each with asingle antigen binding site, and a residual Fc fragment. Pepsintreatment yields a F(ab′)2 fragment and a pFc′ fragment.

The antibody fragments, whether attached to other sequences or not, canalso include insertions, deletions, substitutions, or other selectedmodifications of particular regions or specific amino acids residues,provided the activity of the fragment is not significantly altered orimpaired compared to the non-modified antibody or antibody fragment.These modifications can provide for some additional property, such as toremove/add amino acids capable of disulfide bonding, to increase itsbio-longevity, to alter its secretory characteristics, etc. In any case,the antibody fragment must possess a bioactive property, such as bindingactivity, regulation of binding at the binding domain, etc. Functionalor active regions of the antibody may be identified by mutagenesis of aspecific region of the protein, followed by expression and testing ofthe expressed polypeptide. Such methods are readily apparent to askilled practitioner in the art and can include site-specificmutagenesis of the nucleic acid encoding the antibody fragment.

The antibodies of the invention may further comprise humanizedantibodies or human antibodies. Humanized forms of non-human (e.g.,murine) antibodies are chimeric immunoglobulins, immunoglobulin chainsor fragments thereof (such as Fv, Fab, Fab′ or other antigen-bindingsubsequences of antibodies) which contain minimal sequence derived fromnon-human immunoglobulin. Humanized antibodies include humanimmunoglobulins (recipient antibody) in which residues from acomplementary determining region (CDR) of the recipient are replaced byresidues from a CDR of a non-human species (donor antibody) such asmouse, rat or rabbit having the desired specificity, affinity andcapacity. In some instances, Fv framework (FR) residues of the humanimmunoglobulin are replaced by corresponding non-human residues.Humanized antibodies may also comprise residues which are found neitherin the recipient antibody nor in the imported CDR or frameworksequences. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the CDR regions correspond to thoseof a non-human immunoglobulin and all or substantially all of the FRregions are those of a human immunoglobulin consensus sequence. Thehumanized antibody optimally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin.

Methods for humanizing non-human antibodies are well known in the art.Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source which is non-human. These non-humanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. Humanization canbe essentially performed by substituting rodent CDRs or CDR sequencesfor the corresponding sequences of a human antibody. Accordingly, such“humanized” antibodies are chimeric antibodies (U.S. Pat. No.4,816,567), wherein substantially less than an intact human variabledomain has been substituted by the corresponding sequence from anon-human species. In practice, humanized antibodies are typically humanantibodies in which some CDR residues and possibly some FR residues aresubstituted by residues from analogous sites in rodent antibodies.

Transgenic animals (e.g., mice) that are capable, upon immunization, ofproducing a full repertoire of human antibodies in the absence ofendogenous immunoglobulin production can be employed. For example, ithas been described that the homozygous deletion of the antibody heavychain joining region gene in chimeric and germ-line mutant mice resultsin complete inhibition of endogenous antibody production. Transfer ofthe human germ-line immunoglobulin gene array in such germ-line mutantmice will result in the production of human antibodies upon antigenchallenge. Human antibodies can also be produced in phage displaylibraries.

Antibodies of the invention are preferably administered to a subject ina pharmaceutically acceptable carrier. Typically, an appropriate amountof a pharmaceutically-acceptable salt is used in the formulation torender the formulation isotonic. Examples of thepharmaceutically-acceptable carrier include saline, Ringer's solutionand dextrose solution. The pH of the solution is preferably from about 5to about 8, and more preferably from about 7 to about 7.5. Furthercarriers include sustained release preparations such as semipermeablematrices of solid hydrophobic polymers containing the antibody, whichmatrices are in the form of shaped articles, e.g., films, liposomes ormicroparticles. It will be apparent to those persons skilled in the artthat certain carriers may be more preferable depending upon, forinstance, the route of administration and concentration of antibodybeing administered.

The antibodies can be administered to the subject, patient, or cell byinjection (e.g., intravenous, intraperitoneal, subcutaneous,intramuscular), or by other methods such as infusion that ensure itsdelivery to the bloodstream in an effective form. The antibodies mayalso be administered by intratumoral or peritumoral routes, to exertlocal as well as systemic therapeutic effects. Local or intravenousinjection is preferred.

Effective dosages and schedules for administering the antibodies may bedetermined empirically, and making such determinations is within theskill in the art. Those skilled in the art will understand that thedosage of antibodies that must be administered will vary depending on,for example, the subject that will receive the antibody, the route ofadministration, the particular type of antibody used and other drugsbeing administered. A typical daily dosage of the antibody used alonemight range from about 1 (μg/kg to up to 100 mg/kg of body weight ormore per day, depending on the factors mentioned above. Followingadministration of an antibody, preferably for treating urinary bladdercancer, the efficacy of the therapeutic antibody can be assessed invarious ways well known to the skilled practitioner. For instance, thesize, number, and/or distribution of cancer in a subject receivingtreatment may be monitored using standard tumor imaging techniques. Atherapeutically-administered antibody that arrests tumor growth, resultsin tumor shrinkage, and/or prevents the development of new tumors,compared to the disease course that would occurs in the absence ofantibody administration, is an efficacious antibody for treatment ofcancer.

It is a further aspect of the invention to provide a method forproducing a soluble T-cell receptor (sTCR) (specifically) recognizing aspecific peptide-MHC complex. Such soluble T-cell receptors can begenerated from specific T-cell clones, and their affinity can beincreased by mutagenesis targeting the complementarity-determiningregions. For the purpose of T-cell receptor selection, phage display canbe used (US 2010/0113300, (Liddy et al., 2012)). For the purpose ofstabilization of T-cell receptors during phage display and in case ofpractical use as drug, alpha and beta chain can be linked e.g. bynon-native disulfide bonds, other covalent bonds (single-chain T-cellreceptor), or by dimerization domains (Boulter et al., 2003; Card etal., 2004; Willcox et al., 1999). The T-cell receptor can be linked totoxins, drugs, cytokines (see, for example, US 2013/0115191), anddomains recruiting effector cells such as an anti-CD3 domain, etc., inorder to execute particular functions on target cells. Moreover, itcould be expressed in T cells used for adoptive transfer. Furtherinformation can be found in WO 2004/033685A1 and WO 2004/074322A1. Acombination of sTCRs is described in WO 2012/056407A1. Further methodsfor the production are disclosed in WO 2013/057586A1.

In addition, the peptides and/or the TCRs or antibodies or other bindingmolecules of the present invention can be used to verify a pathologist'sdiagnosis of a cancer based on a biopsied sample.

The antibodies or TCRs may also be used for in vivo diagnostic assays.Generally, the antibody is labeled with a radionucleotide (such as¹¹¹In, ⁹⁹Tc, ¹⁴C, ¹³¹I, ³H, ³²P or ³⁵S) so that the tumor can belocalized using immunoscintiography. In one embodiment, antibodies orfragments thereof bind to the extracellular domains of two or moretargets of a protein selected from the group consisting of theabove-mentioned proteins, and the affinity value (Kd) is less than 1×10μM.

Antibodies for diagnostic use may be labeled with probes suitable fordetection by various imaging methods. Methods for detection of probesinclude, but are not limited to, fluorescence, light, confocal andelectron microscopy; magnetic resonance imaging and spectroscopy;fluoroscopy, computed tomography and positron emission tomography.Suitable probes include, but are not limited to, fluorescein, rhodamine,eosin and other fluorophores, radioisotopes, gold, gadolinium and otherlanthanides, paramagnetic iron, fluorine-18 and other positron-emittingradionuclides. Additionally, probes may be bi- or multi-functional andbe detectable by more than one of the methods listed. These antibodiesmay be directly or indirectly labeled with said probes. Attachment ofprobes to the antibodies includes covalent attachment of the probe,incorporation of the probe into the antibody, and the covalentattachment of a chelating compound for binding of probe, amongst otherswell recognized in the art. For immunohistochemistry, the disease tissuesample may be fresh or frozen or may be embedded in paraffin and fixedwith a preservative such as formalin. The fixed or embedded sectioncontains the sample are contacted with a labeled primary antibody andsecondary antibody, wherein the antibody is used to detect theexpression of the proteins in situ.

Another aspect of the present invention includes an in vitro method forproducing activated T cells, the method comprising contacting in vitro Tcells with antigen loaded human MHC molecules expressed on the surfaceof a suitable antigen-presenting cell for a period of time sufficient toactivate the T cell in an antigen specific manner, wherein the antigenis a peptide according to the invention. Preferably a sufficient amountof the antigen is used with an antigen-presenting cell.

Preferably the mammalian cell lacks or has a reduced level or functionof the TAP peptide transporter. Suitable cells that lack the TAP peptidetransporter include T2, RMA-S and Drosophila cells. TAP is thetransporter associated with antigen processing.

The human peptide loading deficient cell line T2 is available from theAmerican Type Culture Collection, 12301 Parklawn Drive, Rockville, Md.20852, USA under Catalogue No CRL 1992; the Drosophila cell lineSchneider line 2 is available from the ATCC under Catalogue No CRL19863; the mouse RMA-S cell line is described in Ljunggren et al.(Ljunggren and Karre, 1985).

Preferably, before transfection the host cell expresses substantially noMHC class I molecules. It is also preferred that the stimulator cellexpresses a molecule important for providing a co-stimulatory signal forT-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The nucleic acidsequences of numerous MHC class I molecules and of the co-stimulatormolecules are publicly available from the GenBank and EMBL databases.

In case of a MHC class I epitope being used as an antigen, the T cellsare CD8-positive T cells.

If an antigen-presenting cell is transfected to express such an epitope,preferably the cell comprises an expression vector capable of expressinga peptide containing SEQ ID NO: 1 to SEQ ID NO: 149, or a variant aminoacid sequence thereof.

A number of other methods may be used for generating T cells in vitro.For example, autologous tumor-infiltrating lymphocytes can be used inthe generation of CTL. Plebanski et al. (Plebanski et al., 1995) madeuse of autologous peripheral blood lymphocytes (PLBs) in the preparationof T cells. Furthermore, the production of autologous T cells by pulsingdendritic cells with peptide or polypeptide, or via infection withrecombinant virus is possible. Also, B cells can be used in theproduction of autologous T cells. In addition, macrophages pulsed withpeptide or polypeptide, or infected with recombinant virus, may be usedin the preparation of autologous T cells. S. Walter et al. (Walter etal., 2003) describe the in vitro priming of T cells by using artificialantigen presenting cells (aAPCs), which is also a suitable way forgenerating T cells against the peptide of choice. In the presentinvention, aAPCs were generated by the coupling of preformed MHC:peptidecomplexes to the surface of polystyrene particles (microbeads) bybiotin:streptavidin biochemistry. This system permits the exact controlof the MHC density on aAPCs, which allows to selectively eliciting high-or low-avidity antigen-specific T cell responses with high efficiencyfrom blood samples. Apart from MHC:peptide complexes, aAPCs should carryother proteins with co-stimulatory activity like anti-CD28 antibodiescoupled to their surface. Furthermore such aAPC-based systems oftenrequire the addition of appropriate soluble factors, e. g. cytokines,like interleukin-12.

Allogeneic cells may also be used in the preparation of T cells and amethod is described in detail in WO 97/26328, incorporated herein byreference. For example, in addition to Drosophila cells and T2 cells,other cells may be used to present antigens such as CHO cells,baculovirus-infected insect cells, bacteria, yeast, andvaccinia-infected target cells. In addition plant viruses may be used(see, for example, Porta et al. (Porta et al., 1994) which describes thedevelopment of cowpea mosaic virus as a high-yielding system for thepresentation of foreign peptides.

The activated T cells that are directed against the peptides of theinvention are useful in therapy. Thus, a further aspect of the inventionprovides activated T cells obtainable by the foregoing methods of theinvention.

Activated T cells, which are produced by the above method, willselectively recognize a cell that aberrantly expresses a polypeptidethat comprises an amino acid sequence of SEQ ID NO: 1 to SEQ ID NO 149.

Preferably, the T cell recognizes the cell by interacting through itsTCR with the HLA/peptide-complex (for example, binding). The T cells areuseful in a method of killing target cells in a patient whose targetcells aberrantly express a polypeptide comprising an amino acid sequenceof the invention wherein the patient is administered an effective numberof the activated T cells. The T cells that are administered to thepatient may be derived from the patient and activated as described above(i.e. they are autologous T cells). Alternatively, the T cells are notfrom the patient but are from another individual. Of course, it ispreferred if the individual is a healthy individual. By “healthyindividual” the inventors mean that the individual is generally in goodhealth, preferably has a competent immune system and, more preferably,is not suffering from any disease that can be readily tested for, anddetected.

In vivo, the target cells for the CD8-positive T cells according to thepresent invention can be cells of the tumor (which sometimes express MHCclass II) and/or stromal cells surrounding the tumor (tumor cells)(which sometimes also express MHC class II; (Dengjel et al., 2006)).

The T cells of the present invention may be used as active ingredientsof a therapeutic composition. Thus, the invention also provides a methodof killing target cells in a patient whose target cells aberrantlyexpress a polypeptide comprising an amino acid sequence of theinvention, the method comprising administering to the patient aneffective number of T cells as defined above.

By “aberrantly expressed” the inventors also mean that the polypeptideis over-expressed compared to levels of expression in normal tissues orthat the gene is silent in the tissue from which the tumor is derivedbut in the tumor it is expressed. By “over-expressed” the inventors meanthat the polypeptide is present at a level at least 1.2-fold of thatpresent in normal tissue; preferably at least 2-fold, and morepreferably at least 5-fold or 10-fold the level present in normaltissue.

T cells may be obtained by methods known in the art, e.g. thosedescribed above.

Protocols for this so-called adoptive transfer of T cells are well knownin the art. Reviews can be found in: Gattioni et al. and Morgan et al.(Gattinoni et al., 2006; Morgan et al., 2006).

Another aspect of the present invention includes the use of the peptidescomplexed with MHC to generate a T-cell receptor whose nucleic acid iscloned and is introduced into a host cell, preferably a T cell. Thisengineered T cell can then be transferred to a patient for therapy ofcancer.

Any molecule of the invention, i.e. the peptide, nucleic acid, antibody,expression vector, cell, activated T cell, T-cell receptor or thenucleic acid encoding it, is useful for the treatment of disorders,characterized by cells escaping an immune response. Therefore anymolecule of the present invention may be used as medicament or in themanufacture of a medicament. The molecule may be used by itself orcombined with other molecule(s) of the invention or (a) knownmolecule(s).

The present invention is further directed at a kit comprising:

(a) a container containing a pharmaceutical composition as describedabove, in solution or in lyophilized form;

(b) optionally a second container containing a diluent or reconstitutingsolution for the lyophilized formulation; and

(c) optionally, instructions for (i) use of the solution or (ii)reconstitution and/or use of the lyophilized formulation.

The kit may further comprise one or more of (iii) a buffer, (iv) adiluent, (v) a filter, (vi) a needle, or (v) a syringe. The container ispreferably a bottle, a vial, a syringe or test tube; and it may be amulti-use container. The pharmaceutical composition is preferablylyophilized.

Kits of the present invention preferably comprise a lyophilizedformulation of the present invention in a suitable container andinstructions for its reconstitution and/or use. Suitable containersinclude, for example, bottles, vials (e.g. dual chamber vials), syringes(such as dual chamber syringes) and test tubes. The container may beformed from a variety of materials such as glass or plastic. Preferablythe kit and/or container contain/s instructions on or associated withthe container that indicates directions for reconstitution and/or use.For example, the label may indicate that the lyophilized formulation isto be reconstituted to peptide concentrations as described above. Thelabel may further indicate that the formulation is useful or intendedfor subcutaneous administration.

The container holding the formulation may be a multi-use vial, whichallows for repeat administrations (e.g., from 2-6 administrations) ofthe reconstituted formulation. The kit may further comprise a secondcontainer comprising a suitable diluent (e.g., sodium bicarbonatesolution).

Upon mixing of the diluent and the lyophilized formulation, the finalpeptide concentration in the reconstituted formulation is preferably atleast 0.15 mg/mL/peptide (=75 μg) and preferably not more than 3mg/mL/peptide (=1500 μg). The kit may further include other materialsdesirable from a commercial and user standpoint, including otherbuffers, diluents, filters, needles, syringes, and package inserts withinstructions for use.

Kits of the present invention may have a single container that containsthe formulation of the pharmaceutical compositions according to thepresent invention with or without other components (e.g., othercompounds or pharmaceutical compositions of these other compounds) ormay have distinct container for each component.

Preferably, kits of the invention include a formulation of the inventionpackaged for use in combination with the co-administration of a secondcompound (such as adjuvants (e.g. GM-CSF), a chemotherapeutic agent, anatural product, a hormone or antagonist, an anti-angiogenesis agent orinhibitor, an apoptosis-inducing agent or a chelator) or apharmaceutical composition thereof. The components of the kit may bepre-complexed or each component may be in a separate distinct containerprior to administration to a patient. The components of the kit may beprovided in one or more liquid solutions, preferably, an aqueoussolution, more preferably, a sterile aqueous solution. The components ofthe kit may also be provided as solids, which may be converted intoliquids by addition of suitable solvents, which are preferably providedin another distinct container.

The container of a therapeutic kit may be a vial, test tube, flask,bottle, syringe, or any other means of enclosing a solid or liquid.Usually, when there is more than one component, the kit will contain asecond vial or other container, which allows for separate dosing. Thekit may also contain another container for a pharmaceutically acceptableliquid. Preferably, a therapeutic kit will contain an apparatus (e.g.,one or more needles, syringes, eye droppers, pipette, etc.), whichenables administration of the agents of the invention that arecomponents of the present kit.

The present formulation is one that is suitable for administration ofthe peptides by any acceptable route such as oral (enteral), nasal,ophthal, subcutaneous, intradermal, intramuscular, intravenous ortransdermal. Preferably, the administration is s.c., and most preferablyi.d. administration may be by infusion pump.

Since the peptides of the invention were isolated from urinary bladdercancer, the medicament of the invention is preferably used to treaturinary bladder cancer.

The present invention further relates to a method for producing apersonalized pharmaceutical for an individual patient comprisingmanufacturing a pharmaceutical composition comprising at least onepeptide selected from a warehouse of pre-screened TUMAPs, wherein the atleast one peptide used in the pharmaceutical composition is selected forsuitability in the individual patient. In one embodiment, thepharmaceutical composition is a vaccine. The method could also beadapted to produce T cell clones for down-stream applications, such asTCR isolations, or soluble antibodies, and other treatment options.

A “personalized pharmaceutical” shall mean specifically tailoredtherapies for one individual patient that will only be used for therapyin such individual patient, including actively personalized cancervaccines and adoptive cellular therapies using autologous patienttissue.

As used herein, the term “warehouse” shall refer to a group or set ofpeptides that have been pre-screened for immunogenicity and/orover-presentation in a particular tumor type. The term “warehouse” isnot intended to imply that the particular peptides included in thevaccine have been pre-manufactured and stored in a physical facility,although that possibility is contemplated. It is expressly contemplatedthat the peptides may be manufactured de novo for each individualizedvaccine produced, or may be pre-manufactured and stored. The warehouse(e.g. in the form of a database) is composed of tumor-associatedpeptides which were highly overexpressed in the tumor tissue of urinarybladder cancer patients with various HLA-A HLA-B and HLA-C alleles. Itmay contain MHC class I and MHC class II peptides or elongated MHC classI peptides. In addition to the tumor associated peptides collected fromseveral urinary bladder cancer tissues, the warehouse may containHLA-A*02 and HLA-A*24 marker peptides. These peptides allow comparisonof the magnitude of T-cell immunity induced by TUMAPS in a quantitativemanner and hence allow important conclusion to be drawn on the capacityof the vaccine to elicit anti-tumor responses. Secondly, they functionas important positive control peptides derived from a “non-self” antigenin the case that any vaccine-induced T-cell responses to TUMAPs derivedfrom “self” antigens in a patient are not observed. And thirdly, it mayallow conclusions to be drawn, regarding the status of immunocompetenceof the patient.

TUMAPs for the warehouse are identified by using an integratedfunctional genomics approach combining gene expression analysis, massspectrometry, and T-cell immunology (XPresident®). The approach assuresthat only TUMAPs truly present on a high percentage of tumors but not oronly minimally expressed on normal tissue, are chosen for furtheranalysis. For initial peptide selection, urinary bladder cancer samplesfrom patients and blood from healthy donors were analyzed in a stepwiseapproach:

1. HLA ligands from the malignant material were identified by massspectrometry

2. Genome-wide messenger ribonucleic acid (mRNA) expression analysis wasused to identify genes over-expressed in the malignant tissue (urinarybladder cancer) compared with a range of normal organs and tissues

3. Identified HLA ligands were compared to gene expression data.Peptides over-presented or selectively presented on tumor tissue,preferably encoded by selectively expressed or over-expressed genes asdetected in step 2 were considered suitable TUMAP candidates for amulti-peptide vaccine.

4. Literature research was performed in order to identify additionalevidence supporting the relevance of the identified peptides as TUMAPs

5. The relevance of over-expression at the mRNA level was confirmed byredetection of selected TUMAPs from step 3 on tumor tissue and lack of(or infrequent) detection on healthy tissues.

6. In order to assess, whether an induction of in vivo T-cell responsesby the selected peptides may be feasible, in vitro immunogenicity assayswere performed using human T cells from healthy donors as well as fromurinary bladder cancer patients.

In an aspect, the peptides are pre-screened for immunogenicity beforebeing included in the warehouse. By way of example, and not limitation,the immunogenicity of the peptides included in the warehouse isdetermined by a method comprising in vitro T-cell priming throughrepeated stimulations of CD8+ T cells from healthy donors withartificial antigen presenting cells loaded with peptide/MHC complexesand anti-CD28 antibody.

This method is preferred for rare cancers and patients with a rareexpression profile. In contrast to multi-peptide cocktails with a fixedcomposition as currently developed, the warehouse allows a significantlyhigher matching of the actual expression of antigens in the tumor withthe vaccine. Selected single or combinations of several “off-the-shelf”peptides will be used for each patient in a multitarget approach. Intheory an approach based on selection of e.g. 5 different antigenicpeptides from a library of 50 would already lead to approximately 17million possible drug product (DP) compositions.

In an aspect, the peptides are selected for inclusion in the vaccinebased on their suitability for the individual patient based on themethod according to the present invention as described herein, or asbelow.

The HLA phenotype, transcriptomic and peptidomic data is gathered fromthe patient's tumor material, and blood samples to identify the mostsuitable peptides for each patient containing “warehouse” andpatient-unique (i.e. mutated) TUMAPs. Those peptides will be chosen,which are selectively or over-expressed in the patients tumor and, wherepossible, show strong in vitro immunogenicity if tested with thepatients' individual PBMCs.

Preferably, the peptides included in the vaccine are identified by amethod comprising: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient; (b) comparingthe peptides identified in (a) with a warehouse (database) of peptidesas described above; and (c) selecting at least one peptide from thewarehouse (database) that correlates with a tumor-associated peptideidentified in the patient. For example, the TUMAPs presented by thetumor sample are identified by: (a1) comparing expression data from thetumor sample to expression data from a sample of normal tissuecorresponding to the tissue type of the tumor sample to identifyproteins that are over-expressed or aberrantly expressed in the tumorsample; and (a2) correlating the expression data with sequences of MHCligands bound to MHC class I and/or class II molecules in the tumorsample to identify MHC ligands derived from proteins over-expressed oraberrantly expressed by the tumor. Preferably, the sequences of MHCligands are identified by eluting bound peptides from MHC moleculesisolated from the tumor sample, and sequencing the eluted ligands.Preferably, the tumor sample and the normal tissue are obtained from thesame patient.

In addition to, or as an alternative to, selecting peptides using awarehousing (database) model, TUMAPs may be identified in the patient denovo, and then included in the vaccine. As one example, candidate TUMAPsmay be identified in the patient by (a1) comparing expression data fromthe tumor sample to expression data from a sample of normal tissuecorresponding to the tissue type of the tumor sample to identifyproteins that are over-expressed or aberrantly expressed in the tumorsample; and (a2) correlating the expression data with sequences of MHCligands bound to MHC class I and/or class II molecules in the tumorsample to identify MHC ligands derived from proteins over-expressed oraberrantly expressed by the tumor. As another example, proteins may beidentified containing mutations that are unique to the tumor samplerelative to normal corresponding tissue from the individual patient, andTUMAPs can be identified that specifically target the mutation. Forexample, the genome of the tumor and of corresponding normal tissue canbe sequenced by whole genome sequencing: For discovery of non-synonymousmutations in the protein-coding regions of genes, genomic DNA and RNAare extracted from tumor tissues and normal non-mutated genomic germlineDNA is extracted from peripheral blood mononuclear cells (PBMCs). Theapplied NGS approach is confined to the re-sequencing of protein codingregions (exome re-sequencing). For this purpose, exonic DNA from humansamples is captured using vendor-supplied target enrichment kits,followed by sequencing with e.g. a HiSeq2000 (Illumina). Additionally,tumor mRNA is sequenced for direct quantification of gene expression andvalidation that mutated genes are expressed in the patients' tumors. Theresultant millions of sequence reads are processed through softwarealgorithms. The output list contains mutations and gene expression.Tumor-specific somatic mutations are determined by comparison with thePBMC-derived germline variations and prioritized. The de novo identifiedpeptides can then be tested for immunogenicity as described above forthe warehouse, and candidate TUMAPs possessing suitable immunogenicityare selected for inclusion in the vaccine.

In one exemplary embodiment, the peptides included in the vaccine areidentified by: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient by the method asdescribed above; (b) comparing the peptides identified in a) with awarehouse of peptides that have been prescreened for immunogenicity andoverpresentation in tumors as compared to corresponding normal tissue;(c) selecting at least one peptide from the warehouse that correlateswith a tumor-associated peptide identified in the patient; and (d)optionally, selecting at least one peptide identified de novo in (a)confirming its immunogenicity.

In one exemplary embodiment, the peptides included in the vaccine areidentified by: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient; and (b)selecting at least one peptide identified de novo in (a) and confirmingits immunogenicity.

Once the peptides for a personalized peptide based vaccine are selected,the vaccine is produced. The vaccine preferably is a liquid formulationconsisting of the individual peptides dissolved in between 20-40% DMSO,preferably about 30-35% DMSO, such as about 33% DMSO.

Each peptide to be included into a product is dissolved in DMSO. Theconcentration of the single peptide solutions has to be chosen dependingon the number of peptides to be included into the product. The singlepeptide-DMSO solutions are mixed in equal parts to achieve a solutioncontaining all peptides to be included in the product with aconcentration of ˜2.5 mg/ml per peptide. The mixed solution is thendiluted 1:3 with water for injection to achieve a concentration of 0.826mg/ml per peptide in 33% DMSO. The diluted solution is filtered througha 0.22 μm sterile filter. The final bulk solution is obtained.

Final bulk solution is filled into vials and stored at −20° C. untiluse. One vial contains 700 μL solution, containing 0.578 mg of eachpeptide. Of this, 500 μL (approx. 400 μg per peptide) will be appliedfor intradermal injection.

In addition to being useful for treating cancer, the peptides of thepresent invention are also useful as diagnostics. Since the peptideswere generated from urinary bladder cancer cells and since it wasdetermined that these peptides are not or at lower levels present innormal tissues, these peptides can be used to diagnose the presence of acancer.

The presence of claimed peptides on tissue biopsies in blood samples canassist a pathologist in diagnosis of cancer. Detection of certainpeptides by means of antibodies, mass spectrometry or other methodsknown in the art can tell the pathologist that the tissue sample ismalignant or inflamed or generally diseased, or can be used as abiomarker for urinary bladder cancer. Presence of groups of peptides canenable classification or sub-classification of diseased tissues.

The detection of peptides on diseased tissue specimen can enable thedecision about the benefit of therapies involving the immune system,especially if T-lymphocytes are known or expected to be involved in themechanism of action. Loss of MHC expression is a well describedmechanism by which infected of malignant cells escapeimmuno-surveillance. Thus, presence of peptides shows that thismechanism is not exploited by the analyzed cells.

The peptides of the present invention might be used to analyzelymphocyte responses against those peptides such as T cell responses orantibody responses against the peptide or the peptide complexed to MHCmolecules. These lymphocyte responses can be used as prognostic markersfor decision on further therapy steps. These responses can also be usedas surrogate response markers in immunotherapy approaches aiming toinduce lymphocyte responses by different means, e.g. vaccination ofprotein, nucleic acids, autologous materials, adoptive transfer oflymphocytes. In gene therapy settings, lymphocyte responses againstpeptides can be considered in the assessment of side effects. Monitoringof lymphocyte responses might also be a valuable tool for follow-upexaminations of transplantation therapies, e.g. for the detection ofgraft versus host and host versus graft diseases.

The present invention will now be described in the following exampleswhich describe preferred embodiments thereof, and with reference to theaccompanying figures, nevertheless, without being limited thereto. Forthe purposes of the present invention, all references as cited hereinare incorporated by reference in their entireties.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIGS. 1A through 1R show the over-presentation of various peptides innormal tissues (white bars) and urinary bladder cancer (black bars).FIG. 1A: Gene symbol: GATA3, Peptide: VLFNIDGQGNHV (SEQ ID NO.: 110);Tissues from left to right: 3 adipose tissues, 3 adrenal glands, 16blood cells, 15 blood vessels, 9 bone marrows, 10 brains, 7 breasts, 6esophagi, 2 eyes, 3 gallbladders, 6 hearts, 12 kidneys, 19 largeintestines, 19 livers, 45 lungs, 7 lymph nodes, 8 nerves, 3 ovaries, 8pancreases, 3 parathyroid glands, 1 peritoneum, 5 pituitary glands, 6placentas, 3 pleuras, 3 prostates, 7 salivary glands, 5 skeletalmuscles, 12 skins, 3 small intestines, 11 spleens, 5 stomachs, 4 testes,2 thymi, 2 thyroid glands, 9 tracheas, 6 ureters, 5 uteri, 8 urinarybladders, 15 urinary bladder cancer. The peptide has additionally beendetected on 3/15 urinary bladder cancers. FIG. 1B: Gene symbol: KRT7,Peptide: GLLKAYSIRTA (SEQ ID NO.: 2); Tissues from left to right: 3adipose tissues, 3 adrenal glands, 16 blood cells, 15 blood vessels, 9bone marrows, 10 brains, 7 breasts, 6 esophagi, 2 eyes, 3 gallbladders,6 hearts, 12 kidneys, 19 large intestines, 19 livers, 45 lungs, 7 lymphnodes, 8 nerves, 3 ovaries, 8 pancreases, 3 parathyroid glands, 1peritoneum, 5 pituitary glands, 6 placentas, 3 pleuras, 3 prostates, 7salivary glands, 5 skeletal muscles, 12 skins, 3 small intestines, 11spleens, 5 stomachs, 4 testes, 2 thymi, 2 thyroid glands, 9 tracheas, 6ureters, 5 uteri, 8 urinary bladders, 15 urinary bladder cancer. Thepeptide has additionally been detected on 3/15 urinary bladder cancers.FIG. 1C: Gene symbol: CXorf57, Peptide: YLDPSLNSL (SEQ ID NO.: 112);Tissues from left to right: 3 adipose tissues, 3 adrenal glands, 16blood cells, 15 blood vessels, 9 bone marrows, 10 brains, 7 breasts, 6esophagi, 2 eyes, 3 gallbladders, 6 hearts, 12 kidneys, 19 largeintestines, 19 livers, 45 lungs, 7 lymph nodes, 8 nerves, 3 ovaries, 8pancreases, 3 parathyroid glands, 1 peritoneum, 5 pituitary glands, 6placentas, 3 pleuras, 3 prostates, 7 salivary glands, 5 skeletalmuscles, 12 skins, 3 small intestines, 11 spleens, 5 stomachs, 4 testes,2 thymi, 2 thyroid glands, 9 tracheas, 6 ureters, 5 uteri, 8 urinarybladders, 15 urinary bladder cancer. The peptide has additionally beendetected on 3/15 urinary bladder cancers. FIG. 1D: Gene symbol: DYNC1H,Peptide: FVFEPPPGV (SEQ ID NO.: 113); Tissues from left to right: 3adipose tissues, 3 adrenal glands, 16 blood cells, 15 blood vessels, 9bone marrows, 10 brains, 7 breasts, 6 esophagi, 2 eyes, 3 gallbladders,6 hearts, 12 kidneys, 19 large intestines, 19 livers, 45 lungs, 7 lymphnodes, 8 nerves, 3 ovaries, 8 pancreases, 3 parathyroid glands, 1peritoneum, 5 pituitary glands, 6 placentas, 3 pleuras, 3 prostates, 7salivary glands, 5 skeletal muscles, 12 skins, 3 small intestines, 11spleens, 5 stomachs, 4 testes, 2 thymi, 2 thyroid glands, 9 tracheas, 6ureters, 5 uteri, 8 urinary bladders, 15 urinary bladder cancer. Thepeptide has additionally been detected on 2/15 urinary bladder cancers.FIG. 1E: Gene symbol: SNRNP70, Peptide: YLAPENGYLMEA (SEQ ID NO.: 15);Tissues from left to right: 1 cell line (1 kidney), 25 cancer tissues (2colon cancers, 1 leukocytic leukemia cancer, 3 liver cancers, 6 lungcancers, 3 lymph node cancers, 3 prostate cancers, 2 skin cancers, 3urinary bladder cancers, 2 uterus cancers). FIG. 1F: Peptide: GLWHGMFANV(SEQ ID NO.: 10); Tissues from left to right: 8 cell lines (1head-and-neck, 1 ovary, 2 lymphocytes, 3 skins, 1 head-and-neck), 1normal tissue (1 spleen), 25 cancer tissues (1 brain cancer, 1leukocytic leukemia cancer, 1 bone marrow cancer, 1 breast cancer, 3colon cancers, 2 liver cancers, 1 head-and-neck cancer, 1 skin cancer, 2ovarian cancers, 2 brain cancers, 7 lung cancers, 3 urinary bladdercancers); FIG. 1G: Peptide: RLSQLEGVNV (SEQ ID NO.: 17); Tissues fromleft to right: 7 cell lines (1 lymphocyte, 2 skins, 4 pancreas), 1normal tissue (1 adrenal gland), 15 cancer tissues (1 liver cancer, 2head-and-neck cancers, 2 ovarian cancers, 1 lung cancers, 1 kidneycancer, 3 lung cancers, 4 urinary bladder cancers, 1 uterus cancer);FIG. 1H: Peptide: GLALLYSGV (SEQ ID NO.: 26); Tissues from left toright: 7 cell lines (1 urinary bladder, 3 leukocytes, 3 pancreas), 1normal tissue (1 lung), 18 cancer tissues (1 bone marrow cancer, 1breast cancer, 1 leukocytic leukemia cancer, 7 liver cancers, 2 skincancers, 1 stomach cancer, 1 lung cancer, 3 urinary bladder cancers, 1uterus cancer); FIG. 1I: Peptide: GLIDSLMAYV (SEQ ID NO.: 28); Tissuesfrom left to right: 2 normal tissues (1 head-and-neck, 1 thymus), 27cancer tissues (11 head-and-neck cancers, 1 skin cancer, 1 lymph nodecancer, 2 esophageal cancers, 9 lung cancers, 3 urinary bladdercancers); FIG. 1J: Peptide: SLIGGTNFV (SEQ ID NO.: 49); Tissues fromleft to right: 3 normal tissues (2 lymph nodes, 1 spleen), 38 cancertissues (1 myeloid cells cancer, 2 leukocytic leukemia cancers, 1 bonemarrow cancer, 1 prostate cancer, 3 breast cancers, 1 leukocyticleukemia cancers, 2 colon cancers, 7 liver cancers, 2 skin cancers, 8lymph node cancers, 1 esophageal cancer, 4 lung cancers, 3 urinarybladder cancers, 2 uterus cancers); FIG. 1K: Peptide: ILLRDLPTL (SEQ IDNO.: 56); Tissues from left to right: 14 cell lines (9 lymphocytes, 4begnin, 1 pancreas), 11 normal tissues (1 esophagus, 2 livers, 3 lungs,1 parathyroid gland, 1 spleen, 1 stomach, 1 thyroid gland, 1 uterus), 72cancer tissues (17 prostate cancers, 4 breast cancers, 2 colon cancers,1 bile duct cancer, 1 gallbladder cancer, 1 liver cancer, 2head-and-neck cancers, 1 skin cancer, 5 lymph node cancers, 3 ovariancancers, 2 esophageal cancers, 1 esophagus and stomach cancer, 1 stomachcancer, 20 lung cancers, 1 pancreas cancer, 7 urinary bladder cancers, 3uterus cancers); FIG. 1L: Peptide: GLDSSVNVQGSVL (SEQ ID NO.: 58);Tissues from left to right: 2 cell lines (2 leukocytes), 7 normaltissues (1 adrenal gland, 1 lymph node, 5 spleens), 40 cancer tissues (1colon cancer, 1 bile duct cancer, 1 liver cancer, 2 head-and-neckcancers, 2 skin cancers, 4 lymph node cancers, 6 ovarian cancers, 1esophagus and stomach cancer, 1 stomach cancer, 17 lung cancers, 3urinary bladder cancers, 1 uterus cancer); FIG. 1M: Peptide: HLLDSKVPSV(SEQ ID NO.: 85); Tissues from left to right: 2 normal tissues (2spleens), 25 cancer tissues (1 colon cancer, 2 liver cancers, 2head-and-neck cancers, 2 ovarian cancers, 2 esophageal cancers, 1 braincancer, 12 lung cancers, 3 urinary bladder cancers); FIG. 1N: Peptide:ALIGDDVGL (SEQ ID NO.: 99); Tissues from left to right: 6 normal tissues(2 leukocyte samples, 1 lymphocytes, 1 pancreas, 1 spleen, 1 thymus), 34cancer tissues (1 myeloid cells cancer, 1 bone marrow cancer, 2leukocytic leukemia cancers, 2 colon cancers, 1 colorectal cancer, 1gallbladder cancer, 4 head-and-neck cancers, 2 skin cancers, 2 lymphnode cancers, 2 ovarian cancers, 1 esophageal cancer, 1 stomach cancer,9 lung cancers, 4 urinary bladder cancers, 1 uterus cancer); FIG. 1O:Peptide: FVFEPPPGV (SEQ ID NO.: 113); Tissues from left to right: 5 celllines (1 skin, 1 urinary bladder, 1 ovary, 2 pancreas), 25 cancertissues (1 prostate cancer, 1 breast cancer, 1 liver cancer, 2head-and-neck cancers, 6 skin cancers, 1 lymph node cancer, 2 pancreascancers, 1 brain cancer, 2 stomach cancers, 4 lung cancers, 4 urinarybladder cancers); FIG. 1P: Peptide: QLQGYLRSV (SEQ ID NO.: 121); Tissuesfrom left to right: 10 cell lines (1 ovary, 2 primary cultures, 1lymphocytes, 1 leukocytes, 1 kidney, 2 rectum, 2 pancreas), 7 normaltissues (1 adrenal gland, 1 leukocyte sample, 3 bone marrows, 1 colon, 1trachea), 36 cancer tissues (1 cecum cancer, 1 myeloid cells cancer, 1leukocytic leukemia cancer, 4 colon cancers, 1 rectum cancer, 1 bileduct cancer, 5 liver cancers, 6 head-and-neck cancers, 1 lymph nodecancer, 1 esophageal cancer, 1 pancreas cancer, 1 brain cancer, 9 lungcancers, 1 urinary bladder cancer, 2 uterus cancers); FIG. 1Q: Peptide:ILEPSLYTV (SEQ ID NO.: 122); Tissues from left to right: 13 cell lines(1 kidney, 2 leukocytes, 1 skin, 9 pancreas), 10 normal tissues (1adrenal gland, 5 colons, 1 liver, 2 lungs, 1 lymph node), 63 cancertissues (2 myeloid cells cancers, 2 leukocytic leukemia cancers, 1 bonemarrow cancer, 2 prostate cancers, 4 breast cancers, 2 leukocyticleukemia cancers, 1 colon cancer, 1 rectum cancer, 1 bile duct cancer, 7liver cancers, 3 head-and-neck cancers, 5 skin cancers, 2 lymph nodecancers, 2 ovarian cancers, 1 esophageal cancer, 1 pancreas cancer, 5brain cancers, 4 stomach cancers, 5 lung cancers, 3 kidney cancers, 1lung cancer, 4 urinary bladder cancers, 4 uterus cancers); FIG. 1R:Peptide: YLEPKLTQV (SEQ ID NO.: 129); Tissues from left to right: 25cell lines (1 head-and-neck, 1 ovary, 1 PBMCs, 2 lymphocytes, 3 skins, 1kidney, 16 pancreas), 8 normal tissues (3 adrenal glands, 1 bone marrow,1 head-and-neck and salivary gland, 1 kidney, 1 liver, 1 spleen), 62cancer tissues (1 myeloid cells cancer, 1 bone marrow cancer, 1leukocytic leukemia cancer, 3 prostate cancers, 1 breast cancer, 1 coloncancer, 2 bile duct cancers, 6 liver cancers, 3 head-and-neck cancers, 5skin cancers, 2 lymph node cancers, 3 ovarian cancers, 2 esophagealcancers, 2 brain cancers, 1 stomach cancer, 11 lung cancers, 1 kidneycancer, 4 lung cancers, 6 urinary bladder cancers, 6 uterus cancers).

FIGS. 2A through 2D show exemplary expression profiles of source genesof the present invention that are highly over-expressed or exclusivelyexpressed in urinary bladder cancer in a panel of normal tissues (whitebars) and 10 urinary bladder cancer samples (black bars). Tissue fromleft to right: 6 arteries, 2 blood cells, 2 brains, 1 heart, 2 livers, 3lungs, 2 veins, 1 adipose tissue, 1 adrenal gland, 5 bone marrows, 1cartilage, 1 colon, 1 esophagus, 2 eyes, 2 gallbladders, 1 kidney, 6lymph nodes, 4 pancreases, 2 peripheral nerves, 2 pituitary glands, 1rectum, 2 salivary glands, 2 skeletal muscles, 1 skin, 1 smallintestine, 1 spleen, 1 stomach, 1 thyroid gland, 7 tracheas, 1 urinarybladder, 1 breast, 5 ovaries, 5 placentas, 1 prostate, 1 testis, 1thymus, 1 uterus, 10 urinary bladder cancer samples. FIG. 2A: Genesymbol: TMPRSS4; FIG. 2B: Gene symbol: KRT7; FIG. 2C: Gene symbol:CYP4F22; FIG. 2D: Gene symbol: DHRS2.

FIG. 3 shows exemplary immunogenicity data: flow cytometry results afterpeptide-specific multimer staining.

FIG. 4 shows exemplary results of peptide-specific in vitro CD8+ T cellresponses of a healthy HLA-A*02+ donor. CD8+ T cells were primed usingartificial APCs coated with anti-CD28 mAb and HLA-A*02 in complex withSeqID No 30 peptide (A, left panel), SeqID No 50 peptide (B, left panel)and SeqID No 111 peptide (C, left panel), respectively. After threecycles of stimulation, the detection of peptide-reactive cells wasperformed by 2D multimer staining with A*02/SeqID No 30 (A), A*02/SeqIDNo 50 (B) or A*02/SeqID No 111 (C). Right panels (A, B and C) showcontrol staining of cells stimulated with irrelevant A*02/peptidecomplexes. Viable singlet cells were gated for CD8+ lymphocytes. Booleangates helped excluding false-positive events detected with multimersspecific for different peptides. Frequencies of specific multimer+ cellsamong CD8+ lymphocytes are indicated.

EXAMPLES Example 1

Identification and Quantitation of Tumor Associated Peptides Presentedon the Cell Surface

Tissue Samples

Patients' tumor tissues were obtained from: Asterand (Detroit, Mich.,USA & Royston, Herts, UK); Geneticist Inc. (Glendale, Calif., USA);ProteoGenex Inc. (Culver City, Calif., USA); Tissue Solutions Ltd(Glasgow, UK); and University Hospital Tübingen (Tübingen, Germany)

Normal Tissues were Obtained from

Asterand (Detroit, Mich., USA & Royston, Herts, UK); Bio-Options Inc.(Brea, Calif., USA); BioServe (Beltsville, Md., USA);Blutspendezentrale, Zentrum für Klinische Transfusionsmedizin, Tübingen;Capital BioScience Inc. (Rockville, Md., USA); Geneticist Inc.(Glendale, Calif., USA); Kyoto Prefectural University of Medicine (KPUM)(Kyoto, Japan); ProteoGenex Inc. (Culver City, Calif., USA); TissueSolutions Ltd (Glasgow, UK); University Hospital Geneva (Geneva,Switzerland); University Hospital Heidelberg (Heidelberg, Germany);University Hospital Munich (Munich, Germany); and University HospitalTübingen (Tübingen, Germany)

Written informed consents of all patients had been given before surgeryor autopsy. Tissues were shock-frozen immediately after excision andstored until isolation of TUMAPs at −70° C. or below.

Isolation of HLA Peptides from Tissue Samples

HLA peptide pools from shock-frozen tissue samples were obtained byimmune precipitation from solid tissues according to a slightly modifiedprotocol (Falk et al., 1991; Seeger et al., 1999) using theHLA-A*02-specific antibody BB7.2, the HLA-A, —B, C-specific antibodyW6/32, CNBr-activated sepharose, acid treatment, and ultrafiltration.

Mass Spectrometry Analyses

The HLA peptide pools as obtained were separated according to theirhydrophobicity by reversed-phase chromatography (nanoAcquity UPLCsystem, Waters) and the eluting peptides were analyzed in LTQ-velos andfusion hybrid mass spectrometers (ThermoElectron) equipped with an ESIsource. Peptide pools were loaded directly onto the analyticalfused-silica micro-capillary column (75 μm i.d.×250 mm) packed with 1.7μm C18 reversed-phase material (Waters) applying a flow rate of 400 nLper minute. Subsequently, the peptides were separated using a two-step180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nLper minute. The gradient was composed of Solvent A (0.1% formic acid inwater) and solvent B (0.1% formic acid in acetonitrile). A gold coatedglass capillary (PicoTip, New Objective) was used for introduction intothe nanoESI source. The LTQ-Orbitrap mass spectrometers were operated inthe data-dependent mode using a TOP5 strategy. In brief, a scan cyclewas initiated with a full scan of high mass accuracy in the orbitrap(R=30 000), which was followed by MS/MS scans also in the orbitrap(R=7500) on the 5 most abundant precursor ions with dynamic exclusion ofpreviously selected ions. Tandem mass spectra were interpreted bySEQUEST and additional manual control. The identified peptide sequencewas assured by comparison of the generated natural peptide fragmentationpattern with the fragmentation pattern of a synthetic sequence-identicalreference peptide.

Label-free relative LC-MS quantitation was performed by ion countingi.e. by extraction and analysis of LC-MS features (Mueller et al.,2007). The method assumes that the peptide's LC-MS signal areacorrelates with its abundance in the sample. Extracted features werefurther processed by charge state deconvolution and retention timealignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MSfeatures were cross-referenced with the sequence identification resultsto combine quantitative data of different samples and tissues to peptidepresentation profiles. The quantitative data were normalized in atwo-tier fashion according to central tendency to account for variationwithin technical and biological replicates. Thus each identified peptidecan be associated with quantitative data allowing relativequantification between samples and tissues. In addition, allquantitative data acquired for peptide candidates was inspected manuallyto assure data consistency and to verify the accuracy of the automatedanalysis. For each peptide a presentation profile was calculated showingthe mean sample presentation as well as replicate variations. Theprofiles juxtapose urinary bladder cancer samples to a baseline ofnormal tissue samples. Presentation profiles of exemplary over-presentedpeptides are shown in FIGS. 1A-1R. Presentation scores for exemplarypeptides are shown in Table 8.

TABLE 8 Presentation scores. The table lists peptidesthat are very highly over-presented on tumorscompared to a panel of normal tissues (+++),highly over-presented on tumors compared toa panel of normal tissues (++) or over-presentedon tumors compared to a panel of normal tissues(+). The panel of normal tissues consideredrelevant for comparison with tumors consisted of:adipose tissue, adrenal gland, blood cells,blood vessel, bone marrow, brain, esophagus,eye, gallbladder, heart, kidney, large intestine,liver, lung, lymph node, nerve, pancreas,parathyroid gland, peritoneum, pituitary, pleura,salivary gland, skeletal muscle, skin, smallintestine, spleen, stomach, thymus, thyroid gland,trachea, ureter, urinary bladder. SEQ ID No. SequencePeptide Presentation 1 ILLQASVQV +++ 2 GLLKAYSIRTA +++ 3 YLDEIPPKFSM +++4 SLDVVNLLV +++ 6 SIVDFLITA +++ 7 QMFEGQILDV +++ 8 ALSFSSSAGPGLLKA +++ 9SLVDARFQL +++ 10 GLWHGMFANV +++ 11 AMAELRVVV ++ 12 GVALTVTGV +++ 13FLEEKEQAAL +++ 14 GLAGPVRGV +++ 15 YLAPENGYLMEA +++ 16 ILGPQGNTI +++ 17RLSQLEGVNV + 18 SIAAYNPVV +++ 19 SLATTLTKI +++ 20 YLPDSLTQL +++ 21TLIEDDALNGA +++ 23 YTLSKTEFL +++ 24 SLLGGITVV ++ 28 GLIDSLMAYV +++ 30ILDISRSEV +++ 31 SLFDGIATGL +++ 33 VLFGEITRL ++ 34 ALLDEQQVNV ++ 35KLPEPPPLA +++ 36 ALWDEFNQL +++ 37 ILSAILVHL +++ 38 TLTSIIVAV +++ 40VIADRVVTV +++ 41 FLDDGNQMLL +++ 42 FLIDASQRV +++ 43 FLIESKLLSL +++ 44GLAQDPKSLQL +++ 45 IIDSSPTAL +++ 46 SLFIGAEIVAV +++ 47 VLMDDTDPL +++ 48VLMDDTDPLV +++ 49 SLIGGTNFV ++ 50 VLANRVAVV + 51 ALLDKAQINL ++ 53ILVQVIPVV +++ 54 ALNDEINFL +++ 55 KLLETKWTL + 56 ILLRDLPTL ++ 57GLAHFVNEI ++ 58 GLDSSVNVQGSVL +++ 59 WLSTSIPEA ++ 60 SLSDVRVIV ++ 62GQLDFSEFL + 63 LLAGLLVGV +++ 64 GLLSQGSPL +++ 65 IITDLLRSV +++ 66SLWEENQAL ++ 67 FLTPPLLSV +++ 68 TMIVSLAAV ++ 69 QIWDKILSV + 70KLAEISLGV +++ 73 VLKVFLENV ++ 74 LLQEGEVYSA + 77 KVFGGFQVV ++ 80ILLDTPLFLL +++ 81 SLDKGTLYI ++ 82 NLHNSYYSV + 83 VILDKYYFL + 84ALDPASISV + 87 RLLELLQEA ++ 89 YLFPETEFI + 91 NLDAATYQV + 92ALLDEQQVNVLL + 94 ALADGVPVAL ++ 96 KLTNGIWVL + 97 TVGPGLLGV ++ 98YLIGLDPENLAL ++ 99 ALIGDDVGL ++ 100 SLQSFIHGV + 102 GLYEGLDWL +++ 103GLYSGEVLV + 104 NAVVELVTV ++ 106 ILLDTPLFL + 107 LULAKLEKV +++ 110VLFNIDGQGNHV +++ 111 LLDVTPKAV +++ 112 YLDPSLNSL +++ 113 FVFEPPPGV +++114 IITKDLFQV +++ 115 SLLDFERSL +++ 116 QLAWFDTDL + 117 YMLDIFHEVL +++118 RLLDFPTLLV +++ 119 SLDEKQNLV +++ 120 IIIPEIQKV ++ 121 QLQGYLRSV ++122 ILEPSLYTV +++ 123 NLAGVYSEV ++ 124 QIDGTLSTI ++ 125 VLDEGSASV ++ 126SLLRVGWSV ++ 129 YLEPKLTQV ++ 130 TLTSKLYSL + 132 YILEGEPGKV ++ 133GLDPLGYEIQL + 134 IVAPGTFEV + 135 FLLPLIIVL +++ 136 GLSEPIFQL +++ 137ALFPHLLQPVL ++ 138 YLTNEGIQYL ++ 139 LLYPTEITV +++ 140 ALLDGRVQL ++ 141SMFGAGLTV + 142 FLGENISNFL +++ 143 TLVTGLASV + 146 YLARIQGFQV + 147QMLELITRL + 149 VLLRVLILL +

Example 2

Expression Profiling of Genes Encoding the Peptides of the Invention

Over-presentation or specific presentation of a peptide on tumor cellscompared to normal cells is sufficient for its usefulness inimmunotherapy, and some peptides are tumor-specific despite their sourceprotein occurring also in normal tissues. Still, mRNA expressionprofiling adds an additional level of safety in selection of peptidetargets for immunotherapies. Especially for therapeutic options withhigh safety risks, such as affinity-matured TCRs, the ideal targetpeptide will be derived from a protein that is unique to the tumor andnot found on normal tissues.

RNA Sources and Preparation

Surgically removed tissue specimens were provided as indicated above(see Example 1) after written informed consent had been obtained fromeach patient. Tumor tissue specimens were snap-frozen immediately aftersurgery and later homogenized with mortar and pestle under liquidnitrogen. Total RNA was prepared from these samples using TRI Reagent(Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy (QIAGEN,Hilden, Germany); both methods were performed according to themanufacturer's protocol.

Total RNA from healthy human tissues for RNASeq experiments was obtainedfrom: Asterand (Detroit, Mich., USA & Royston, Herts, UK); BioCat GmbH(Heidelberg, Germany); BioServe (Beltsville, Md., USA); CapitalBioScience Inc. (Rockville, Md., USA); Geneticist Inc. (Glendale,Calif., USA); Istituto Nazionale Tumori “Pascale” (Naples, Italy);ProteoGenex Inc. (Culver City, Calif., USA); and University HospitalHeidelberg (Heidelberg, Germany).

Total RNA from tumor tissues for RNASeq experiments was obtained from:Asterand (Detroit, Mich., USA & Royston, Herts, UK); Geneticist Inc.(Glendale, Calif., USA); ProteoGenex Inc. (Culver City, Calif., USA);and Tissue Solutions Ltd (Glasgow, UK).

Quality and quantity of all RNA samples were assessed on an Agilent 2100Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 PicoLabChip Kit (Agilent).

RNAseq Experiments

Gene expression analysis of—tumor and normal tissue RNA samples wasperformed by next generation sequencing (RNAseq) by CeGaT (Tübingen,Germany). Briefly, sequencing libraries are prepared using the IlluminaHiSeq v4 reagent kit according to the provider's protocol (IlluminaInc., San Diego, Calif., USA), which includes RNA fragmentation, cDNAconversion and addition of sequencing adaptors. Libraries derived frommultiple samples are mixed equimolar and sequenced on the Illumina HiSeq2500 sequencer according to the manufacturer's instructions, generating50 bp single end reads. Processed reads are mapped to the human genome(GRCh38) using the STAR software. Expression data are provided ontranscript level as RPKM (Reads Per Kilobase per Million mapped reads,generated by the software Cufflinks) and on exon level (total reads,generated by the software Bedtools), based on annotations of the ensemblsequence database (Ensembl77). Exon reads are normalized for exon lengthand alignment size to obtain RPKM values. Exemplary expression profilesof source genes of the present invention that are highly over-expressedor exclusively expressed in urinary bladder cancer are shown in FIGS.2A-2D. Expression scores for further exemplary genes are shown in Table9.

TABLE 9 Expression scores. The table lists peptides fromgenes that are very highly over-expressed in tumorscompared to a panel of normal tissues (+++),highly over-expressed in tumors compared to a panelof normal tissues (++) or over-expressed intumors compared to a panel of normal tissues (+).The baseline for this score was calculated frommeasurements of the following relevant normaltissues: adipose tissue, adrenal gland, artery,blood cells, bone marrow, brain, cartilage, colon,esophagus, eye, gallbladder, heart, kidney, liver,lung, lymph node, pancreas, peripheral nerve,pituitary, rectum, salivary gland, skeletal muscle,skin, small intestine, spleen, stomach, thyroidgland, trachea, urinary bladder, and vein. In caseexpression data for several samples of the sametissue type were available, the arithmetic mean ofall respective samples was used for the calculation. SEQ ID No. SequenceGene Expression 1 ILLQASVQV +++ 2 GLLKAYSIRTA +++ 3 YLDEIPPKFSM ++ 4SLDVVNLLV ++ 5 IQDPVIFYV + 6 SIVDFLITA + 8 ALSFSSSAGPGLLKA +++ 11AMAELRVVV +++ 18 SIAAYNPVV +++ 21 TLIEDDALNGA ++ 22 SIAKEGVVGA ++ 34ALLDEQQVNV +++ 35 KLPEPPPLA +++ 36 ALWDEFNQL +++ 37 ILSAILVHL +++ 38TLTSIIVAV +++ 40 VIADRVVTV + 46 SLFIGAEIVAV + 50 VLANRVAVV +++ 53ILVQVIPVV + 54 ALNDEINFL +++ 55 KLLETKWTL +++ 56 ILLRDLPTL +++ 69QIWDKILSV +++ 76 AVVSSVNTV ++ 83 VILDKYYFL +++ 85 HLLDSKVPSV ++ 87RLLELLQEA +++ 89 YLFPETEFI ++ 92 ALLDEQQVNVLL +++ 100 SLQSFIHGV +++ 109RLIDDMVAQA + 110 VLFNIDGQGNHV +++ 117 YMLDIFHEVL +++ 124 QIDGTLSTI + 135FLLPLIIVL + 139 LLYPTEITV ++ 140 ALLDGRVQL +++ 142 FLGENISNFL +++ 149VLLRVLILL ++

Example 3

In Vitro Immunogenicity for MHC Class I Presented Peptides

In order to obtain information regarding the immunogenicity of theTUMAPs of the present invention, the inventors performed investigationsusing an in vitro T-cell priming assay based on repeated stimulations ofCD8+ T cells with artificial antigen presenting cells (aAPCs) loadedwith peptide/MHC complexes and anti-CD28 antibody. This way theinventors could show immunogenicity for HLA-A*0201 restricted TUMAPs ofthe invention, demonstrating that these peptides are T-cell epitopesagainst which CD8+ precursor T cells exist in humans (Table 10).

In Vitro Priming of CD8+ T Cells

In order to perform in vitro stimulations by artificial antigenpresenting cells loaded with peptide-MHC complex (pMHC) and anti-CD28antibody, the inventors first isolated CD8+ T cells from fresh HLA-A*02leukapheresis products via positive selection using CD8 microbeads(Miltenyi Biotec, Bergisch-Gladbach, Germany) of healthy donors obtainedfrom the University clinics Mannheim, Germany, after informed consent.

PBMCs and isolated CD8+ lymphocytes were incubated in T-cell medium(TCM) until use consisting of RPMI-Glutamax (Invitrogen, Karlsruhe,Germany) supplemented with 10% heat inactivated human AB serum(PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin/100 μg/mlStreptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro,Oberdorla, Germany), 20 μg/ml Gentamycin (Cambrex). 2.5 ng/ml IL-7(PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Novartis Pharma,Nümberg, Germany) were also added to the TCM at this step.

Generation of pMHC/anti-CD28 coated beads, T-cell stimulations andreadout was performed in a highly defined in vitro system using fourdifferent pMHC molecules per stimulation condition and 8 different pMHCmolecules per readout condition.

The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung etal., 1987) was chemically biotinylated usingSulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer(Perbio, Bonn, Germany). Beads used were 5.6 μm diameter streptavidincoated polystyrene particles (Bangs Laboratories, Illinois, USA).

pMHC used for positive and negative control stimulations wereA*0201/MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 206) from modifiedMelan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO.207), respectively.

800.000 beads/200 μl were coated in 96-well plates in the presence of4×12.5 ng different biotin-pMHC, washed and 600 ng biotin anti-CD28 wereadded subsequently in a volume of 200 μl. Stimulations were initiated in96-well plates by co-incubating 1×10⁶ CD8+ T cells with 2×10⁵ washedcoated beads in 200 μl TCM supplemented with 5 ng/ml IL-12 (PromoCell)for 3 days at 37° C. Half of the medium was then exchanged by fresh TCMsupplemented with 80 U/ml IL-2 and incubating was continued for 4 daysat 37° C. This stimulation cycle was performed for a total of threetimes. For the pMHC multimer readout using 8 different pMHC moleculesper condition, a two-dimensional combinatorial coding approach was usedas previously described (Andersen et al., 2012) with minor modificationsencompassing coupling to 5 different fluorochromes. Finally, multimericanalyses were performed by staining the cells with Live/dead near IR dye(Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD,Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BDLSRII SORP cytometer equipped with appropriate lasers and filters wasused. Peptide specific cells were calculated as percentage of total CD8+cells. Evaluation of multimeric analysis was done using the FlowJosoftware (Tree Star, Oreg., USA). In vitro priming of specificmultimer+CD8+ lymphocytes was detected by comparing to negative controlstimulations. Immunogenicity for a given antigen was detected if atleast one evaluable in vitro stimulated well of one healthy donor wasfound to contain a specific CD8+ T-cell line after in vitro stimulation(i.e. this well contained at least 1% of specific multimer+ among CD8+T-cells and the percentage of specific multimer+ cells was at least 10×the median of the negative control stimulations).

In Vitro Immunogenicity for Urinary Bladder Cancer Peptides

For tested HLA class I peptides, in vitro immunogenicity could bedemonstrated by generation of peptide specific T-cell lines. Exemplaryflow cytometry results after TUMAP-specific multimer staining for 2peptides of the invention are shown in FIG. 3 together withcorresponding negative controls. Exemplary flow cytometry results afterTUMAP-specific multimer staining for 3 peptides of the invention areshown in FIG. 4 together with corresponding negative controls. Resultsfor 25 peptides from the invention are summarized in Table 10A.Additional results for 26 peptides from the invention are summarized inTable 10B.

TABLE 10A in vitro immunogenicity of HLA class I peptidesof the invention. Exemplary results of in vitroimmunogenicity experiments conducted by theapplicant for the peptides of the invention.<20% = +; 20%-49% = ++; 50%-69% = +++; >=70% = ++++ SEQ ID No. SequenceWells 155 VLSSGLTAA + 156 KLVEFDFLGA + 159 SLIEDLILL + 160 SLLGGNIRL ++162 TLLAAEFLKQV + 164 ALADLTGTVV + 167 SLWGGDVVL ++ 168 LTAPPEALLMV +170 GLIEIISNA + 172 LLYGHTVTV ++ 173 FVFSFPVSV ++ 176 SMSGYDQVL + 177NLLQVLEKV + 178 ALNEEAGRLLL + 182 YLAPFLRNV ++ 184 LMTKEISSV + 186VLYPHEPTAV + 189 ALLRTVVSV + 192 ALNPADITV ++ 193 ALVQDLAKA ++ 198NLIEKSIYL + 200 YLNVQVKEL + 203 FLIPYAIML + 204 GVYDGEEHSV + 205KIVDFSYSV ++

TABLE 10B In vitro immunogenicity of HLA class I peptidesof the invention. Exemplary results of in vitroimmunogenicity experiments conducted by theapplicant for HLA-A*02 restricted peptides ofthe invention. Results of in vitro immunogenicityexperiments are indicated. Percentage of positivewells and donors (among evaluable) are summarizedas indicated <20% = +; 20%-49% = ++; 50%-69% = +++; >=70% = ++++SEQ ID NO: Sequence Wells positive [%] 4 SLDVVNLLV + 5 IQDPVIFYV +++ 6SIVDFLITA + 9 SLVDARFQL + 10 GLWHGMFANV ++ 14 GLAGPVRGV + 15YLAPENGYLMEA + 16 ILGPQGNTI + 17 RLSQLEGVNV + 23 YTLSKTEFL + 24SLLGGITVV ++ 27 STTNGGILTV + 29 ALSSPPPTV + 30 ILDISRSEV ++++ 41FLDDGNQMLL + 50 VLANRVAVV ++++ 53 ILVQVIPVV ++ 57 GLAHFVNEI + 59WLSTSIPEA + 60 SLSDVRVIV + 75 RVISSVISV ++ 111 LLDVTPKAV +++ 114IITKDLFQV + 126 SLLRVGWSV ++ 146 YLARIQGFQV ++ 148 TLGVIPESV +

Example 4

Synthesis of Peptides

All peptides were synthesized using standard and well-established solidphase peptide synthesis using the Fmoc-strategy. Identity and purity ofeach individual peptide have been determined by mass spectrometry andanalytical RP-HPLC. The peptides were obtained as white to off-whitelyophilizates (trifluoro acetate salt) in purities of >50%. All TUMAPsare preferably administered as trifluoro-acetate salts or acetate salts,other salt-forms are also possible.

Example 5

MHC Binding Assays

Candidate peptides for T cell based therapies according to the presentinvention were further tested for their MHC binding capacity (affinity).The individual peptide-MHC complexes were produced by UV-ligandexchange, where a UV-sensitive peptide is cleaved upon UV-irradiation,and exchanged with the peptide of interest as analyzed. Only peptidecandidates that can effectively bind and stabilize the peptide-receptiveMHC molecules prevent dissociation of the MHC complexes. To determinethe yield of the exchange reaction, an ELISA was performed based on thedetection of the light chain (β2m) of stabilized MHC complexes. Theassay was performed as generally described in Rodenko et al. (Rodenko etal., 2006).

96 well MAXISorp plates (NUNC) were coated over night with 2 ug/mlstreptavidin in PBS at room temperature, washed 4× and blocked for 1 hat 37° C. in 2% BSA containing blocking buffer. RefoldedHLA-A*02:01/MLA-001 monomers served as standards, covering the range of15-500 ng/ml. Peptide-MHC monomers of the UV-exchange reaction werediluted 100 fold in blocking buffer. Samples were incubated for 1 h at37° C., washed four times, incubated with 2 ug/ml HRP conjugatedanti-β2m for 1 h at 37° C., washed again and detected with TMB solutionthat is stopped with NH₂SO₄. Absorption was measured at 450 nm.Candidate peptides that show a high exchange yield (preferably higherthan 50%, most preferred higher than 75%) are generally preferred for ageneration and production of antibodies or fragments thereof, and/or Tcell receptors or fragments thereof, as they show sufficient avidity tothe MHC molecules and prevent dissociation of the MHC complexes.

TABLE 11 MHC class I binding scores. Binding of HLA-classI restricted peptides to HLA-A*02:01 was ranged by peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++SEQ ID No Sequence Peptide exchange 1 ILLQASVQV ++++ 2 GLLKAYSIRTA +++ 3YLDEIPPKFSM ++++ 4 SLDVVNLLV ++++ 5 IQDPVIFYV ++++ 6 SIVDFLITA +++ 7QMFEGQILDV +++ 8 ALSFSSSAGPGLLKA +++ 9 SLVDARFQL ++++ 10 GLWHGMFANV ++++11 AMAELRVVV ++++ 12 GVALTVTGV ++++ 13 FLEEKEQAAL +++ 14 GLAGPVRGV +++15 YLAPENGYLMEA +++ 16 ILGPQGNTI +++ 17 RLSQLEGVNV +++ 18 SIAAYNPVV ++++19 SLATTLTKI +++ 20 YLPDSLTQL ++++ 21 TLIEDDALNGA +++ 23 YTLSKTEFL ++++24 SLLGGITVV ++++ 25 SLDSSGFSL +++ 26 GLALLYSGV ++++ 27 STTNGGILTV +++28 GLIDSLMAYV ++++ 29 ALSSPPPTV +++ 30 ILDISRSEV +++ 31 SLFDGIATGL ++++32 YQAPDIDVQL +++ 33 VLFGEITRL +++ 34 ALLDEQQVNV +++ 35 KLPEPPPLA +++ 36ALWDEFNQL +++ 37 ILSAILVHL +++ 38 TLTSIIVAV +++ 39 AMASHLTST +++ 40VIADRVVTV +++ 41 FLDDGNQMLL ++++ 42 FLIDASQRV +++ 43 FLIESKLLSL ++++ 44GLAQDPKSLQL +++ 45 IIDSSPTAL ++ 47 VLMDDTDPL +++ 48 VLMDDTDPLV +++ 49SLIGGTNFV +++ 50 VLANRVAVV +++ 52 SLATLEGIQL +++ 53 ILVQVIPVV +++ 54ALNDEINFL +++ 55 KLLETKWTL ++++ 56 ILLRDLPTL +++ 57 GLAHFVNEI ++++ 58GLDSSVNVQGSVL +++ 59 WLSTSIPEA ++++ 60 SLSDVRVIV ++++ 62 GQLDFSEFL +++63 LLAGLLVGV +++ 64 GLLSQGSPL +++ 65 IITDLLRSV ++++ 66 SLWEENQAL +++ 67FLTPPLLSV ++++ 68 TMIVSLAAV +++ 69 QIWDKILSV +++ 70 KLAEISLGV ++ 71LLSEDFVSV ++ 72 SLFTGLRSI +++ 73 VLKVFLENV ++++ 74 LLQEGEVYSA +++ 75RVISSVISV +++ 76 AVVSSVNTV +++ 77 KVFGGFQVV ++++ 78 FIPDFAVAI ++++ 79FLDPATPRV +++ 80 ILLDTPLFLL +++ 81 SLDKGTLYI +++ 82 NLHNSYYSV +++ 83VILDKYYFL ++++ 84 ALDPASISV +++ 85 HLLDSKVPSV +++ 86 FLIJLIISV +++ 87RLLELLQEA ++++ 88 ALASLENHV +++ 89 YLFPETEFI +++ 90 GMTELYFQL +++ 91NLDAATYQV +++ 92 ALLDEQQVNVLL +++ 93 LLDLIQTKV +++ 94 ALADGVPVAL +++ 95YLIGQHVTA ++++ 96 KLTNGIWVL +++ 97 TVGPGLLGV +++ 98 YLIGLDPENLAL +++ 99ALIGDDVGL +++ 100 SLQSFIHGV +++ 101 ILDEMRAQL +++ 102 GLYEGLDWL +++ 103GLYSGEVLV ++++ 105 TLFPSKIGV +++ 106 ILLDTPLFL +++ 107 LULAKLEKV ++ 108YLDPNQRDL +++ 109 RLIDDMVAQA +++ 110 VLFNIDGQGNHV +++ 111 LLDVTPKAV +++112 YLDPSLNSL +++ 113 FVFEPPPGV ++++ 114 IITKDLFQV +++ 115 SLLDFERSL +++116 QLAWFDTDL +++ 117 YMLDIFHEVL +++ 118 RLLDFPTLLV +++ 119 SLDEKQNLV+++ 120 IIIPEIQKV +++ 121 QLQGYLRSV +++ 122 ILEPSLYTV ++++ 123 NLAGVYSEV++++ 124 QIDGTLSTI +++ 126 SLLRVGWSV ++++ 127 KLNATNIEL +++ 128KLWGQSIQL ++++ 129 YLEPKLTQV +++ 130 TLTSKLYSL ++++ 131 ILTSIQSLL ++++132 YILEGEPGKV ++++ 133 GLDPLGYEIQL ++++ 134 IVAPGTFEV +++ 135 FLLPLIIVL+++ 136 GLSEPIFQL +++ 137 ALFPHLLQPVL ++++ 138 YLTNEGIQYL +++ 139LLYPTEITV +++ 140 ALLDGRVQL ++++ 141 SMFGAGLTV ++++ 142 FLGENISNFL +++143 TLVTGLASV +++ 144 YLAGEAPTL +++ 145 ALYPGQLVQL +++ 146 YLARIQGFQV++++ 147 QMLELITRL +++ 148 TLGVIPESV ++++

REFERENCE LIST

-   Allison, J. P. et al., Science 270 (1995): 932-933-   American Cancer Society, (2015), www.cancer.org-   Andersen, R. S. et al., Nat. Protoc. 7 (2012): 891-902-   Appay, V. et al., Eur. J Immunol. 36 (2006): 1805-1814-   Arafat, H. et al., Surgery 150 (2011): 306-315-   Azevedo, R. et al., J Control Release 214 (2015): 40-61-   Banchereau, J. et al., Cell 106 (2001): 271-274-   Beatty, G. et al., J Immunol 166 (2001): 2276-2282-   Beggs, J. D., Nature 275 (1978): 104-109-   Benjamini, Y. et al., Journal of the Royal Statistical Society.    Series B (Methodological), Vol. 57 (1995): 289-300-   Bidkhori, G. et al., PLoS. One. 8 (2013): e67552-   Boulter, J. M. et al., Protein Eng 16 (2003): 707-711-   Braumuller, H. et al., Nature (2013)-   Brody, J. R. et al., Cancer Biol Ther. (2016): 0-   Brossart, P. et al., Blood 90 (1997): 1594-1599-   Bruckdorfer, T. et al., Curr. Pharm. Biotechnol. 5 (2004): 29-43-   Cahill, D. P. et al., CNS. Oncol 4 (2015): 287-294-   Card, K. F. et al., Cancer Immunollmmunother. 53 (2004): 345-357-   Chang, W. et al., Int. J Cancer 125 (2009): 2844-2853-   Chanock, S. J. et al., Hum. Immunol. 65 (2004): 1211-1223-   Cohen, C. J. et al., J Mol. Recognit. 16 (2003a): 324-332-   Cohen, C. J. et al., J Immunol. 170 (2003b): 4349-4361-   Cohen, S. N. et al., Proc. Natl. Acad. Sci. U.S.A 69 (1972):    2110-2114-   Coligan, J. E. et al., Current Protocols in Protein Science (1995)-   Colombetti, S. et al., J Immunol. 176 (2006): 2730-2738-   Daugaard, I. et al., Sci. Rep. 6 (2016): 35807-   Davis, J. E. et al., Oncotarget. (2016)-   Dengjel, J. et al., Clin Cancer Res 12 (2006): 4163-4170-   Denkberg, G. et al., J Immunol. 171 (2003): 2197-2207-   Falk, K. et al., Nature 351 (1991): 290-296-   Follenzi, A. et al., Nat Genet. 25 (2000): 217-222-   Fong, L. et al., Proc. Natl. Acad. Sci. U.S.A 98 (2001): 8809-8814-   Fuge, O. et al., Res Rep. Urol. 7 (2015): 65-79-   Gabrilovich, D. I. et al., Nat. Med 2 (1996): 1096-1103-   Gandhi, A. V. et al., Ann Surg. Oncol 20 Suppl 3 (2013): S636-S643-   Gardina, P. J. et al., BMC. Genomics 7 (2006): 325-   Gattinoni, L. et al., Nat. Rev. Immunol. 6 (2006): 383-393-   Georgiou, G. K. et al., World J Surg. Oncol 11 (2013): 213-   Gnjatic, S. et al., Proc Natl. Acad. Sci. U.S.A 100 (2003):    8862-8867-   Godkin, A. et al., Int. Immunol 9 (1997): 905-911-   Green, M. R. et al., Molecular Cloning, A Laboratory Manual 4th    (2012)-   Greenfield, E. A., Antibodies: A Laboratory Manual 2nd (2014)-   Grivas, P. D. et al., Semin. Cancer Biol 35 (2015): 125-132-   Gustafsson, C. et al., Trends Biotechnol. 22 (2004): 346-353-   Harris, T. M. et al., Arch. Pathol. Lab Med. 139 (2015): 494-507-   Huang, Q. et al., Proc. Natl. Acad. Sci. U.S.A 101 (2004): 3456-3461-   Hwang, M. L. et al., J Immunol. 179 (2007): 5829-5838-   Jang, S. Y. et al., Cancer Lett. 314 (2012): 185-197-   Jones, R. T. et al., Urol. Clin North Am. 43 (2016): 77-86-   Jung, G. et al., Proc Natl Acad Sci USA 84 (1987): 4611-4615-   Kang, C. Y. et al., J Gastrointest. Surg. 18 (2014): 7-15-   Kaz, A. M. et al., Genes Chromosomes. Cancer 51 (2012): 384-393-   Kibbe, A. H., Handbook of Pharmaceutical Excipients rd (2000)-   Knollman, H. et al., Ther. Adv. Urol. 7 (2015a): 312-330-   Knollman, H. et al., Ther. Adv. Urol. 7 (2015b): 312-330-   Krieg, A. M., Nat. Rev. Drug Discov. 5 (2006): 471-484-   Kuball, J. et al., Blood 109 (2007): 2331-2338-   Leivo, I. et al., Cancer Genet. Cytogenet. 156 (2005): 104-113-   Li, Y. et al., Mol. Biol Rep. 40 (2013): 4543-4551-   Liddy, N. et al., Nat. Med. 18 (2012): 980-987-   Ljunggren, H. G. et al., J Exp. Med 162 (1985): 1745-1759-   Longenecker, B. M. et al., Ann N.Y. Acad. Sci. 690 (1993): 276-291-   Lonsdale, J., Nat. Genet. 45 (2013): 580-585-   Lukas, T. J. et al., Proc. Natl. Acad. Sci. U.S.A 78 (1981):    2791-2795-   Lundblad, R. L., Chemical Reagents for Protein Modification 3rd    (2004)-   Meziere, C. et al., J Immunol 159 (1997): 3230-3237-   Morgan, R. A. et al., Science 314 (2006): 126-129-   Mori, M. et al., Transplantation 64 (1997): 1017-1027-   Mortara, L. et al., Clin Cancer Res. 12 (2006): 3435-3443-   Mostafa, W. Z. et al., J Cutan. Pathol. 37 (2010): 68-74-   Mueller, L. N. et al., J Proteome. Res. 7 (2008): 51-61-   Mueller, L. N. et al., Proteomics. 7 (2007): 3470-3480-   Mumberg, D. et al., Proc. Natl. Acad. Sci. U.S.A 96 (1999):    8633-8638-   National Cancer Institute, (May 6, 2015), www.cancer.gov-   Oeda, S. et al., Int. J Dev. Biol 57 (2013): 383-389-   Otani, K. et al., J Pathol. 234 (2014): 302-315-   Papagerakis, S. et al., Hum. Pathol. 34 (2003): 565-572-   Persson, F. et al., Cancer Lett. 260 (2008): 37-47-   Pinheiro, J. et al., nlme: Linear and Nonlinear Mixed Effects Models    (CRAN.R-project.org/packe=nlme) (2015)-   Plebanski, M. et al., Eur. J Immunol 25 (1995): 1783-1787-   Porta, C. et al., Virology 202 (1994): 949-955-   Rammensee, H. G. et al., Immunogenetics 50 (1999): 213-219-   Rauch, T. A. et al., Tumour. Biol 33 (2012): 287-296-   Rini, B. I. et al., Cancer 107 (2006): 67-74-   Rock, K. L. et al., Science 249 (1990): 918-921-   Rodenko, B. et al., Nat. Protoc. 1 (2006): 1120-1132-   Rouanne, M. et al., Crit Rev Oncol Hematol. 98 (2016): 106-115-   Saiki, R. K. et al., Science 239 (1988): 487-491-   Sanchez-Palencia, A. et al., Int. J Cancer 129 (2011): 355-364-   Schlienger, S. et al., Mol. Biol Cell 25 (2014): 17-29-   Schlienger, S. et al., Oncotarget. 7 (2016): 15811-15827-   Schmitt, T. M. et al., Hum. Gene Ther. 20 (2009): 1240-1248-   Schmitt-Graeff, A. et al., Histopathology 51 (2007): 87-97-   Scholten, K. B. et al., Clin Immunol. 119 (2006): 135-145-   Scotto, L. et al., Genes Chromosomes. Cancer 47 (2008): 755-765-   Seeger, F. H. et al., Immunogenetics 49 (1999): 571-576-   SEER Stat facts, (2014), seer. cancer.gov/Sherman,-   F. et al., Laboratory Course Manual for Methods in Yeast Genetics    (1986)-   Sherman-Baust, C. A. et al., Cancer Cell 3 (2003): 377-386-   Shi, J. et al., Xi. Bao. Yu Fen. Zi. Mian. Yi. Xue. Za Zhi. 32    (2016): 360-363-   Simonova, O. A. et al., Mol. Biol (Mosk) 49 (2015): 667-677-   Singh-Jasuja, H. et al., Cancer Immunol. Immunother. 53 (2004):    187-195-   Small, E. J. et al., J Clin Oncol. 24 (2006): 3089-3094-   Smith, M. J. et al., Br. J Cancer 100 (2009): 1452-1464-   So, P. L. et al., Mech. Dev. 84 (1999): 157-160-   Sobolik-Delmaire, T. et al., Cell Commun. Adhes. 14 (2007): 99-109-   Steinberg, R. L. et al., Urol. Oncol (2016a)-   Steinberg, R. L. et al., Urol. Oncol (2016b)-   Sturm, M. et al., BMC. Bioinformatics. 9 (2008): 163-   Tan, X. et al., Exp. Ther. Med 1 (2010): 211-216-   Teufel, R. et al., Cell Mol. Life Sci. 62 (2005): 1755-1762-   Thorsen, K. et al., Mol. Cell Proteomics. 7 (2008): 1214-1224-   Tokar, E. J. et al., Chem Res Toxicol. 26 (2013): 96-105-   Tran, E. et al., Science 344 (2014): 641-645-   Unger, K. et al., Endocr. Relat Cancer 17 (2010): 87-98-   von Rundstedt, F. C. et al., Transl. Androl Urol. 4 (2015): 244-253-   Walter, S. et al., J. Immunol. 171 (2003): 4974-4978-   Walter, S. et al., Nat Med. 18 (2012): 1254-1261-   Willcox, B. E. et al., Protein Sci. 8 (1999): 2418-2423-   Xie, X. et al., Oncol Lett. 7 (2014): 1537-1543-   Yang, C. et al., Tumour. Biol (2015)-   Yang, S. et al., Biochim. Biophys. Acta 1772 (2007): 1033-1040-   Yu, J. et al., Gut 64 (2015): 636-645-   Zaremba, S. et al., Cancer Res. 57 (1997): 4570-4577-   Zhang, H. et al., Cancer Genet. 208 (2015a): 482-491-   Zhang, X. Q. et al., J Neurooncol. 125 (2015b): 253-263-   Zhang, Z. et al., Hum. Mol. Genet. 20 (2011): 4167-4174-   Zufferey, R. et al., J Virol. 73 (1999): 2886-2892

1. A peptide consisting of the amino acid sequence SLFDGIATGL (SEQ IDNO: 31) in the form of a pharmaceutically acceptable salt.
 2. Thepeptide of claim 1, wherein said peptide has the ability to bind to anMHC class-1 molecule, and wherein said peptide, when bound to said MHC,is capable of being recognized by CD8 T cells.
 3. The peptide of claim1, wherein the pharmaceutically acceptable is chloride salt.
 4. Thepeptide of claim 1, wherein the pharmaceutically acceptable is acetatesalt.
 5. A composition comprising the peptide of claim 1, wherein thecomposition comprises an adjuvant and a pharmaceutically acceptablecarrier.
 6. The composition of claim 5, wherein the peptide is in theform of a chloride salt.
 7. The composition of claim 5, wherein thepeptide is in the form of an acetate salt.
 8. The composition of claim 5wherein the adjuvant is selected from the group consisting of anti-CD40antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib,bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides andderivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulateformulations with poly(lactide co-glycolide) (PLG), virosomes,interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, andIL-23.
 9. The composition of claim 8, wherein the adjuvant is IL-2. 10.The composition of claim 8, wherein the adjuvant is IL-7.
 11. Thecomposition of claim 8, wherein the adjuvant is IL-12.
 12. Thecomposition of claim 8, wherein the adjuvant is IL-15.
 13. Thecomposition of claim 8, wherein the adjuvant is IL-21.
 14. A pegylatedpeptide consisting of the amino acid sequence of SLFDGIATGL (SEQ ID NO:31) or a pharmaceutically acceptable salt thereof.
 15. The peptide ofclaim 14, wherein the pharmaceutically acceptable is chloride salt. 16.The peptide of claim 14, wherein the pharmaceutically acceptable isacetate salt.
 17. A composition comprising the pegylated peptide ofclaim 14 or pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier.
 18. A peptide consisting of theamino acid sequence of SLFDGIATGL (SEQ ID NO: 31), wherein at least oneamino acid of the peptide is a D-amino acid.
 19. The peptide in the formof a pharmaceutically acceptable salt of claim 1, wherein said peptideis produced by solid phase peptide synthesis or produced by a yeast cellor bacterial cell expression system.
 20. A composition comprising thepeptide of claim 1, wherein the composition is a pharmaceuticalcomposition and comprises water and a buffer.